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 Mankind’s greatest attribute is the capability of higher order intellect being applied to 
prolonging life and improving one’s overall health. Modern medicine and the research therein has 
created opportunities to understand and combat disease at incredible levels. Yet, some of the most 
befuddling diseases are ones that our own bodies inheritably produce. Autoimmune disease is a 
condition in which the body’s own defense mechanisms begin to target healthy cells as if they 
were foreign threats. Cancer is a condition in which abnormal cell growth can spread throughout 
the body and begin to shut down vital bodily functions. Medicinal chemistry has difficulty 
combating and understanding such diseases due to the fact that intervention targets of the disorders 
are derived from human anatomy. The research presented within aims to aid in the scientific 
understanding of the two diseases discussed.  
Part I: Lipids isolated for Porphyromonas gingivalis have been recently implicated in 
possible development and/or progression of multiple sclerosis. The lipids are produced in bacteria, 
which are found throughout the GI track, and are shown to invade into the body. First, this study 
is intended as a structural proof and stereochemical elucidation of the proposed lipid compounds 
labeled lipid 430 and 654. Second, synthesis of stereochemically pure material is needed for further 
biological testing to establish a greater understanding of disease implications. We present  
  
Christopher James Dietz, Ph.D. 
University of Connecticut 2017 
the details of the convergent synthesis of lipids 430 and 654, which confirm the proposed structure 
of P. gingivalis lipid 654 to be (3R and 3S)-L-serine.  The bis(fatty acid) (3R)-L-serine 2 was 
prepared as well as the synthetic precursor, serine dipeptide mono-fatty acid (3R)-L-serine 1, 
which is the structure of lipid 430. We also synthesized the (3S)-L-serine diastereomer 2 as well 
as (3S)-L-serine 1.  Using these synthetic standards, we confirmed that phospholipase A2 (PLA2)-
mediated hydrolysis of lipid 654 is enantioselective in that only the (3R)-L-serine 2, but not (3S)-
L-serine 2 is enzymatically hydrolyzed. 
Part II: Cancerous tumors have been shown to have a hypoxic microenvironment that 
creates resistance to radiation therapy and ineffectiveness of common chemotherapy drugs. There 
is a need for improved noninvasive imaging techniques that detect hypoxic tumors and monitor 
the effects of administered cancer treatments. To do this we have synthesized hypoxic targeting 
fluorescence probes derived from FDA approved Indocyanine green dye to be used for optical 
imaging. Extending our previous work with 2-nitroimidazole-piperazine-indocyanine dye-
conjugate 3, we prepared the 4-nitroimidazole-piperazine-indocyanine derivative 12. We also 
prepared imidazole derivative 14 as a control.  We compared the in vivo hypoxia targeting 
performance of both with the previously tested 2-nitro dye conjugate, and the 4-nitro derivative 
showed a higher fluorescent intensity after 15 min post-injection. All findings were supported with 
fluorescence images of histological sections of tumor samples an immunohistochemistry technique 
for tumor hypoxia. New generations of the dyes are being created to increase the efficiency of the 
imaging technique.        
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Convergent Total Synthesis of Bioactive Dipeptide–Lipids Isolated 
from Porphyromonas gingivalis: Possible Biomarker for Multiple 
Sclerosis 
1.1 Introduction 
1.1.1 Disease, introducing the human microbiome 
 Chemistry, the study of matter, and biology, the study of life, can be linked in a number of ways. 
Medicinal chemistry is the nexus of modern chemistry and biology. Today, nothing is more 
important than the collaboration between the two sciences and how this plays in the development, 
progression, and regression of human disease.  
 Disease is classified as a disorder in the structure or function of a living organism. The 
causes of such conditions are seemingly endless. However, the vast majority of diseases are caused 
by either viruses or bacteria. Viruses, often with extremely complicated pathology, are seemingly 
simple to understand as to how they can cause disease. They infect human cells and force their 
exponential reproduction. The chemistry behind this can be extremely complex, but the underlying 
fact that the infecting agent is on the inside of the cell gives almost definite cause to why or how 
a viral disease can exist. On the other hand, bacteria produce disease through a wider group of 
pathogenic mechanisms, some of which are progressively being studied and befuddling 
researchers as to how they can interact with the human body and its anatomy. 
 It is easy to understand how a disease can develop from a bacterial infection including 
invasion and proliferation within the human body. It is like an invader behind enemy lines. On the 
contrary, the human microbiome, "the ecological community of commensal, symbiotic and 
pathogenic microorganisms that literally share our body space", has begun to grasp the attention 
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of scientists due to the extreme complexity of the relationship between the human body and its 
symbiotic partners.1 For this reason, the human microbiome has become an area of utmost interest 
in disease relations over the past few decades. 
 The Human Microbiome Project (NMP) can be looked at as a continuation of the Human 
Genome Project. Its Goals include: (1) characterize the human microbiome and (2) Determine the 
relationship between heath/disease and changes in the biome.2 The ratio of bacteria to human cells 
of an average human has been estimated to 1.3. The vast majority reside on internal and external 
surfaces of the human body including the; gastrointestinal track, urinary track, skin, saliva, oral 
mucosa, and conjunctiva.3 This microbial community has been associated with the heath and 
disease of host multicellular organisms with roles in physiology, metabolism, immunodeficiency, 
and hypersensitivity.4   
 
1.1.2 Multiple Sclerosis (MS) 
 Autoimmune disorders incorporate nearly 80 different diseases and are considered a 
leading cause of death and disability, with nearly 24 million reported cases in Americans.5 This 
number could be much higher due to the number of undiagnosed patients. Such disorders are a 
result of the human immune system becoming unable to recognize self from non-self. Normally 
the immune system responds to foreign materials and has built in safe ways to avoid attacking its 
own tissues.6 When this mechanism breaks down, the body begins to combat healthy cells/tissues 
of various organs including the pancreatic beta cells in diabetes, the joint synovia in rheumatoid 
arthritis and the central nervous system in multiple sclerosis, resulting in autoimmune disease. 
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 Multiple sclerosis (MS) is one of the more severe autoimmune diseases, as it affects more 
than 2.3 million people worldwide. The disorder is considered chronic as symptoms range from 
blurred vision or poor coordination, to more severe effects such as paralysis or blindness. The 
symptoms differ in every patient, can be permanent or episodic, and often worsen overtime. The 
disease is found in patients of all ethnicities and can be diagnosed at any age as symptoms develop.7 
 One of the most significant problems with MS is the difficultly of diagnosing the disease. 
To date, no single laboratory test is available for disease identification. This is extremely 
problematic because most common treatments aim to suppress the body’s immune system which 
can drastically increase the risk of further illness and infection. Instead of testing for the MS, one 
is evaluated for common symptoms and cross examined to rule out any other possibile 
explanations of causality. Physicians test mental functions, movement mobility, and vision for 
insight into the disease. When significant abnormal neurological findings are apparent, the use of 
magnetic resonance imaging (MRI) and invasive techniques are used to provide confirmatory 
evidence that MS is the cause. In 2010, the Revised McDonald Criteria was published by the 
international panel on diagnosis of multiple sclerosis.8 This gives the most accurate test to date, as 
it gives strict guidelines for using the 
MRI to speed up the process of diagnosis. 
However it is far from a positive test, as 
it simply aims to visualize damage that 
may be the result of MS. 
Within the human body, Multiple 
Sclerosis is characterized as the immune 
system producing an inflammatory 
Figure 1. Example of myelin destruction resulting from 
autoimmune disease.63 
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response within the central nervous system.9 This causes damage to cells that make up the signaling 
pathways of this delicate system. Though there is many theories discussed, the onset and 
progression of the process remains poorly understood. The universally accepted belief is that MS 
results from the body’s self-produced T cells, a subclass of white blood cells, attack the CNS 
myelin surrounding nerve cells.10 The biochemistry for the inflammatory response is unknown but 
can be facilitated by a number of factors, including environmental factors.  
The causes of MS are not exactly established, however researchers have suggested several 
possibilities of factors that could contribute to disease progression. Genetic factors are thought to 
play a small roll but there is evidence that the illness isn’t directly inherited.11 Habits and 
environment are thought to play a larger roll. Populations further from the equator have increased 
frequencies of MS and attribute this to vitamin D deficiencies. Cigarette smoking has also proven 
to increase the possibility of developing symptoms of the disease. In totality, the disease is thought 
to be contributed to 4 causes: immunology, genetics, environmental, and infection factors. 
Understanding the reason for the autoimmune response could shed light onto the prevention, 
treatment, and/or detection of the disease.12 Reading further will shift focus towards the role that 
human microbiome might play in the pathology of the disease and what evidence this might 
suggest.  
1.1.3 Porphyromonas gingivalis 
 Inflammatory periodontal disease in adults is initiated with the accumulation of specific 
bacteria in the sulcus around the teeth, followed by a chronic inflammatory reaction by the host 
against the colonizing microorganisms. Periodontitis is labeled as an oral inflammatory gum 
disease that effects the tissues needed to support the teeth.13 Often, progression of periodontitis 
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leads to loss of bone in the jaw and eventually tooth loss. The disease is proceeded by certain forms 
of gingivitis that may be directly caused from bacterial biofilms, or plaques, that buildup on tooth 
surfaces. Several microorganisms are associated with gingivitis/periodontitis, but substantial 
studies have implicated Porphyromonas gingivalis as a major pathogen in the destructive form of 
periodontal disease.14  
 P. gingivalis is an anaerobic, rod-shaped, non-motile, Gram-negative bacteria found in the 
oral cavity and the digestive track.15 Expanding upon the implications P. gingivalis displays in 
dental disease, evidence has suggested that this bacterium may play a role in autoimmune 
disorders.16 Rheumatoid arthritis is another such autoimmune disease associated with periodontal 
disease. P. gingivalis has been shown to contain an enzyme arginine deiminase (ADI) that can 
modify protein amino acid arginine to citrulline.18 This transformation is called citrullination. 
Citrullinated proteins are recognized/attacked by the immune system and can be considered a 
direct cause of autoimmune diseases that result from the body trying to defend itself from its own 
proteins. 
 Several studies have reported findings of P. gingivalis’ role in pathogenesis of the central 
nervous systems inflammatory response, leading to the aggravation of MS.18 It is not understood 
exactly how or why this happens, but it has been shown that peripheral bacteria in the 
gastrointestinal track can trigger autoimmune reactivity. This is thought to be the result of the body 
recognizing agonists that are produced by the bacteria, not necessarily bacterial infection per se. 
These agonists can be bound to receptors of external tissue cells. Our work leads to the idea that 
P. gingivalis activates in the innate immune system and in such a way to lead to multiple scleroses. 
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1.1.4 Toll-Like Receptors (TLRs) 
 The innate immune system, or non-specific immune system, is an important part of the 
overall immune system. It protects the body from developing infection from microorganisms. 
Sentinel cells are the body’s first line of defense verses pathogens derived from microorganisms 
that pose potential threats. There is a class of receptor proteins that are embedded in the sentinel 
cell’s membranes that are designed to recognize such structural molecules. The general receptor 
class is known as Toll-like receptors (TLRs).19 Their mode of action is triggered by binding 
pathogen’s, small molecules, located on the exterior of the bacteria and are produced by a wide 
range of microbes. The interaction with these stimuli cause a cascade of signaling pathways inside 
tissues to activate the innate immune system to fight the foreign invading microbes.20  
A total of 13 TLRs are known to exist, conveniently labeled TLR1- TLR13, with the first 
11 being found in humans. Each receptor has the ability to recognize certain aspects of structurally 
similar molecules that are shared by a broad range of pathogens. A recent study has shown that 
TLR2 and TLR4 can play a direct role in CNS damage associated with multiple sclerosis.21 
Ligation to these receptors causes a cascade effect in the immune system that ultimately leads to 
leukocyte migration across the blood-brain barrier. This is problematic to the nervous system as 
white blood cells begin to destroy the protective coating, myelin, of nerve cells. Worse yet, through 
a similar mechanism, differentiation of regulatory T cells is inhibited. The regulatory T cells play 
an important role in suppressing CNS autoimmunity.22  
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Figure 2. Toll-like receptors in Multiple Sclerosis. 
Ligation of TLR2 and TLR4 induces the production of IL1, IL6 and IL12, which induce the differentiation of naïve T 
cells into Th1 and Th17 cells. Th17 and Th1 cells secrete IL17 and INFγ respectively. IL17/INFγ-producing cells 
facilitate leukocyte migration across the blood-brain barrier and contribute to CNS damage. IL1 and IL6 also inhibit 
the differentiation of induced regulatory T cells (iTregs). Tregs are a major source of IL10, a cytokine that plays a 
critical role in suppressing CNS autoimmunity. Activation of TLR3, TLR7 and/or TLR9 can lead to the production of 
IFNβ, which activates T suppressor cells and inhibits the production of IL17 and IL23.21 
Reprinted directly from Miranda-Hernandez, S.; Baxter, A. G. Am. J. Clin. Exp. Immunol. 2013, 2, 75-93. 
 
 Toll-like receptor 2 (TLR2) is known to recognize a broad class of structures from micro 
bacteria. Many of the substrates that do this closely resemble lipoproteins or fatty acids.23 A recent 
report revealed that the lipid extract from P. gingivalis promotes activation of mouse dendritic 
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cells and inhibits osteoblast-mediated bone deposition through engagement of TLR2.24 Studies 
originally claimed that Porphyromonas gingivalis lipoprotein, lipopolysaccharide (LPS), and 
fimbriae were the cause for TLR2 activation.25 However, the extent these products mediate such 
reactions is disputed.26 Upon further investigation, specific serine containing lipids isolated from 
P. gingivalis were structurally characterized and proven to be TLR2 ligands.27  
 
1.1.5 Potential Serum Biomarker for MS 
 The role that P. gingivalis plays in the progression of gingivitis and periodontal disease 
can be directly correlated to the ligation of the bacteria’s pathogens to TLR2. Inflammation of the 
gums is a major part of the disease. However, as stated earlier, P. gingivalis and similar commensal 
bacteria may be contributing to the inflammatory response of the central nervous system in MS. 
This potential etiologic environmental factor can give definite evidence towards a mechanism or 
causality. But the study of the bacteria populating the GI tract could lead to a diagnostic aid, 
progression predictor, and/or possible target for therapeutic intervention for multiple sclerosis. 
 Recently, lipidomic work done by Clark et al at the University of Connecticut Health 
Center, showed that one of the serine lipids of P. Gingivalis, Lipid 654 (2), is detectable in the 
blood serum of all individuals.28 This was done using multiple-reaction-monitoring (MRM) mass 
spectrometry. The most important finding in this work was that this lipid was found at significantly 
lower levels in patients diagnosed with MS. This was compared to the serum of healthy individuals 
and patients with Alzheimer’s disease. This result, along with the involvement the serine lipids 
have in TLR activation, create a need for structural validation and stereochemical elucidation 
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1.1.6 Serine Lipid Targets 
 
 Lipid 1 and 2 are the hypothesized structures of the bioactive ligands responsible for TLR2 
activation and are commonly observed in chronically inflamed human tissues.27 They were 
deduced using nuclear magnetic resonance (NMR) and tandem mass spectroscopy (MS/MS). The 
lipids are composed of a serine glycine dipeptide in an amide linkage to a 3-OH isobranched (iso) 
C17:0 fatty acid. This base compound is labeled lipid 430 (1) which is indicative of its mass. The 
3-OH iso-C17:0 fatty acid moiety may form a 3-OH ester linkage to a saturated fatty acid, most 
frequently to iso-C15:0. This esterified lipid is labeled lipid 654 (2). 
 A search of the literature indicated that this structure was originally proposed for a serine 
lipid product isolated from a limited number of Flavobacteria and was termed flavolipin.29-32 We 
have also observed that lipid 430 was produced by enzymatic hydrolysis of lipid 654 and was, 
therefore, a logical synthetic precursor. Other fatty acids can substitute into these lipid classes, but 
they are less abundant relative to branched C15:0 and 3-OH iso C17:0.
33 Both of the serine dipeptide 
lipids, lipid 430 and lipid 654, are recovered in lipid extracts of P. gingivalis, but lipid 430 is 
recovered in low levels compared with lipid 654. Chiral GC-MS analysis showed that the serine 
lipids only contained L-serine stereochemistry. The absolute configuration of the β carbon of 3- 
OH iso C17:0 fatty acid portion of the lipids was not as easy to elucidate. To do this the lipids would 
need a high level of quantification and difficult derivations to run 2D NMR experiments.  
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1.1.7 Phospolidase A2 
Previously, catalytic deesterification of P. gingivalis derived lipid 654 to lipid 430 was 
observed using commercially available preparations of phospholipase A2 (PLA2).33 PLA2 is an 
important enzyme in the release of arachidonic acid from glycerol-based phospholipids and levels 
of this enzyme are increased in chronically inflamed tissues.  However, it was noted that a portion 
of lipid 654 isolated from P. gingivalis was not hydrolyzed by PLA2.  Chiral fractionations show 
about 10-15% of one isoform and 85-90% of the other 654 isoform. In the P. gingivalis derived 
654, recent HPLC analysis with direct infusion into the mass spectrometer suggest that the one 
isoform is less than 10%. These results suggest that enzymatic hydrolysis is stereospecific. 
Identification of the stereochemistry of 1 and 2, as well as confirmation of which isoform is 
selectively hydrolyzed, required verification by total synthesis for enzymatic hydrolysis studies. 
 
1.1.8 Literature Synthetic Approaches to Target Lipids 
This investigation aimed to prepared both (3R) and (3S)-L-serine-lipid 430 and thereby 
both (3R) and (3S)-L-serine-lipid 654 and to ascertain if only one diastereomeric form of synthetic 
lipid 654 was susceptible to PLA2 enzymatic hydrolysis. If selective hydrolysis is observed, the 
diastereospecificity of the partial hydrolysis of P. gingivalis lipid 654 by PLA2 would be 
confirmed. This could be accompanied by the role that the diastereomers play in TLR2 ligation. 
The biological activity associated with lipid 654 and lipid 430 is sufficiently important that 
synthesis is a priority for structural verification, the accumulation of synthetic standards, and the 
preparation of each lipid in sufficient quantity for further biological evaluation. 
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Structure 2 has been reported as an isolate from several natural products. Uchida and 
coworkers isolated dipeptide lipids from Flavobacterium sp. No. 3559, and the compound labeled 
WB-3559 D.29 In this work, WD-3559 D was shown to be a platelet aggregation inhibitor, and 
stimulated mouse plasma euglobulin clot lysis time. Kawai and coworkers identified a serine-
containing lipid along with ornithine containing lipids from extractable cellular lipids in 
Flavabacterium meningosepticum and F. indologes, which are opportunistic pathogens.30 The 
serine-containing lipid was identified and shown to be an immunoactivator that exhibited 
immuomodulator activity, and it was also identified as a blocking agent against endotoxemia.31 
Finally, Andoh and coworkers isolated a dipeptide lipid from strain B-572 of Flexibacter 
topostinus sp. nov. and it was named topostin D640.32 Topostins are inhibitors of mammalian DNA 
topoisomerase I (topo I). All of these isolated compounds were deduced a structure of what we 
call lipid 654 (2). To date, these biological results have led to three synthetic strategies for 
structural validation and stereochemical correlation of the lipid. 
 
 
Uchida and coworkers were the first to isolate and synthesize Lipid 654 (2).29,34 Their 
synthetic strategy started with aldehyde 3, (3aR,5S,6aR)-2,2dimethyltetrahydrofuro[2,3-
d][1,3]dioxole-5-carbaldehyde, functionalized from D-glucose in 10 steps.35  The isobranched lipid 
chain was built into the complexity of the molecule via Wittig reaction with separately prepared 
  
Scheme 1. Synthesis from Uchida et al.34 
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11-methyl dodecyltriphenyl- phosphorane to produce olefin  4. Hydrogenation over Adam’s 
catalyst and cleavage of the isopropylidene ketal, afforded the cyclic diol that was cleaved with 
sodium periodate and oxidized to produce (3R)-hydroxy-15-methylhexadecanal (5R). This 
sequence of reactions led to an overall yield as high as 41% in 7 synthetic steps.  
Uchida and coworkers then reported a linear synthesis of lipid 654 from the crucial 
intermediate 5R.  Glycine benzyl ester and 13-methyltetradecanoic acid were coupled via 
amidation using N-hydroxy succinimide to activate the acid moiety and simple acid chloride 
acylation of the β hydroxy group respectively. The stepwise elongation was finished by hydrolysis 
deprotection of the benzyl ester and similar acid activation coupling with L-serine. From the steps 
that were reported, lipid 2R was produced in 27% yield over 13 steps, from complex starting 
material 3.  
 
Shiozaki and coworkers prepared β hydroxy acid 5S in 7 steps from the same aldehyde (3) 
as Uchida, however this was done in a different schematic manner.36 Reduction of the aldehyde 
  
Scheme 2. Synthesis from Shiozaki et al.36 
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and benzyl protection led to compound 6. This 3-deoxy-pentose derivative was deprotected to the 
hemiacetal before treatment with sodium borohydride to open the ring between the oxygen and 
carbon 1 to produce the triol backbone for compound 7. Protection of this triol ultimately yielded 
7. Sequential silyl ether cleavage, followed by Swern oxidation and a Wittig reaction with prepared 
11-methyldodecyltriphenylphosphorane gave olefin 8. This produced the scaffold for isobranched 
lipid chain in a similar manor as the previous synthesis, but utilized the oxygen atoms in a different 
orientation to produce the opposite enantiomer. 
Compound 8 was subjected to hydrogenation conditions, reduction of the alkene and a 
global deprotection. Then the vicinal diol was cleaved with sodium periodate before ultimately 
being oxidized to β hydroxy fatty acid 3S. The acid was esterified with diphenyl diazomethane, 
the hydroxyl group was acylated with 13-methyltetradecanioic acid, then hydrogenolysis yielded 
acid 9. Tandem coupling/hydrogenolysis of glycine benzyl ester and then L-serine benzyl ester 
respectively, yielded lipid 2S. The 19 step synthesis from D-glucose produced the product lipid in 
a reported 4% overall yield. 
  
Scheme 3. Synthesis from Shioiri et al.37 
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Shioiri and coworkers synthesized lipid 2R from economically friendly 1,10-decanediol.37 
Starting by stoichemetric benzylation followed by Swern oxidation of the free alcohol, allowed for 
the production of olefin 10 via Wittig reaction with isoamyltriphenylphosphonium bromide. 
Therefore the isobranched lipid chain was built into the molecule very efficiently. Catalytic 
hydrogenation over palladium-carbon would result in the reduction of the alkene and deprotection 
of the benzylated alcohol. Then oxidation to the carboxylic acid proceeded a magnesium enolate 
anion coupling of ethyl hydrogen malonate to afforded β keto ester 11.38 Asymmetric 
hydrogenation via ruthenium (II) catalyst system with (R)-BINAP as a ligand produced β hydroxy 
acid 5R after saponification. 
Much like the other syntheses, the final steps utilized a stepwise elongation of the molecule. 
First, condensation with glycine tert-butyl ester and O-acylaation with 13-methyltetradecanoic 
acid. Then, acid deprotection of the tert-butyl ester before coupling with L-serine benzyl ester and 
sequential deprotection, yielded lipid 2R. This was the most efficient and nearly enantiomerically 
pure synthesis, achieved in 13 steps in a linear sequence that utilized asymmetric hydrogenation 
of a β-keto ester intermediate in an overall yield of about 11%. It also should be noted that this 
procedure is the only one that could yield both enantiomers of 5 with identical procedures. 
Each synthesis incorporated unique and creative transitions throughout. The major goal 
was to produce intermediate 5 as efficiently and stereospecifically as possible. Chiral starting 
materials allow for the production of this lipid chain enantiomerically pure. However 
stereospecific production in the later stage of shiori’s work, allowed for the production of both 
enantiomers. All three strategies chose to build the tagets in a stepwise elongation from the 
produced lipid chain. Since the β-hydroxy acid 5 is valuable material, a convergent synthesis could 
be utilized to increase yields, as it would carry material through less synthetic steps. 
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1.1.9 Retro Synthesis of Target Lipids 
The synthetic goal was to verify the structural identity of lipid 654 (2), which would 
correlate with the previously identified and synthesized flavolipin. The previous syntheses 
produced hydroxy acid 5, which could be converted to serine-glycine derivative 1, which we 
believed to be lipid 430. While the stereochemistry of our lipid 430 and lipid 654 were unknown, 
our previous work indicated that the serine dipeptide lipids of P. gingivalis are primarily 
constituted with L-serine. This assumption is also consistent with previous reports of 2 by Uchida, 
Shiozaki, and Shioiri.  
 
Our retrosynthesis began with cleavage of the labile ester linkage from the putative 
structure for lipid 654 (2), which generated the putative structure of lipid 430 (1) and 13-
 
Scheme 4. Retro synthesis of L-serine lipids 
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methyltetradecanoic acid (16).  Disconnection of the peptide linkage to the β-hydroxy fatty acid 
moiety in 12 gave the L-serine-glycine dipeptide 14 and β-hydroxy acid derivative 11. We therefore 
envisioned a convergent strategy that utilized elements of our previous work that would take 
advantage of the previously published syntheses to prepare 1 and then 2 using a protected L-serine-
glycine dipeptide 14.  We believed that this approach would allow us to generate both 
diastereomers of L-serine 1 and of L-serine 2, and in a shorter linear synthesis than previously 
reported.  
Disconnection of 11 led to an acetate surrogate and 13-methyltetradecanal, 15.  
Disconnection of 14 led to protected serine and glycine derivatives 17 and 18.  Aldehyde 15 can 
be prepared from 13-methyltetadean-1-ol (16) using previously published coupling of the Grignard 
reagent prepared from 1-bromo-2-methylpropane with 11-bromoundecan-1-ol.39 We planned a 
coupling reaction of ethyl diazoacetate with 15 to give a β-keto ester 11.40  Subsequent reduction 
of the ketone, followed by saponification, would generate the racemic β-hydroxy acid, 5.  One 
approach could use the asymmetric hydrogenation procedure reported by Shioiri.37 Alternatively, 
a classical resolution of this β-hydroxy fatty acid would yield each enantioenriched product. 
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1.2 Results and Discussion 
1.2.1 Synthesis of Lipid 430 and Lipid 654 
 The initial steps of the synthesis focused on the fatty acid portion of the targeted lipids and 
the preparation of 16, based on our published synthesis of dihydroceramides isolated from P. 
gingivalis.41  The Grignard reagent prepared from 1-bromo-2-methylpropane was coupled to 11-
bromoundecanol, in the presence of a lithium tetrachlorocuprate complex.  A large excess of 
Grignard reagent was used to convert the alcohol to an alkoxide in situ, thus avoiding the use of a 
protecting group.  The use of excess reagent can be avoided if 11-bromoundecanol is protected 
prior to the coupling reaction and additives are incorporated.  In the latter case, however, there was 
a decrease in overall yield mainly attributed to the handling over the three steps.  The fact that 2-
methylbromopropane is much cheaper than the other reagents led us to use the unprotected alcohol 
in the coupling step.  Oxidation of alcohol 16 with an oxoammonium reagent “Bobbitt’s salt” (4-
acetamido-2,2,6,6-tetramethylpiperidine 1-oxyl)  yielded aldehyde 15 with no over-oxidation to 
the acid.42  Upon exposure to air at ambient temperature, this aldehyde proved to be rather unstable, 
with rapid oxidation to the carboxylic acid 13.  If aldehyde 15 was maintained in wet THF solution 
until needed, the yield was near quantitative for the oxidation step and 91% from starting material 
11-bromoundecanol. 
 The β–Keto ester 11 was prepared by the reaction of 16 with ethyl diazoacetate in the 
presence of catalytic tin (II) chloride, using the protocol developed by Roskamp et al.40 Under 
these conditions, ester 11 was obtained in 80-90% yield under very mild conditions, although small 
amounts of carboxylic acid 13 were also observed.  Reduction of the ketone moiety with sodium 
borohydride generated racemic β–hydroxy ester 19.  Saponification using lithium hydroxide 
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yielded racemic β-hydroxy acid 20 in an overall yield of 62% from starting material 11-
bromoundecanol.  
Scheme 5. Synthesis of β-hydroxy acids. 
 
Our first attempt to generate enantiopure or enantioenriched β-hydroxy acid relied on an 
enzymatic resolution of racemic 20. Sugai and Ohta reported the use of a Pseudomonas lipase with 
vinyl acetate for the enzymatic transesterification of 2-hydroxytetracosanoic acid.43 Mori and 
coworkers used lipase PS and vinyl acetate to resolve 3-hydroxy-15-methylhexadecanoic acid 
(20), and used the (3R)-hydroxy-15-methylhexadecanoic acid provided by this procedure in a 
synthesis of sulfobactin.44 We applied this enzymatic resolution technique to compound 20, using 
commercially available Amano lipase PS.  After several attempts, our best result provided (3R)-
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20 in about 77% ee and (3S)-20 in about 79% ee, based on the conversion to the respective 
Mosher’s ester followed by 1H NMR analysis that showed a 84R:15S mixture and a 11R:89S 
mixture.45 We modified the exposure time of racemic 20 to the lipase, but we observed no 
improvement in enantiomeric enrichment.   
 A traditional resolution of the acid using brucine was also attempted.  Racemic β-hydroxy 
acid 20 was heated at reflux with brucine in different polar solvents (methanol, ethanol, acetone, 
and chloroform).  We obtained crystals from the reaction in chloroform, but all attempts to separate 
the diastereomeric salts failed because the resolving agent co-crystallized with both diastereomers 
under all conditions examined. We therefore abandoned this approach.  
 We obtained 20 in high enantiopurity using the asymmetric hydrogenation approach 
reported by Shioiri with β–keto ester 11.37 Catalytic hydrogenation of the ketone moiety in 11 
using ruthenium catalyst complexed with (S)-BINAP or (R)-BINAP as chiral ligands led to β-
hydroxy esters (3S)-19 and (3R)-19 respectively. The specific rotation of each β-hydroxy acid 
revealed [α]
21
𝐷
 +14.5 and [α]
21
𝐷
 –10.5 (c 1.0, CHCl3) for the (R) and (S) enantiomers  respectively. 
Shioiri reported the specific rotation of (3R)-10 to be [α] 
21
𝐷
 –12.5° (c 1.02, CHCl3).37  To confirm 
our results, we prepared Mosher’s esters of these compounds, and 1H NMR analysis indicated that 
(3R)-19 was formed in 98 % ee and (3S)-19 was formed in 98 %ee.45  These samples were 
subjected to the LiOH saponification conditions to yield (3R)-20 in 68 % and (3S)-20 in 70 %, 
respectively, over 5 steps from 11-bromoundecanol. 
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Scheme 6. Synthesis protected serine-glycine dipeptide. 
The glycine-serine dipeptide portion of lipid 654 was prepared using standard 
methodology. The amino group of glycine was protected as the benzyl carbamate to produce amino 
acid derivative 18.  Both the carboxylic acid and alcohol moieties of L-serine required protection 
to avoid undesired byproducts in the planned couplings.  The reaction of L-serine with thionyl 
chloride in methanol gave the L-serine methyl ester, which reacted with tert-butyldimethylsilyl 
chloride to give the protected derivative 17.  Dipeptide 14 was prepared by coupling the amino 
portion of 17 to the carboxyl group of 18 using DCC, where HOBt was used to generate the needed 
activated ester.  
  The coupling reaction of deprotected 14 and 20 proved challenging.  Peptides with free 
amines, especially ones containing glycine, are known to undergo cyclisation to form a 
diketopiperazine derivative.46 Dipeptides substituted with an amine at one terminus and an ester at 
the other can spontaneously cyclize to form a 2,5-DKP at a range of pH. Deprotection of the amino 
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moiety by hydrogenation of dipeptide 14 using a palladium catalyst gave almost exclusively the 
DKP product and little coupling to give 12.  Formation of this unwanted product could be partially 
suppressed with the addition of methanolic HCl to protonate the amine, but we were unable to 
isolate 14 free of DKP.  Attempts to couple the HCl salt of 14 with β–hydroxy acid 20 failed and 
coupling was only observed upon neutralization of the amine salt. The addition of a stoichiometric 
amount of base led to the DKP and the yield of our coupling product was only 30-40%. 
 Methodology developed by Shute and Rich for the coupling of dipeptides to tetrapeptides 
provided a solution to the coupling problem Activation of acid 20 with N-hydroxysuccinimide 
formed the reactive ester and this crude product was added to the hydrogenolysis reaction of 
dipeptide 14.47 The presence of the activated ester gives a competitive reaction against the 
formation of undesired DKP product and facilitated the production of (Rac)-12.  When 12 was 
obtained, deprotection with TBAF followed by LiOH saponification gave (Rac)-1 (75% yield).  
Using an identical procedure beginning with (3R)-20, we obtained (3R)-1 in 68% yield, and using 
(3S)-20 in the sequence gave (3S)-1 in 71% yield.  Spectroscopic evaluation demonstrated that 1 
correlates with the proposed structure of lipid 430 and the biological evaluation confirmed this 
conclusion. 
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 The final synthetic step was esterification of the alcohol moiety in (Rac)-12 with fatty acid 
13.  A DCC mediated coupling gave product (Rac)-22 in > 90% yield.  The use of EDC did prove 
to make the ease of purification easier but did lower yields of the transformation. The sensitivity 
of the ester linkage in the lipid 654 derivatives led to deprotection of 12 and 22 using two different 
methods. First, the silyl ether was removed using tetrabutylammonium fluoride to liberate the 
hydroxyl derivative of the serine moiety.  The desilylation of lipid derivative 22 was done in the 
same manner as before but a different hydrolysis of the methyl ester was used because 
 
Scheme 7. Synthesis of Lipid 430 and 654. 
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saponification of the fatty acid occurred under basic conditions.  After treatment with TBAF, 
reaction with potassium trimethylsilanolate led to (Rac)-2.48  This SN2 type of deprotection was 
successful, but the yield was lower over the two steps, giving 66% of (Rac)-2.  In an identical 
manner, (3R)-22 gave (3R)-2 (58%) and (3S)-22 gave (3S)-2 (67%).  Spectroscopic analysis of 
(3R)-L-serine-2 showed that it correlates structurally with lipid 654.  
 
1.2.2 Synthesis of Deuterium Labeled Lipids 
 In order to implicate this lipid class in human disease, accurate quantification of Lipid 654 
requires supplementing biological samples with a stable isotope internal standard for subsequent 
quantification using conventional mass spectrometric approaches.  For this reason the preparation 
of a deuterated serine lipid internal standard (25) for use in quantifying 2 in biological samples.  
In addition to quantifying the bacterial lipid 2 in biological samples, the deuterated lipid standard 
24 can also be used for the evaluation of enzymatic hydrolysis of the parent lipid by known 
esterases as well as peptidases.  In addition, the deuterated lipid 25 can be used for evaluation of 
metabolic breakdown of 2 by cells important in chronic inflammatory disease processes associated 
with the accumulation of bacterial serine dipeptide lipids.   
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 Deuterium labeled serine dipeptide lipid was successfully prepared for use in the analysis 
of biological samples. The first step was to prepare the non-deuterated straight chain fatty ester 
dipeptide via procedures that mimic the convergent synthesis of lipids 430 and 654 mentioned 
previously.49 The straight chain non-deuterated lipids 26 and 27 were used as a control to correlate 
the spectral data for the production of deuterated lipids. We first protected the commercially 
available 11-bromoundecanol as the dimethyl(t-butyl)silyl derivative, 28, in 61% yield. The 
Grignard reagent prepared from 1-bromobutane was coupled to 28, in the presence of a lithium 
cuprate complex with N-methylpyrrolidone (NMP) as an additive. The use of NMP as well as a 
catalytic amount of lithium tetrachlorocuprate is an alteration to the previous synthesis and will be 
elaborated upon in the deuterium labeled production. Deprotection of 28 and oxidation with the 
oxoammonium salt known as Bobbitt’s reagent provided pentadecanal 31 in 80% yield.  Coupling 
with ethyl diazoacetate gave 32 (89.6%), using our standard methodology and reduction with 
NaBH4, followed by deprotection with LiOH, afforded β-hydroxy acid 34 in 65% yield.  Coupling 
of 34 and the previously prepared protected dipeptide 14 using N-hydroxy succinimide activated 
ester in the presence of hydrolysis of the N-Cbz group by catalytic hydrogenation, gave 35 in 67% 
yield.  Deprotection of the ester of serine protecting groups afforded 26 in 68% yield, whereas 
esterification with 13-methyltetradecanoic acid gave 36 in 63.4% yield.  Deprotection gave 27 in 
50% yield.   The overall conversion for the linear sequence of 9 steps to 26 was 6% overall yield, 
whereas the linear sequence of 11 steps gave 27 in 3% overall yield. 
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Reagents: (a) TBDMSCl, imidazole, 97.7%; (b) (i) 1-bromobutane, Mg0, THF (ii) CuCl2, LiCl, NMP, 93%; (c) TBAF, 
87.4%; (d) Bobbitt’s salt, SiO2, 90.8%; (e) SnCl2, ethyl diazoacetate, 89.6%; (f) NaBH4, 77.6%; (g) LiOH, 83.6%;  (h) 
(i) NHS, EDC, DMAP (ii) Pd/C, H2, 67%; (i) (i) TBAF, 80.5% (ii) LiOH, 84%; (j) 13-methylpentadecanoic acid, 
EDC, DMAP, 63.4%; (k) (i) TBAF, 76.1% (ii) KOSi(CH)3, 65%. 
 
 Following a similar synthetic methodology, the synthesis of deuterated lipids initially 
focused on the fatty acid portion of the lipid and the preparation of 42. To avoid undesired 
reactivity of expensive deuterated Grignard reagent with the acidic hydroxy proton, commercially 
available 11-bromoundecan-1-ol was protected with tert-butyl dimethyl silyl chloride to form silyl 
ether 28. This was coupled with the Grignard derivative of 37, prepared by bromination of the 
commercially available d9-butan-1-ol, in the presence of a lithium tetrachlorocuprate complex with 
N-methylpyrrolidone (NMP) as an additive.50 The use of NMP as well as a catalytic amount of 
 
Scheme 8. Synthesis of non-deuterated straight chain lipid 654. 
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lithium tetrachlorocuprate insured that a minimum amount of d9-1-bromobutane was used to 
produce deuterated silyl ether 37.  Deprotection using tetrabutylammonium fluoride generated 
alcohol 38. Oxidation of the alcohol with the oxoammonium reagent Bobbitt’s salt yielded 
aldehyde 39 with no over-oxidation to the acid and in excellent yield. β–keto ester 40 was prepared 
by the reaction of the aldehyde with ethyl diazoacetate in the presence of catalytic tin (II) chloride. 
Selective reduction of the ketone moiety with sodium borohydride generated racemic β–hydroxy 
ester 41.  Saponification of this ester using lithium hydroxide yielded racemic β-hydroxy acid 42 
in an overall yield of 42% from 11-bromoundecanol.  
Reagents: (a) TBDMSCl, imidazole, 97.7%; (b) (i) d9-1-bromobutane, Mg0, THF (ii) CuCl2, LiCl, NMP, 98.3%; (c) 
TBAF, 99.1%; (d) Bobbitt’s salt, SiO2, 75.6%; (e) SnCl2, ethyl diazoacetate, 80.6%; (f) NaBH4, 79.7%; (g) LiOH, 
89.3%  (h) (i) 10, NHS, EDC, DMAP (ii) Pd/C, H2, 78.2%; (i) (i) TBAF, 85.1% (ii) LiOH, 73%; (j) 13-
methylpentadecanoic acid, EDC, DMAP, 79.6%; (k) (i) TBAF, 85.1% (ii) KOSi(CH)3, 58%. 
 
Scheme 9. Synthesis of deuterated L-serine lipid 654 
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 With d9-β-hydroxy acid 42 prepared, the convergent synthesis proceeded by amidation 
coupling with protected dipeptide 10. Activation of the acid with N-hydroxysuccinimide combined 
with the hydrogenolysis product from the dipeptide facilitated the protected lipid 43.  Subsequent 
deprotection with TBAF followed by LiOH saponification gave d9-lipid 24 in 49% yield from the 
C17 fatty acid.   
 The other targeted lipid utilized esterification of the alcohol moiety of 43 with 13-
methylpentadecanoic acid.  An EDC/DMAP mediated coupling gave d9-protected lipid 44.  
Deprotection proceeded via removal of the silyl ether using tetrabutylammonium fluoride to 
liberate the serine hydroxyl group. The sensitivity of the ester linkage in the lipid led to liberation 
of the methyl ester in a different method.  Reaction with potassium trimethylsilanolate led to 25.  
This SN2 type of deprotection was successful, but the yield was lower over the two steps, giving 
27% from synthetic fragments 42 and 14. 
 
1.2.3 MS/MS Fragmentation of Synthetic Lipids 
 The analysis via MS/MS of synthetic lipids was correlated with isolated lipid 654 from P. 
gingivalis to confirm proposed structure (Figure 3). The fragmentation pattern of L-serine (rac)-
654-(2) matched identically and proved the hypothesized structure of bioactive compounds. Both 
diastereomers, (R)-2 and (S)-2, were also evaluated by MS/MS. The diastermically enriched lipids 
showed identical fragmentation patterns. Therefore, no stereoisomer-specific precursor-to-
fragment transitions available for differential quantitation of the (R) and (S) isoforms by MRM 
MS. That is not an unexpected result, however it is disappointing since the stereochemistry of 
future isolated lipid batches cannot determined solely by mass spectrometry. The deuterated lipid 
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25 showed the same MS/MS spectrum as the parent lipid 2 and indicating that it is a viable internal 
standard for accurate quantitation of L-serine-Lipid 654 stereoisomers.  
Figure 3. MS/MS spectrum of synthetic lipids. 
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1.2.4 Enzymatic Hydrolysis of Synthetic Lipid 654 (2). 
Figure 4. Hydrolysis of (3R)-L-serine-2 and (3S)-L-serine -2 by PLA2 enzyme preparations. 
  
Each lipid preparation was aliquoted (250 ng/sample) and were dried.  Samples were processed as described in the 
text.   Multiple Reaction Monitoring (MRM) was performed using a Sciex QTrap 4000.  The 654.3-381.3 or 430.3- 
382.3 m/z transitions were used to calculate the lipid 430/lipid 654 ratios.  
 
  
 HPLC purified synthetic (3R)-L-serine-2 and (3S)-L-serine-2 were subjected to enzymatic 
hydrolysis using commercially available PLA2 preparations.  Approximately 250 ng of each 
synthetic lipid was sonicated in Tris buffer (10 mM, pH 7.5, 1 mL) containing 150 mM NaCl and 
2.5 mM CaCl2.  Control samples received no enzyme.  Approximately 100 U of either porcine 
pancreatic PLA2 or honey bee venom PLA2 (both from Sigma) was added and all samples were 
stirred for 5 days at 25°C.  At 5 days, the samples were acidified with glacial acetic acid and 
extracted with CHCl3 (1 mL x 3 extractions).  The pooled extracts were dried and suspended in 
HPLC solvent (hexane:isopropanol:water, 6:8:0.75, v/v/v).  The samples were evaluated using 
MRM-MS and the ratio of lipid 430 to lipid 654 was determined for both control and enzyme 
treated samples.  The results in Figure 1 show that the (3R) diastereomer of synthetic lipid 654, 
(3R)-L-serine-2, is hydrolyzed by PLA2 but the (3S)-L-serine-2 is not.  This evidence suggests that 
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the partial hydrolysis of P. gingivalis lipid 654 results from the presence of both (3R) and (3S) 
diastereomers of lipid 654 in this organism where only the (3R) form is hydrolyzed.  Of note, it 
was recently reported that the lipid 430 recovered following porcine pancreatic PLA2 hydrolysis 
of P. gingivalis lipid 654 is a potent inhibitor of osteoblast function both in vivo and in vitro.33   
 
1.2.5 Conclusions 
 We have prepared (3R)-L-serine-2 and (3R)-L-serine 1, as well as (3S)-L-serine-2 and (3S)-
L-serine 1 by a convergent synthetic route that is significantly shorter than other published routes, 
producing the targeted compounds in higher yield. In summary, the convergent synthesis described 
herein confirms the proposed structures of lipid 654 produced from P. gingivalis.  Our convergent 
synthesis gave lipid 430, (R)-1, in 8 linear steps and 24% overall yield, using the protected 
dipeptide 13 prepared separately.  We similarly prepared (S)-1 in 8 linear steps and 27% overall 
yield.  Lipid 654, (R)-2, was prepared in 9 linear steps and 28% overall yield.  We similarly 
prepared (S)-2 in 8-linear steps and 34% overall yield.  Using the same approaches, (rac)-1 was 
prepared in 8 linear steps and 46% overall yield and (rac)-2 was prepared in 9 linear steps ad 40% 
overall yield.  
 We have also successfully incorporated nine deuterium atoms into 24 and 25 from the 
commercially available 11-bromoundecan-1-ol using commercially available d9-butan-1-ol as the 
deuterium source.  The convergent synthesis prepared 24 in 9 linear steps and 13% overall yield 
from 11-bromoundecan-1-ol and 25 in 10 linear steps and 6% overall yield.  Using an identical 
route we have prepared 26 in 9 linear steps and 12% overall yield and 27 in 10 linear steps and 3% 
overall yield.   The d9-24 will be used as a standard for the lipid 430 isolated from Porphyromonas 
gingivalis and d9-25 will be used as a standard for 654 isolated from P. gingivalis. 
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 Demonstration that there is a difference in enzymatic reactivity with the different 
diastereomers allows us to use the (R) and (S) synthetic preparations of lipid 654 to evaluate 
biological properties of enantioenriched or enantiopure lipids to engage the innate immune system, 
including the engagement of Toll-like receptor 2.   Furthermore, it is important to determine the 
levels of (R) and (S) lipid 654 present in other members of the Bacteroidetes phylum as well as the 
levels of these isoforms in diseased tissues where lipid 654 is known to accumulate.  These studies 
have begun, and the results will be the subject of a future communication. 
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1.3 Experimental 
General 
All glassware was oven-dried, and all reactions were performed under a nitrogen atmosphere.  All 
chemicals were purchased from the Sigma-Aldrich Chemical Co., and used without further 
purification unless otherwise noted.  Tetrahydrofuran (THF) was distilled from sodium 
benzophenone ketyl, methylene chloride (dichloromethane, DCM) was distilled from calcium 
hydride, and dimethylformamide (DMF) was distilled in vacuo from calcium hydride.  Ethyl 
acetate (EtOAc), methanol (MeOH), and diethyl ether were used as obtained from the vendor.  
Bobbitt’s salt42 was provided as a gift from Dr. James Bobbitt (Department of Chemistry, The 
University of Connecticut)), but it is commercially available from Sigma-Aldrich as 4-acetamido-
2,2,6,6-tetramethylpiperidine 1-oxyl. d9-Butan-1-ol was purchased from Sigma-Aldrich.  
 Thin-layer chromatography was done on Sorbent Technologies aluminum-backed TLC 
plates with fluorescent indicator and 0.2 mm silica gel layer thickness, and p-anisaldehyde or 
phosphomolybdic acid were used as developing agents.  Column chromatography was done using 
60 Å porosity, 32-63 µm silica gel. 1H and 13C NMR were collected on a Bruker Avance 300 
(300.13 MHz 1H, 75.48 MHz 13C), Bruker DRX-400 (400.144 MHz 1H, 100.65 MHz 13C) or a 
Bruker Avance 500 (500.13 MHz 1H, 125.65 MHz 13C).  Chemical shifts are reported in ppm 
downfield from tetramethylsilane (TMS) in the following format chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet). Coupling constants are reported in Hz.  
Mass spectrometry data was collected on a HP 5870B GC/MSD mass spectrometer with an HP-1 
column, and high resolution MS and MS/MS spectra of synthetic 2 and 1 were obtained by direct 
infusion of the target lipids into a QTOF mass spectrometer, QSTAR Elite from Sciex (Foster City, 
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CA) or directly by using AccuTOF™ DART, JEOL (Peabody, MA).  Multiple reaction monitoring 
(MRM) transitions were selected based the MS/MS spectra of 2 and 1.  Lipid samples were injected 
into a triple quadrupole mass spectrometer, 4000 QTrap from Sciex (Foster City, CA).  IR spectra 
were taken on FT/IR-410/C031560585 JASCO and Nexus 670 FT-IR E.S.P, neat, unless otherwise 
stated.  All melting points to an upper limit of 270 °C were obtained using a Uni-melt capillary 
melting point apparatus or Digimelt MPA160. Perfect.  For products described as waxy solid or 
semi-solids, melting points could not be obtained. 
 
Methyl L-serinate 
 
 Thionyl chloride (2.75 mL, 37.8 mmol) was added, dropwise, to a suspension of L-serine 
(4.015 g, 38.2 mmol) in 50 mL of dry methanol. The solution was heated at reflux with stirring for 
5 h and then cooled to ambient temperature.  The solvent was removed in vacuo and the crude 
white solid was redissolved in a minimal amount of methanol.  This solution was treated with an 
equal volume of toluene and the flask was swirled periodically to induce crystallization. Filtration 
yielded methyl L-serinate as a crystalline solid (3.9675 g, 33.3 mmol, 87.2%).51  MP, 161-162 °C.  
1H NMR (400 MHz, Methanol-d4) δ 4.14 (t, J=3.9 Hz, 1H), 4.01 (dd, J=11.8, 4.5 Hz, 1H), 3.93 
(dd, J=11.8, 3.1 Hz, 1H), 3.85 (s, 3H). 13C NMR (101 MHz, Methanol-d4) δ 169.4, 60.7, 56.1, 
53.71. 
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Methyl O-(tert-butyldiphenylsilyl)-L-serinate, (17) 
 
 A stirring solution of methyl L-serinate (2.003 g, 16.8 mmol) in 15 mL of DMF was treated 
with imidazole (3.435 g, 50.4 mmol).52  (tert-Butyl)diphenylsilyl chloride (4.80 mL, 18.5 mmol) 
was added, dropwise, and the reaction was stirred overnight at ambient temperature.  At this time, 
the solvent was removed in vacuo and the resulting oil was dissolved in 100 mL of diethyl ether.  
This solution was washed with water (5 X 400 mL), 10 % LiCl (2 X 100), and brine (50 mL).  
Drying with MgSO4, filtering, and concentration under reduced pressure yielded methyl O-(tert-
butyldiphenylsilyl)-L-serinate, 17, as a yellow oil (5.331 g, 14.9 mmol, 88.7%). 1H NMR (400 
MHz, CDCl3) δ 7.64 (td, J = 7.7, 1.6 Hz, 4H), 7.50-7.35 (m, 6H), 3.98 (dd, J = 9.9, 4.3 Hz, 1H), 
3.89 (dd, J = 9.9, 3.8 Hz, 1H), 3.71 (s, 3H), 3.58 (t, J = 4.1 Hz, 1H), 1.04 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 135.6, 133.1, 133.0, 129.9, 127.8, 127.7, 66.1, 56.5, 52.1, 26.8, 19.3. HRMS 
(AccuTOF): [MH]+ Calc’d for C20H28NO3Si m/z 358.1838. Found: m/z 358.1819. 
 
((Benzyloxy)carbonyl)glycine [N-Cbz-Glycine], (18) 
 
 Glycine (3.000 g, 40.0 mmol) and sodium bicarbonate (6.710 g, 79.9 mmol) were dissolved 
in 100 mL of H2O at ambient temperature and this solution was cooled to 0 °C using an ice bath.  
Benzyl chloroformate (8.56 mL, 59.9 mmol) in 25 mL of dioxane was added, dropwise.  This 
solution was slowly warmed to ambient temperature and stirred overnight. The reaction mixture 
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was transferred to a separatory funnel and washed with EtOAc (2 X 50 mL).  The aqueous layer 
was acidified with 10 % HCl to a pH=1 (to pH paper) and extracted with EtOAc (3 X 50 mL).  The 
later organic layers were dried, filtered, and solvents evaporated at reduced pressure to yield 
((benzyloxy)carbonyl)glycine, 18,53  as a white solid (6.982 g, 33.4 mmol, 83.5 %), MP, 112-114 
°C.  1H NMR (400 MHz, Methanol-d4) δ 7.40–7.24 (m, 5H), 5.10 (s, 2H), 3.84 (s, 2H). 13C NMR 
(101 MHz, Methanol-d4) δ 173.6, 159.1, 138.1, 129.4, 129.0, 128.8, 67.7, 43.1. 
 
Methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate, (14) 
 
 A solution of ((benzyloxy)carbonyl)glycine (1.748 g, 8.36 mmol) in 10 mL of DMF was 
cooled to 0°C using an ice bath.  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI, 1.603 
g, 8.36 mmol), HOBt (1.280 g, 8.36 mmol) and then diisopropylethylamine (DIPEA, 1.46 mL, 
8.36 mmol) were added in that order.  The solution was stirred for 15 min before the addition of 
methyl O-(tert-butyldiphenylsilyl)-L-serinate, 12 (2.988 g, 8.36 mmol). The reaction was warmed 
to ambient temperature and stirred for 48 h.  At that time, the DMF was removed in vacuo and the 
resulting oil was dissolved in 100 mL of diethyl ether.  The ether was washed with water (5 X 400 
mL), saturated NaHCO3 (3 X 100) mL, and brine (50 mL).  The organic layer was dried, filtered, 
and solvents evaporated at reduced pressure. Purification by column chromatography (1 % 
MeOH:DCM) yielded (((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate, 14, 
as a clear oil (3.390 g, 6.18 mmol, 73.9%). 1H NMR (400 MHz, CDCl3) δ 7.59 (t, J = 7.6 Hz, 4H), 
7.49–7.34 (m, 6H), 6.77 (d, J = 6.9 Hz, 1H), 5.36 (s, 1H), 5.12 (q, J= 12.3, 7.6 Hz, 2H) 4.68 (dt, J 
= 8.3, 2.9 Hz, 1H), 4.13 (dd, J = 10.3, 2.8 Hz, 1H), 3.93–3.75 (m, 3H), 3.74 (s, 3H), 1.04 (s, 9H). 
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13C NMR (101 MHz, CDCl3) δ 170.5, 168.6, 156.4, 136.1, 135.5, 132.8, 132.6, 130.1, 128.6, 
128.2, 128.1, 127.9, 127.8, 67.3, 64.2, 54.1, 52.5, 44.4, 26.7, 19.3. HRMS (AccuTOF): [MH]+ 
Calc’d for C30H37N2O6Si m/z 549.2421. Found: m/z 549.2423. 
 
13-Methyltetradecan-1-ol, (16) 
 
 Magnesium turnings (2.90 g, 0.119 mol) were added to a 500 mL round bottom flask with 
a stirbar and flame-dried under a nitrogen atmosphere.  After cooling, the Mg turnings were 
suspended in dry THF (50 mL) and 1-bromo-2-methylpropane (8.00 mL, 0.0736 mol) was rapidly 
added with vigorously stirring.  Upon initiation, dry THF (50 mL) was added and the flask was 
immersed in an ice bath to modulate the exothermic reaction.  The reaction was stirred until the 
flask cooled to ambient temperature and the temperature was lowered to -78 °C using  dry ice 
acetone bath.  11-Bromoundecan-1-ol (4.005 g, 0.0172 mol) dissolved in THF (20 mL) and LiCl 
(1.53 g, 0.036 mol) and copper (II) chloride (2.54 g, 0.019 mol), dissolved in THF (30 mL), were 
added.  The mixture was slowly warmed to ambient temperature and stirred overnight. The 
reaction was quenched with satd NH4Cl (100 mL) before being transferred to a separatory funnel 
with diethyl ether (200 mL) and H2O (100 mL). The layers were separated and the organic layer 
was washed with satd NaHCO3 (50 mL X 3) and brine (50 mL).  The organic phase was dried with 
MgSO4, gravity filtered, and solvents removed in vacuo. The crude product was purified by 
column chromatography on silica gel (10% EtOAc:hexane) to yield 13-methyltetradecan-1-ol, 
16,37,54 as a white solid (3.793 g, 0.017 mol, 96.7%), MP, 26-27 °C.  1H NMR (400 MHz, CDCl3) 
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δ 3.64 (t, 2H), 1.63–1.44 (m, 3H), 1.27 (m, 18H), 1.17 (m, 3H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR 
(101 MHz, CDCl3) δ 63.3, 39.2, 33.0, 30.1, 29.9, 29.8, 29.8, 29.6, 28.1, 27.6, 25.9, 22.8. 
 
13-Methyltetradecanal, (15) 
 
 4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium tetrafluoroborate42 (Bobbit’s salt, 
5.285 g, 0.0176 mol) was added to 13-ethyltetradecanol (7, 3.498 g, 0.0153 mol) dissolved in 250 
mL of dry DCM.  An equal mass of silica was slowly added to the stirring mixture. The bright 
yellow solution stirred at ambient temperature until the color faded, giving a solution with a pale 
yellow tint.  The solution was filtered to remove the silica, and the filtrate was concentrated in 
vacuo.  The crude product was purified by column chromatography (5% EtOAc:hexanes) to yield 
13-methyltetradecanal, 15,41 as a clear solid, (3.319 g, 0.0147 mol, 95.8%), MP, ~25 °C.  1H 
NMR(400 MHz, CDCl3) δ 9.76 (t, J = 1.9 Hz, 1H), 2.41 (td, J = 7.4, 1.9 Hz, 2H), 1.63 (quin, J = 
7.2 Hz, 2H), 1.51 (sep, 1H), 1.36–1.22 (m, 16H), 1.15 (m, 2H), 0.86 (d, J = 6.6 Hz, 6H) 13C NMR 
(101 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 203.0, 44.0, 39.1, 30.0, 29.8, 29.7, 29.6, 
29.5, 29.4, 29.2, 28.0, 27.5, 22.7, 22.2. 
 
13-Methyltetradecanoic acid, (13) 
 
 13-Methyltetradecanal (15, 1.251 g, 5.53 mmol) was dissolved in 50 mL of THF, and 5 
mL of H2O and 0.5 mL of 1M HCl were added.  The reaction mixture was stirred for 72 h at 
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ambient temperature.  The resulting solution was concentrated under reduced pressure, the residue 
dissolved in 15 mL of H2O, and extracted with DCM (15 mL X 3).  The resulting solution was 
filtered through a small plug of silica gel and rinsed with DCM before being concentrated in vacuo 
to yield 13-methyltetradecanoic acid32,37,55 (13) as a white solid (1.307 g, 5.39 mmol, 97.6%), MP, 
48-49 °C.  1H NMR (400 MHz, CDCl3) δ 2.35 (t, J = 7.5 Hz, 2H), 1.63 (quin, J = 7.4 Hz, 2H), 
1.51 (sep, J = 6.6 Hz, 1H), 1.39–1.18 (m, 16H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 
13C NMR (101 MHz, CDCl3) δ 13C NMR (101 MHz, CDCl3) δ 179.6, 39.1, 34.0, 30.0, 29.8, 29.7, 
29.7, 29.5, 29.3, 29.1, 28.0, 27.5, 24.8, 22.7. 
 
Ethyl 15-methyl-3-oxohexadecanoate, (11) 
 
 Tin (II) chloride dehydrate (0.417 g, 1.85 mmol) was suspended in 15 mL of dry DCM.  
Ethyl diazoacetate (2.60 g, 19.4 mmol) was added, dropwise via syringe, and the reaction was 
stirred for 15 min.  13-Methylpentadecanal (15, 4.186 g, 18.5 mmol) was dissolved in 10 mL of 
DCM and added to the reaction, dropwise, via cannula.  The mixture was stirred at ambient 
temperature for about 6 h, until nitrogen evolution ceased.  The reaction mixture was diluted with 
100 mL of DCM and washed with a satd brine solution (2 X 50 mL).  The aqueous layers were 
combined and extracted with DCM (2 X 25 mL).  All organic layers were combined, dried with 
MgSO4, filtered, and solvents evaporated at reduced pressure.  The resulting crude product was 
purified via column chromatography (5% EtOAc:hexanes) to yield ethyl 15-methyl-3-
oxohexadecanoate,37,56 11, as a clear solid (4.871 g, 0.0156 mol, 84.3%), MP, ~25 °C.  1H NMR 
(400 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz, 2H), 3.42 (s, 2H), 2.53 (t, J = 7.3 Hz, 2H), 1.60 (quin, J 
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= 7.2 Hz, 2H), 1.50 (sep, J = 6.5 Hz, 1H), 1.30-1.20 (m, 20H), 1.15 (q, J = 7.3, 6.8 Hz, 2H), 0.86 
(d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 203.0, 167.3, 61.4, 49.4, 43.1, 39.1, 30.0, 29.8, 
29.7, 29.7, 29.5, 29.4, 29.1, 28.0, 27.5, 23.5, 22.7, 14.2. 
 
Ethyl 3-hydroxy-15-methylhexadecanoate, (19) 
 
 A solution of ethyl 15-methyl-3-oxohexadecanoate (11, 3.114 g, 0.001 mol) in 2.5 mL of 
ethanol and 22.5 mL of THF was cooled to 0 °C on an ice bath.  Sodium borohydride (0.301 g, 
0.008 mol) was added and the resulting slurry was stirred vigorously for 1 h.  The reaction was 
quenched by the slow addition of 50 mL of a 10 % aq citric acid solution.  Subsequent 
neutralization with satd K2CO3 solution was followed by extraction with EtOAc (3 X 50 mL).  
The organic layers were washed with 25 mL of satd brine solution, dried with MgSO4, filtered, 
and the solvents were removed at reduced pressure.  The crude product was purified by column 
chromatography (10% EtOAc:hexanes) to yield ethyl 3-hydroxy-15-methylhexadecanoate,37 19 as 
a clear oil (2.674 g, 0.0085 mol, 85.3 %).  1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 
4.06–3.93 (m, 1H), 2.91 (d, J = 3.9 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J = 16.4, 
9.0 Hz, 1H), 1.60–1.20 (m, 23H), 1.15 (q, J = 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 
MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 25.5, 
22.7, 14.2. 
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Ethyl (3R)-hydroxy-15-methylhexadecanoate, ((3R)-19) 
 
 In a nitrogen atmosphere glove box, (R)-BINAP (45 mg, 0.072 mmol) and bis(2-
methylallyl)(1,5-cyclooctadiene)ruthenium(II) (20 mg, 0.063 mmol) were dissolved in 9 mL of 
freshly distilled acetone.   Methanolic HBr (0.22 mL, 0.73 M, 0.16 mmol) was added, and the 
solution was stirred for 1 h.  The reaction was concentrated to dryness in vacuo before being 
redissolved in 15 mL of ethanol and β-keto ester 11 (0.962 g, 3.08 mmol) was added. The system 
was flushed with hydrogen and heated at reflux for 48 h.  The resulting solution was filtered and 
the solvents removed at reduced pressure.  Subsequent purification via column chromatography 
(10% EtOAc:hexanes) yielded ethyl (3R)-hydroxy-15-methylhexadecanoate, (3R)-1937 as a clear 
solid (0.901 g, 2.86 mol, 93.0 %), MP, ~25 °C.  1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.2 Hz, 
2H), 4.05–3.94 (m, 1H), 2.91 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J = 
16.4, 9.0 Hz, 1H), 1.60–1.20 (m, 23H), 1.15 (q, J = 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 
27.5, 25.5, 22.7, 14.2.  A 1H NMR analysis that showed a 97R:03S mixture for (3R)-19. 
 
Ethyl (3S)-hydroxy-15-methylhexadecanoate, ((3S)-19) 
 
 In a nitrogen atmosphere glove box, (S)-BINAP (45 mg, 0.072 mmol) and bis(2-
methylallyl)(1,5-cyclooctadiene)ruthenium(II) (20 mg, 0.063 mmol) were dissolved in 9 mL of 
freshly distilled acetone.  Methanolic HBr (0.22 mL, 0.73 M, 0.16 mmol) was added, and the 
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solution stirred for 1 h.  The reaction was concentrated to dryness in vacuo before being redissolved 
in 15 mL of ethanol and β-keto ester 11 (0.954 g, 3.05 mmol) was added.  The system was flushed 
with hydrogen gas and heated at reflux for 48 h.  The resulting solution was filtered and the 
solvents removed at reduced pressure.  Subsequent purification via column chromatography (10% 
EtOAc:hexanes) yielded ethyl (3S)-hydroxy-15-methylhexadecanoate, (3S)-1937 as a clear solid 
(0.917 g, 2.92 mol, 95.5 %), MP, ~25 °C.  [α]D23 +11.8° (c 1.0, CHCl3), 1H NMR (400 MHz, 
CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 4.06–3.93 (m, 1H), 2.91 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 
3.1 Hz, 1H), 2.39 (dd, J = 16.4, 9.0 Hz, 1H), 1.55–1.39 (m, 3H), 1.38–1.21 (m, 20H), 1.15 (q, J = 
7.1, 6.6 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.2, 68.1, 60.7, 41.4, 
39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 25.5, 22.7, 14.2.  A 1H NMR analysis that 
showed a 02R:98S mixture for (3S)-19. 
 
Enzymatic Resolution 
 Lipase PS (.275 g) was added to a stirred solution of (±)-19 (5.50 g, 1.92 mmol) and 2,6-
di-tert-butyl-4-methylphenol (5 mg) in vinyl acetate (8.8 mL), and stirred at 52-58 °C for 168 h. 
The resulting mixture was cooled to ambient temperature and filtered through Celite and 
concentrated under reduced pressure.  Column chromatography (MeOH: DCM), yielded (3R)-5 
(128 mg) as a white solid; [α] 
23
D
  +6.4° (c 1.02, CHCl3).  After saponification of the acetate 
product, (3S)-5 (177 mg) was purified to give a white solid; [α] 
23
D
  –8.7° (c 1.02, CHCl3).  
1H 
NMR spectra were identical with those of (±)-5.16c  Conversion to the corresponding Mosher’s 
ester as described above was followed by 1H NMR analysis that showed a 84R:15S mixture for 
(3R)-19 and a 11R:89S mixture for (3S)-19. 
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Ethyl (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl) oxy)- 
Hexadecanoate 
 
 Under a nitrogen atmosphere, (S)-(–)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid 
(Mosher’s acid,45 23 mg, 0.098 mmol) was dissolved in 2 mL of dry DCM and cooled to 0 °C in 
an ice bath. Subsequent addition of DCC (24 mg, 0.12 mol) was followed by stirring for 15 min, 
at which time ethyl (3R)-hydroxy-15-methylhexadecanoate, (3R)-19 (29 mg, 0.092 mmol) was 
added, along with a catalytic amount of DMAP.  The reaction was equilibrated to ambient 
temperature slowly and stirred overnight.  Evaporation of solvents in vacuo was followed by 
addition of 15 mL of EtOAc and washing with H2O 3 X 10 mL and 10 mL of satd brine.   The 
resulting organic layer was dried over MgSO4, filtered, and the solvents removed at reduced 
pressure.  Subsequent purification via column chromatography (1-10% EtOAc:hexanes) yielded 
ethyl (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)hexadecanoate as 
a clear oil (38 mg, 0.072 mmol, 78 %).  1H NMR (400 MHz, CDCl3) δ 7.55-7.50 (m, 2H), 7.42-
7.37 (m, 3H), 5.52-5.45 (p, J = 6.4 Hz, 1H), 4.06 (q, J = 7.1 Hz, 2H), 3.53 (s, 3H),  2.64 (dd, J = 
16.0, 7.9 Hz, 1H), 2.55 (dd, J= 16.0, 5.0 Hz, 1H) 1.80-1.60 (m, 2H), 1.55-1.47 (sep, J = 6.6 Hz, 
1H), 1.36-1.12 (m, 23H), 0.86 (d, J = 6.6 Hz, 6H). 
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Ethyl (S)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)- 
Hexadecanoate 
 
 Under a nitrogen atmosphere, (S)-(–)-α-Methoxy-α-(trifluoromethyl)phenylacetic acid 
(Mosher’s acid,45 23 mg, 0.098 mmol) was dissolved in 2 mL of dry DCM and cooled to 0 °C in 
an ice bath. Subsequent addition of DCC (23 mg, 0.11 mmol) was followed by stirring for 15 min, 
at which time ethyl (3S)-hydroxy-15-methylhexadecanoate, (3S)-19 ((28 mg, 0.089 mmol) was 
added, along with a catalytic amount of DMAP.  The reaction was equilibrated to ambient 
temperature slowly and stirred overnight.  Evaporation of solvents in vacuo was followed by 
addition of 15 mL of EtOAc and washing with H2O 3 X 10 mL and 10 mL of satd brine.   The 
resulting organic layer was dried over MgSO4, filtered, and the solvents removed at reduced 
pressure.  Subsequent purification via column chromatography (1-10% EtOAc:hexanes) yielded 
ethyl  (R)-15-methyl-3-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)hexadecanoate as 
a clear oil (45 mg, 0.084 mmol, 94 %).  1H NMR (400 MHz, CDCl3) δ 7.50-7.55 (m, 2H), 7.37-
7.42 (m, 3H), 5.48 (quin, J = 6.3 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.55 (s, 3H), 2.69 (dd, J = 16.0, 
8.0 Hz, 1H), 2.59 (dd, J= 16.0, 4.8 Hz, 1H), 1.70-1.57 (m, 2H), 1.52 (sep, J = 6.6 Hz, 1H), 1.36-
1.12 (m, 23H), 0.86 (d, J = 6.6 Hz, 6H). 
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3-Hydroxy-15-methylhexadecanoic acid, ((rac)-20) 
 
 Hydroxy ester 19 (2.674 g, 0.0085 mol) was dissolved in 8 mL of MeOH and 16 mL of 
THF and 1 M aqueous LiOH (9.40 mL, 0.0094 mol) were added.  The mixture was stirred 
overnight at ambient temperature.  The reaction was then acidified with 1 M HCl and extracted 
with EtOAc (3 X 50 mL).  The organic layers were washed with 25 mL of brine, dried with MgSO4, 
filtered, and the solvents were removed at reduced pressure.  The crude solid was recrystallized 
from hexanes to yield 3-hydroxy-15-methylhexadecanoic acid,37 (3R+3S)-20, as a white solid 
(2.257 g, 0.0079 mol, 92.7 %), MP, 54-56 °C.  1H NMR (400 MHz, CDCl3) δ 4.09–3.98 (m, 1H), 
2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–1.43 (m, 3H), 1.35-1.20 (m, 
18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 177.4, 
68.1, 41.2, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.6, 29.5, 28.0, 27.5, 25.5, 22.7. 
 
3(R)-Hydroxy-15-methylhexadecanoic acid, ((3R)-20) 
 
 Hydroxy ester (3R)-19 (0.818 g, 0.0026 mol) was dissolved in 8 mL of methanol and 16 
mL of THF and 1 M aqueous LiOH (2.9 mL, 0.0029 mol) were added.  The mixture was stirred 
overnight at ambient temperature.  The reaction was then acidified with 1 M HCl and extracted 
with EtOAc (3 X 50 mL).  The organic layers were washed with 25 mL of brine, dried with MgSO4, 
filtered, and the solvents were removed at reduced pressure.  The crude solid was recrystallized 
from hexanes to yield (3R)-3-hydroxy-15-methylhexadecanoic acid,37 (3R)-20, as a white solid 
45 
 
(0.708 g, 0.0024 mol, 92 %), [α]D23 –10.5° (c 1.0, CHCl3), MP, 54-55 °C.  1H NMR (400 MHz, 
CDCl3) δ 4.09–3.98 (m, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–
1.43 (m, 4H), 1.35-1.20 (m, 18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 177.8, 68.1, 41.1, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.5, 28.0, 27.5, 25.5, 
22.7. 
 
3(S)-Hydroxy-15-methylhexadecanoic acid, ((3S)-20) 
 
 Hydroxy ester (3S)-19 (0.815 g, 0.0026 mol) was dissolved in 8 mL of methanol and 16 
mL of THF and 1 M aqueous LiOH (2.9 mL, 0.0029 mol) were added.  The mixture was stirred 
overnight at ambient temperature.  The reaction was then acidified with 1 M HCl and extracted 
with EtOAc (3 X 50 mL).  The organic layers were washed with 25 mL of brine, dried with MgSO4, 
filtered, and the solvents were removed at reduced pressure.  The crude solid was recrystallized 
from hexanes to yield (3S)-3-hydroxy-15-methylhexadecanoic acid,37 (3S)-20, as a white solid 
(0.679 g, 0.0024 mol, 92 %), [ ]
D
23
 +14.5° (c 1.0, CHCl3), MP, 54-55 °C.  
1H NMR (400 MHz, 
CDCl3) δ 4.09–3.98 (m, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.59–
1.43 (m, 4H), 1.35-1.20 (m, 18H), 1.15 (q, J = 6.7 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR 
(101 MHz, CDCl3) δ 177.3, 68.1, 41.0, 39.1, 36.6, 30.0, 29.8, 29.7, 29.6, 29.5, 28.0, 27.5, 25.5, 
22.7. 
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Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate, ((rac)-12) 
 
 N-Hydroxysuccinimide (116 mg, 1.00 mmol) and dicyclohexylcarbodiimide (DCC, 216 
mg, 1.05 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid (20, 
250 mg, 0.873 mmol) in 10 mL of dry THF.  The solution was stirred for 5 h at ambient 
temperature, filtered, and the filtrate was concentrated in vacuo.  The resulting white solid was 
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N-
(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 598 mg, 1.09 mmol) 
and Pd/C (176 mg) in 10 mL of dioxane.  The reaction vessel was flushed with H2 and the mixture 
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude 
product was purified via column chromatography (2% MeOH:DCM) to yield methyl O-(tert-
butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R+3S)-L-serine-
12, as a clear oil (0.478 g, 0.700 mmol, 80.2%).  1H NMR (400 MHz, CDCl3) δ 7.62-7.55 (m, 4H), 
7.49–7.34 (m, 6H), two signals [6.86 and 6.99 (d, J= 7.0 and 8.1 Hz, 1H)], two signals [6.34 and 
6.56 (d, J= 5.4 and 5.6 Hz, 1H), 4.67 (dt, J = 8.2, 3.0 Hz, 1H), 4.17–4.06 (m, 2H), 4.04–3.82 (m, 
3H), 3.82–3.71 (m, 4H), 2.40 (dt, J = 14.7, 2.2 Hz, 1H), 2.26 (dd, J = 14.5, 9.4 Hz, 1H), 1.57-1.35 
(m, 4H), 1.35-1.18 (m, 18H), 1.16 (dd, J = 13.6, 7.8 Hz, 2H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ 172.9, 172.8, 170.8, 168.9, 168.7, 135.5, 135.5, 132.9, 132.9, 
132.7, 132.6, 130.0, 127.9, 127.9, 68.9, 68.9, 64.2, 54.3, 52.6, 43.1, 43.0, 43.0, 42.8, 39.1, 37.1, 
30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3. HRMS (AccuTOF): [MH]+ Calc’d 
for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4470. 
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Methyl O-(tert-butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate, ((3R)-12)  
 
 N-Hydroxysuccinimide (96 mg, 0.830 mmol) and dicyclohexylcarbodiimide (DCC, 188 
mg, 0.913 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid 
(3R)-20, 159 mg, 0.554 mmol) in 10 mL of dry THF.  The solution was stirred for 5 h at ambient 
temperature, filtered, and the filtrate was concentrated in vacuo.  The resulting white solid was 
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N-
(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 349 mg, 0.637 mmol) 
and Pd/C (122 mg) in 10 mL of dioxane.  The reaction vessel was flushed with H2 and the mixture 
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude 
product was purified via column chromatography (2% MeOH:DCM) to yield O-(tert-
butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R)-L-serine-12 
as a clear oil (0.279 g, 0.405 mmol, 73.6%) 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.54 (m, 4H), 
7.49 – 7.35 (m, 6H), 6.89 (d, J = 8.1 Hz, 1H), 6.39 (t, J = 5.6 Hz, 1H), 4.67 (dt, J = 8.2, 2.9 Hz, 
1H), 4.18 – 4.06 (m, 2H), 3.97 (s, 1H), 3.94 – 3.77 (m, 2H), 3.75 (s, 3H), 3.36 (d, J = 3.6 Hz, 1H), 
2.41 (dd, J = 14.6, 2.6 Hz, 1H), 2.27 (dd, J = 14.6, 9.4 Hz, 1H), 1.56 – 1.34 (m, 4H), 1.34 – 1.20 
(m, 18H), 1.19 – 1.13 (m, 2H), 1.04 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ 172.8, 170.7, 168.6, 135.6, 135.5, 132.9, 132.6, 130.1, 128.0, 127.9, 77.4, 77.1, 76.8, 68.9, 64.3, 
54.3, 52.6, 43.1, 42.9, 39.1, 37.2, 30.0, 29.8, 29.7, 29.6, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3. 
HRMS (AccuTOF): [MH]+ Calc’d for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4434. 
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Methyl O-(tert-butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate, ((S)-12) 
 
 N-Hydroxysuccinimide (87 mg, 0.752 mmol) and dicyclohexylcarbodiimide (DCC, 171 
mg, 0.827 mmol) were added to a stirring solution of 3-hydroxy-15-methylhexadecanoic acid 
((3S)-20, 144 mg, 0.501 mmol) in 10 mL of dry THF.  The solution was stirred for 5 h at ambient 
temperature, filtered, and the filtrate was concentrated in vacuo.  The resulting white solid was 
dissolved in 5 mL of dioxane and this solution was added via cannula to a solution of methyl N-
(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate (14, 316 mg, 0.576 mmol) 
and Pd/C (111 mg) in 10 mL of dioxane.  The reaction vessel was flushed with H2 and the mixture 
was stirred overnight, filtered through Celite, and concentrated under reduced pressure. The crude 
product was purified via column chromatography (2% MeOH:DCM) to yield O-(tert-
butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3S)-L-serine-12 
as a clear oil (0.261 g, 0.382 mmol,  76.0%) 1H NMR (400 MHz, CDCl3) δ 7.64 – 7.54 (m, 4H), 
7.49 – 7.34 (m, 6H), 6.86 (d, J = 7.0 Hz, 1H), 6.34 (d, J = 5.4 Hz, 1H), 4.67 (dt, J = 8.2, 3.0 Hz, 
1H), 4.13 (dd, J = 10.4, 2.9 Hz, 1H), 4.03 – 3.81 (m, 4H), 3.74 (s, 3H), 3.53 – 3.44 (m, 1H), 2.40 
(dd, J = 14.6, 2.6 Hz, 1H), 2.26 (dd, J = 14.7, 9.5 Hz, 1H), 1.57 – 1.36 (m, 4H), 1.35 – 1.20 (m, 
18H), 1.20 – 1.11 (m, 2H), 1.04 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 
172.8, 170.7, 168.5, 135.6, 133.0, 132.7, 130.1, 127.9, 127.9, 77.4, 77.1, 76.7, 68.9, 64.3, 54.3, 
52.6, 43.0, 42.8, 39.1, 37.2, 30.0, 29.8, 29.7, 29.7, 29.6, 28.0, 27.5, 26.8, 25.5, 22.7, 19.3. HRMS 
(AccuTOF): [MH]+ Calc’d for C39H63N2O6Si m/z 683.4455. Found: m/z 683.4435. 
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Methyl (3-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((rac)-21) 
 
 Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate ((3R+3S)-L-serine-12, 162 mg, 0.237 mmol) was dissolved in 5 mL of dry THF under 
nitrogen.  The solution was cooled to 0°C and was treated with 1 M tetrabutylammonium fluoride 
(TBAF, 0.26 mL, 0.261 mmol).  The reaction was slowly warmed to ambient temperature and 
stirred for 6 h.  The solvent was removed under reduced pressure, and the resulting oil was purified 
by column chromatography (2.5 % MeOH:DCM) to yield methyl (3-hydroxy-15-
methylhexadecanoyl)glycyl-L-serinate, (3R+3S)-21, as a white solid, (101 mg, 0.227 mmol, 95.8 
%), MP, 105-107 °C.  1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 7.6 Hz, 1H), 7.20 – 7.11 (m, 
1H), 4.67 – 4.58 (m, 1H), 4.12 (dd, J = 16.9, 6.2 Hz, 1H), 4.03 – 3.83 (m, 5H), 3.76 (s, 3H), 2.44 
(dd, J = 14.0, 2.4 Hz, 1H), 2.30 (dd, J = 14.1, 9.7 Hz, 1H), 1.60 – 1.05 (m, 23H), 0.86 (d, J = 6.6 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.4, 173.3, 171.2, 171.0, 169.6, 77.4, 77.1, 76.7, 69.6, 
62.6, 54.9, 52.8, 43.7, 43.2, 39.1, 37.5, 30.0, 29.8, 29.8, 29.7, 29.6, 28.0, 27.5, 25.7, 22.7. HRMS 
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3307. 
 
Methyl (3(R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((R)-21) 
 
 Methyl O-(tert-butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate ((3R)-L-serine-12, 276 mg, 0.403 mmol) was dissolved in 5 mL of dry THF under nitrogen.  
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The solution was cooled to 0 °C and was treated with 1 M tetrabutylammonium fluoride (TBAF, 
0.44 mL, 0.444 mmol).  The reaction was slowly warmed to ambient temperature and stirred for 6 
h.  The solvent was removed under reduced pressure, and the resulting oil was purified by column 
chromatography (2.5 % MeOH:DCM) to yield methyl (3R-hydroxy-15-
methylhexadecanoyl)glycyl-L-serinate, (3R)-L-serine-21, as a white solid, (129 mg, 0.289 mmol, 
71.6 %), MP, 100-104 °C. 1H NMR (500 MHz, CDCl3) δ 7.56 (d, J = 7.8 Hz, 1H), 7.00 (t, J = 5.9 
Hz, 1H), 4.73 – 4.65 (m, 1H), 4.19 (dd, J = 16.9, 6.3, 2.1 Hz, 1H), 4.12-4.04 (m, 1H), 4.04 – 3.86 
(m, 3H), 3.82 (s, 3H), 2.50 (dt, J = 14.1, 2.6 Hz, 1H), 2.40 – 2.30 (m, 1H), 1.63 – 1.44 (m, 4H), 
1.44 – 1.23 (m, 18H), 1.19 (q, J = 6.8 Hz, 2H), 0.91 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.31, 171.10, 169.40, 77.27, 77.02, 76.76, 69.56, 62.71, 54.85, 52.80, 43.67, 43.30, 
39.08, 37.43, 29.97, 29.75, 29.70, 29.63, 29.54, 27.98, 27.44, 25.62, 25.56, 22.67. HRMS 
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3285. 
 
Methyl (3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate, ((S)-21) 
 
 Methyl O-(tert-butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-
serinate ((3S)-L-serine-12, 216 mg, 0.316 mmol) was dissolved in 5 mL of dry THF under nitrogen.  
The solution was cooled to 0°C and was treated with 1 M tetrabutylammonium fluoride (TBAF, 
0.35 mL, 0.347 mmol).  The reaction was slowly warmed to ambient temperature and stirred for 6 
h.  The solvent was removed under reduced pressure, and the resulting oil was purified by column 
chromatography (2.5 % MeOH:DCM) to yield methyl (3S-hydroxy-15-
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methylhexadecanoyl)glycyl-L-serinate, (3S)-L-serine-21, as a white solid, (96 mg, 0.216 mmol, 
68.4 %), MP, 109-111 °C. 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J= 7.4 Hz, 1H), 6.88-6.78 (m, 
1H), 4.65 (dt, J = 7.3, 3.4 Hz, 1H), 4.21 – 4.10 (m, 1H), 4.04 (s, 1H), 3.98 – 3.92 (m, 2H), 3.92 – 
3.80 (m, 2H), 3.78 (s, 3H), 2.45 (dt, J = 13.9, 2.5 Hz, 1H), 2.35 – 2.26 (m, 1H), 1.56 – 1.45 (m, 
3H), 1.29 – 1.23 (m, 18H), 1.15 (q, J = 6.8 Hz, 2H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ 173.16, 170.90, 169.43, 77.28, 77.02, 76.77, 69.27, 62.83, 62.80, 54.86, 54.81, 52.84, 
43.51, 43.26, 39.09, 37.25, 29.97, 29.75, 29.70, 29.63, 29.53, 28.00, 27.45, 25.60, 22.68. HRMS 
(AccuTOF): [MH]+ Calc’d for C23H45N2O6 m/z 445.3278. Found: m/z 445.3242. 
 
 (3-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((rac)- 1) 
 
 A solution of 0.96 M LiOH (0.49 mL, 0.466 mmol) was added to a solution of methyl (3-
hydroxy-15-methylhexadecanoyl)glycyl-L-serinate ((3R+3S)-L-serine-21, 189 mg, 0.424 mmol) in 
2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added.  The resulting 
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized 
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X 
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was 
recrystallized from hot EtOAc to yield (3-hydroxy-15-methylhexadecanoyl)glycyl-L-serine, 
(3R+3S)-L-serine-1, as a crystalline solid (177 mL, 0.412 mmol, 97.1 %), MP, 117-120 °C. 1H 
NMR 1H NMR (400 MHz, Methanol-d4) δ 4.49 and 4.51 (two s, 1H), 4.11 (d, J= 17.3 Hz, 1H), 
4.04 – 3.86 (m, 2H), 3.85 – 3.74 (m, 2H), 3.66 (d, J= 17.0 Hz, 1H), 3.37 – 3.29 (m, 1H), 2.41 – 
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2.33 (m, 1H), 2.27 – 2.19 (m, 1H), 1.53 – 1.34 (m, 4H), 1.34 – 1.14 (m, 18H), 1.09 (q, J = 7.1, 6.7 
Hz, 2H), 0.80 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CD3OD+CDCl3) δ 173.79, 173.58, 172.23, 
172.09, 169.65, 169.56, 77.38, 77.06, 76.74, 69.24, 68.90, 62.14, 62.04, 54.69, 54.56, 49.83, 49.62, 
49.40, 49.19, 48.97, 48.76, 48.55, 43.48, 43.29, 42.87, 42.77, 38.99, 37.44, 37.17, 29.87, 29.65, 
29.60, 29.54, 29.47, 27.89, 27.34, 25.48, 25.43, 22.54. HRMS (AccuTOF): [MH]+ Calc’d for 
C22H43N2O6 m/z 431.3121. Found: m/z 431.3131. 
 
(3(R)-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((R)-1) 
 
 A solution of 0.51 M LiOH (0..33 mL, 0.168 mmol) was added to a solution of methyl 
(3R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate ((3R)-L-serine-21, 68 mg, 0.153 mmol) 
in 2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added.  The resulting 
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized 
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X 
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was 
recrystallized from hot EtOAc to yield (3(R)-hydroxy-15-methylhexadecanoyl)glycyl-L-serine, 
(3R)-L-serine-1, as a crystalline solid (44 mg, 0.102 mmol, 66.7 %), MP, 122-126 °C. 1H NMR 
(500 MHz, CDCl3) δ 4.53 (s, 1H), 4.15 (d, J = 16.8 Hz, 1H), 3.95 (s, 1H), 3.68 (d, J = 16.9 Hz, 
1H), 3.31 (d, 25.0 Hz, 1H), 2.38 (d, J = 13.7 Hz, 1H), 2.24 (t, J = 12.1 Hz, 1H), 1.60 – 1.42 (m, 
3H), 1.40 – 1.20 (m, 18H), 1.13 – 1.09 (m, 2H), 0.82 (d, 6H). 13C NMR (126 MHz, CDCl3) δ 
173.74, 172.42, 169.59, 77.31, 77.06, 77.06, 76.80, 69.32, 62.23, 55.93, 43.54, 42.96, 39.04, 37.47, 
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29.92, 29.69, 29.65, 29.58, 29.51, 27.94, 27.39, 25.48, 22.65, 22.60. HRMS (AccuTOF): [MH]+ 
Calc’d for C22H43N2O6 m/z 431.3121. Found: m/z 431.3131. 
 
(3(S)-Hydroxy-15-methylhexadecanoyl)glycyl-L-serine, ((S)-1) 
 
 A solution of 0.51 M LiOH (0.40 mL, 0.203 mmol) was added to a solution of methyl 
(3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serinate (3S)-L-serine-21, 82 mg, 0.184 mmol) in 
2 mL of methanol at 0 °C, and 4 mL of tetrahydrofuran was subsequently added.  The resulting 
solution was warmed to ambient temperature and stirred for 2 h. The solution was then neutralized 
with 10% HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X 
25 mL) and the organic layers were concentrated in vacuo. The resulting crude material was 
recrystallized from hot EtOAc to yield (3(S)-hydroxy-15-methylhexadecanoyl)glycyl-L-serine, 
(3S)-L-serine-1, as a crystalline solid (59 mg, 0.137 mmol, 74.6 %), MP, 109-111 °C. 1H NMR 
(400 MHz, CDCl3) δ 4.53 (s, 1H), 4.13 (d, J = 16.9 Hz, 1H), 3.94 (d, J = 11.6 Hz, 2H), 3.82 (d, J 
= 11.6 Hz, 1H), 3.76 – 3.64 (m, 2H), 2.38 (d, J = 13.8 Hz, 1H), 2.24 (t, J = 12.0 Hz, 1H), 1.21 (s, 
17H), 1.11 (s, 2H), 0.82 (d, J = 6.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.77, 172.35, 169.54, 
77.37, 77.06, 76.74, 69.31, 62.20, 54.59, 43.53, 42.91, 39.02, 37.47, 29.90, 29.68, 29.63, 29.56, 
29.49, 27.92, 27.38, 25.46, 22.59. HRMS (AccuTOF): [MH]+ Calc’d for C22H43N2O6 m/z 
431.3121. Found: m/z 431.3131. 
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6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silahexacosan-13-yl 13-methyltetradecanoate, ((rac)-22) 
 
 13-Methyltetradecanoic acid (35 mg, 0.156 mmol) was dissolved in 5 mL of dry DCM and 
stirred at 0 °C. To the solution was then treated with DCC (32 mg, 0.156 mmol), HOBt (21 mg, 
0.156 mmol), and a catalytic amount of DMAP.  After stirring for 15 min, methyl O-(tert-
butyldiphenylsilyl)-N-((3-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, ((3R+3S)-12, 98 
mg, 0.142 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula.  The 
resulting solution was warmed to ambient temperature and stirred overnight.  The solvent was 
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.  
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL).  The 
organic layer was dried, filtered, and solvents evaporated under reduced pressure.  Purification via 
column chromatography (1% MeOH:DCM) yielded 6-(methoxycarbonyl)-2,2,25-trimethyl-8,11-
dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, (3R+3S)-L-
serine-22, as a clear oil (124 mg, 0.137 mmol, 96.3%). 1H NMR (400 MHz, CDCl3) δ 7.58 (tt, J = 
6.8, 1.6 Hz, 4H), 7.49–7.34 (m, 6H), 6.54 (dd, J = 8.1, 5.2 Hz, 1H), 6.36 (t, J= 4.6 Hz, 1H),  5.16 
(quin, J = 6.3 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.02–3.81 (m, 3H), 3.74 
(s, 3H), 2.55–2.42 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.70-1.59 (m, 4H), 1.50 (sep, J = 6.6 Hz, 2H), 
1.37-1.20 (m, 36H), 1.15 (q, J = 7.1, 6.7 Hz, 4H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR 
(101 MHz, CDCl3) δ 173.41, 170.44, 170.40, 169.95, 168.24, 135.55, 135.51, 132.83, 132.80, 
132.64, 130.10, 130.05, 127.96, 127.87, 77.38, 77.06, 76.74, 71.10, 64.15, 54.25, 52.56, 42.88, 
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41.42, 39.11, 34.55, 34.17, 30.00, 29.77, 29.73, 29.61, 29.56, 29.41, 29.35, 29.20, 28.02, 27.47, 
26.77, 25.31, 25.05, 22.71, 19.30.   HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z 
907.6596. Found: m/z 907.6557. 
 
(6S,13R)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-
3-silahexacosan-13-yl 13-methyltetradecanoate, ((R)-22) 
 
 13-Methyltetradecanoic acid (77 mg, 0.316 mmol) was dissolved in 5 mL of dry DCM and 
stirred at 0 °C. To the solution was then treated with DCC (78 mg, 0.380 mmol), HOBt (58 mg, 
0.379 mmol), and a catalytic amount of DMAP.  After stirring for 15 min, methyl O-(tert-
butyldiphenylsilyl)-N-((3R-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3R)-L-serine-12 
(178 mg, 0.261 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula.  The 
resulting solution was warmed to ambient temperature and stirred overnight.  The solvent was 
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.  
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL).  The 
organic layer was dried, filtered, and solvents evaporated under reduced pressure.  Purification via 
column chromatography (1% MeOH:DCM) yielded (6S,13R)-6-(methoxycarbonyl)-2,2,25-
trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl 13-
methyltetradecanoate, (3R)-L-serine-22 as a clear oil (231 mg, 0.255 mmol, 97.7%).  1H NMR (400 
MHz, CDCl3) δ 7.58 (t, J = 6.6 Hz, 4H), 7.49 – 7.34 (m, 6H), 6.53 (d, J = 8.1 Hz, 1H), 6.36 (t, J= 
4.6 Hz, 1H), 5.16 (d, J = 24.6 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.00 – 
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3.82 (m, 3H), 3.74 (s, 3H), 2.55 – 2.43 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.70 – 1.55 (m, 4H), 1.50 
(sep, J = 6.6 Hz, 2H), 1.25 (s, 36H), 1.15 (q, J = 7.1, 6.7 Hz, 4H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 
12H). 13C NMR (101 MHz, CDCl3) δ 173.43, 170.42, 169.96, 168.23, 135.56, 135.52, 132.83, 
132.65, 130.10, 130.05, 127.96, 127.87, 77.38, 77.06, 76.74, 71.10, 64.15, 54.28, 52.57, 42.87, 
41.43, 39.12, 34.55, 34.17, 30.00, 29.78, 29.73, 29.62, 29.57, 29.42, 29.35, 29.21, 28.02, 27.48, 
26.78, 25.32, 25.05, 22.71, 19.31, 1.07. HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z 
907.6596. Found: m/z 907.6586. 
 
(6S,13S)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silahexacosan-13-yl 13-methyltetradecanoate, ((S)-22) 
 
 13-Methyltetradecanoic acid (84 mg, 0.346 mmol) was dissolved in 5 mL of dry DCM and 
stirred at 0 °C. The solution was then treated with DCC (85 mg, 0.415 mmol), HOBt (64 mg, 0.418 
mmol), and a catalytic amount of DMAP.  After stirring for 15 min, methyl O-(tert-
butyldiphenylsilyl)-N-((3S-hydroxy-15-methylhexadecanoyl)glycyl)-L-serinate, (3S)-L-serine-12 
(189 mg, 0.277 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula.  The 
resulting solution was warmed to ambient temperature and stirred overnight.  The solvent was 
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.  
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL).  The 
organic layer was dried, filtered, and solvents evaporated under reduced pressure.  Purification via 
column chromatography (1% MeOH:DCM) yielded (6S,13S)-6-(methoxycarbonyl)-2,2,25-
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trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silahexacosan-13-yl 13-
methyltetradecanoate, (3S)-L-serine-22 as a clear oil (245 mg, 0.269 mmol, 97.4%). 1H NMR (400 
MHz, CDCl3) δ 7.63 – 7.54 (m, 4H), 7.48 – 7.34 (m, 6H), 6.53 (d, J = 8.1 Hz, 1H), 6.36 (t, J= 4.6 
Hz, 1H), 5.16 (d, J = 24.6 Hz, 1H), 4.69-4.62 (m, 1H), 4.12 (dd, J = 10.3, 2.9 Hz, 1H), 4.04 – 3.79 
(m, 2H), 3.73 (s, 3H), 2.57 – 2.41 (m, 2H), 2.28 (t, J = 7.5 Hz, 2H), 1.70-1.40 (m, 6H), 1.35-1.10 
(m, 40H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 173.40, 170.46, 
169.98, 168.31, 135.53, 135.49, 132.78, 132.62, 130.08, 130.02, 127.93, 127.85, 77.38, 77.06, 
76.74, 71.08, 64.13, 54.24, 52.52, 42.89, 41.37, 39.09, 34.53, 34.15, 29.98, 29.76, 29.71, 29.60, 
29.55, 29.39, 29.33, 29.19, 28.00, 27.45, 26.75, 26.69, 25.29, 25.03, 22.69, 22.63, 19.27, 1.05. 
HRMS (AccuTOF): [MH]+ Calc’d for C54H91N2O7Si m/z 907.6596. Found: m/z 907.6583. 
 
1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-
oxohexadecan-3-yl 13-methyltetradecanoate, ((rac)-23) 
 
 6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silahexacosan-13-yl 13-methyltetradecanoate ((3R+3S)-L-serine-22, 197 mg, 0.217 mmol) was 
dissolved in 5 mL of dry THF under nitrogen.  The solution was cooled to 0 °C and was treated 
with 1 M TBAF (0.24 mL, 0.24 mmol).  The reaction was slowly warmed to ambient temperature 
and stirred for 6 h.  The solvent was removed under reduced pressure, and the resulting oil was 
purified by column chromatography (2% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1-methoxy-
1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-
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methyltetradecanoate, (3R+3S)-L-serine-23, as a clear oil (132 mg, 0.202 mmol, 93.1 %).  1H NMR 
(400 MHz, CDCl3) δ two signals [7.05 and 7.12 (d, J= 7.6 and 7.8 Hz, 1H), 6.74 – 6.64 (m, 1H), 
5.26 – 5.11 (m, 1H), 4.65 (h, J = 7.7, 3.8 Hz, 1H), 4.08 – 3.87 (m, 4H), 3.78 (d, J = 1.9 Hz, 3H), 
2.52 – 2.45 (m, 2H), 2.30 (td, J = 7.6, 1.7 Hz, 2H), 1.68 – 1.43 (m, 6H), 1.40 – 1.20 (m, 36H), 1.15 
(t, J = 6.6 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3) δ 174.45, 174.28, 
170.92, 170.80, 170.70, 169.05, 169.01, 77.38, 77.06, 76.74, 71.46, 62.82, 55.05, 52.72, 43.32, 
41.91, 41.81, 39.12, 39.08, 34.60, 34.56, 34.50, 30.01, 29.78, 29.74, 29.70, 29.62, 29.57, 29.40, 
29.33, 29.22, 29.19, 28.02, 27.48, 25.31, 25.06, 25.01, 22.71. HRMS (AccuTOF): [MH]+ Calc’d 
for C38H73N2O7 m/z 669.5418. Found: m/z 669.5425. 
 
(R)-1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-
methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((R)-23) 
 
 (6S,13R)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-
diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, ((3R)-L-serine-22, 231 mg, 0.255 mmol) 
was dissolved in 5 mL of dry THF under nitrogen.  The solution was cooled to 0 °C and was treated 
with 1 M TBAF (0.25 mL, 0.25 mmol).  The reaction was slowly warmed to ambient temperature 
and stirred for 6 h.  The solvent was removed under reduced pressure, and the resulting oil was 
purified by column chromatography (2% MeOH:DCM) to yield ((R)-1-((2-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-
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methyltetradecanoate, (3R)-L-serine-23, as a clear oil (153 mg, 0.229 mmol, 89.9 %) 1H NMR (400 
MHz, CDCl3) δ 7.12 (d, J= 7.7 Hz, 1H), 6.45 (t, J = 5.5 Hz, 1H), 5.25-5.10 (m, 1H), 4.67 (dq, J = 
7.1, 3.5 Hz, 1H), 4.13-3.87 (m, 4H), 3.79 (s, 3H), 2.49 (d, J = 6.1 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 
1.69 – 1.44 (m, 6H), 1.38-1.20 (m, 36H), 1.15 (q, J = 6.7 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C 
NMR (101 MHz, CDCl3) δ 174.56, 170.70, 170.65, 168.95, 77.38, 77.06, 76.74, 71.54, 62.99, 
55.01, 52.77, 43.43, 42.06, 39.12, 34.62, 30.01, 29.78, 29.74, 29.62, 29.56, 29.38, 29.33, 29.19, 
28.03, 27.48, 25.32, 25.06, 25.01, 22.72.  HRMS (AccuTOF): [MH]+ Calc’d for C38H73N2O7 m/z 
669.5418. Found: m/z 669.5389. 
 
(S)-1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-
methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, , ((S)-23)  
 
 (6S,13S)-6-(Methoxycarbonyl)-2,2,25-trimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-
diaza-3-silahexacosan-13-yl 13-methyltetradecanoate, ((3S)-L-serine-22, 245 mg, 0.269 mmol) 
was dissolved in 5 mL of dry THF under nitrogen.  The solution was cooled to 0 °C and was treated 
with 1 M TBAF (0.27 mL, 0.27 mmol).  The reaction was slowly warmed to ambient temperature 
and stirred for 6 h.  The solvent was removed under reduced pressure, and the resulting oil was 
purified by column chromatography (2% MeOH:DCM) to yield ((S)-1-((2-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-
methyltetradecanoate, (3S)-L-serine-23, as a clear oil (164 mg, 0.245 mmol, 90.8 %) 1H NMR (400 
MHz, CDCl3) δ 7.05 (d, J= 7.6 Hz, 1H), 6.49 (t, J = 5.3 Hz, 1H), 5.26-5.10 (m, 1H), 4.70 – 4.61 
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(m, 1H), 4.13 – 3.88 (m, 4H), 3.79 (s, 3H), 2.49 (d, J = 5.9 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.72 
– 1.44 (m, 6H), 1.43 – 1.19 (m, 36H), 1.15 (q, J = 6.7 Hz, 4H), 0.86 (d, J = 6.6 Hz, 12H). 13C NMR 
(101 MHz, CDCl3) δ 174.38, 170.79, 170.61, 168.94, 77.38, 77.06, 76.74, 71.54, 62.92, 55.02, 
52.76, 43.43, 41.94, 39.12, 34.63, 34.55, 30.01, 29.79, 29.74, 29.62, 29.57, 29.38, 29.34, 29.22, 
28.03, 27.48, 25.32, 25.06, 22.72. HRMS (AccuTOF): [MH]+ Calc’d for C38H73N2O7 m/z 
669.5418. Found: m/z 669.5395. 
 
(15-Methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((rac)-2) 
 
 A stirring solution of 1-((2-(3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate ((3R+3S)-L-serine-23, 
119 mg, 0.178 mmol), in 10 mL of dry DCM, was cooled to 0 °C.  Potassium trimethylsilonoate 
(25 mg, 0.196 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being 
warmed to ambient temperature and stirred for an additional 1.5 hrs.  The solvents were evaporated 
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with 
10% HCl.  The resulting precipitate was filtered to yield 15-methyl-3-((13-
methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3R+3S)-L-serine-2, as a white sticky 
solid (105 mg, 0.161 mmol, 90.2%). 1H NMR (500 MHz, CDCl3) δ 5.17 (bs, 1H), 4.27 (bs, 1H), 
4.12-3.50 (s, 5H), 1.67 – 1.41 (m, 6H), 1.40-1.20 (m, 36H), 1.12 (t, J = 6.6 Hz, 4H), 0.83 (d, J = 
6.6 Hz, 12H). 13C NMR (126 MHz, CDCl3) δ 174.04, 171.67, 169.92, 77.32, 77.06, 76.81, 71.21, 
62.26, 55.95, 42.78, 41.09, 39.07, 34.58, 34.33, 31.91, 29.98, 29.76, 29.70, 29.67, 29.60, 29.52, 
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29.38, 29.22, 27.96, 27.44, 25.28, 25.07, 22.63. HRMS (+TOF MS): [MNa]+ Calc’d for 
C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081. 
 
((R)-15-methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((R)-2) 
 
 A stirring solution of 1(R)-1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((3R)-L-serine-23, 25 
mg, 0.037 mmol) in 10 mL of dry DCM was cooled to 0 °C.  Potassium trimethylsilonoate (5.3 
mg, 0.051 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being 
warmed to ambient temperature and stirred for an additional 1.5 hrs.  The solvents were evaporated 
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with 
10% HCl.  The resulting precipitate was filtered to yield ((R)-15-methyl-3-((13-
methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3R)-L-serine-2, as a white sticky solid 
(18 mg, 0.028 mmol, 74%).  
23
D
  = +12.85° (c 1.02, CHCl3).  
1H NMR (400 MHz, CDCl3) δ 
5.15 (bs, 1H), 4.31 (bs, 1H), 4.11 – 3.44 (m, 4H), 2.47 (s, 2H), 2.24 (t, J = 7.5 Hz, 2H), 1.68 – 1.35 
(m, 6H), 1.35 – 0.99 (m, 36H), 0.81 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CD3OD+ CDCl3) 
δ 174.08, 173.94, 171.48, 169.54, 77.38, 77.06, 76.74, 71.08, 62.05, 49.39, 49.17, 48.96, 48.74, 
48.53, 48.32, 48.10, 42.63, 40.87, 38.89, 34.37, 34.09, 29.78, 29.56, 29.52, 29.48, 29.43, 29.37, 
29.26, 29.16, 29.00, 27.78, 27.25, 25.06, 24.87, 22.39. HRMS (+TOF MS): [MNa]+ Calc’d for 
C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081. 
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((S)-15-methyl-3-((13-methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, ((S)-2) 
 
 A stirring solution of 1(S)-1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
oxoethyl)amino)-15-methyl-1-oxohexadecan-3-yl 13-methyltetradecanoate, ((3S)-L-serine-23, 25 
mg, 0.037 mmol) in 10 mL of dry DCM was cooled to 0 °C.  Potassium trimethylsilonoate (5.3 
mg, 0.051 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being 
warmed to ambient temperature and stirred for an additional 1.5 hrs.  The solvents were evaporated 
under reduced pressure, and the resulting oil was dissolved in 10 mL of H2O and acidified with 
10% HCl.  The resulting precipitate was filtered to yield ((S)-15-methyl-3-((13-
methyltetradecanoyl)oxy)hexadecanoyl)glycyl-L-serine, (3S)-L-serine-2, as a white sticky solid 
(16 mg, 0.024 mmol, 65%).  
23
D
  = +6.3° (c 1.02, CHCl3).  
1H NMR (400 MHz, CDCl3) δ 5.16 
(t, J= 5.6 Hz, 1H), 4.29 (s, 1H), 4.10 – 3.60 (m, 4H), 2.56 – 2.35 (m, 2H), 2.23 (t, J = 7.5 Hz, 2H), 
1.65 – 1.40 (m, 6H), 1.40 – 0.99 (m, 40H), 0.81 (d, J = 6.6 Hz, 12H). 13C NMR (101 MHz, CDCl3) 
δ 174.03, 173.75, 171.50, 169.73, 77.38, 77.06, 76.74, 71.20, 62.24, 55.60, 50.01, 49.80, 49.58, 
49.37, 49.16, 48.94, 48.73, 42.74, 41.11, 39.04, 34.53, 34.33, 29.95, 29.73, 29.70, 29.66, 29.62, 
29.55, 29.46, 29.40, 29.33, 29.18, 27.93, 27.41, 25.24, 25.02, 22.60. HRMS (+TOF MS): [MNa]+ 
Calc’d for C37H70N2NaO7 m/z 677.5075. Found: m/z 677.5081. 
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((11-Bromoundecyl)oxy)(tert-butyl)dimethylsilane, (28) 
 
 A flame-dried 100 mL round bottom flask was charged with 11-bromoundecan-1-ol (2.00 
g, 7.96 mmol).  The starting material was dissolved in CH2Cl2 (50 mL) and cooled on an ice bath.  
tert-Butyldimethylsilyl chloride (1.40 g, 9.15 mmol) was added and stirred for 15 min before the 
addition of imidazole (0.705 g, 10.4 mmol). The reaction was stirred overnight at room 
temperature. Upon completion the suspension was gravity filtered and concentrated under reduced 
pressure. The crude product was purified by column chromatography on silica gel (5% 
EtOAc:hexane) to yield ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane,57 28, as a clear liquid 
(2.85 g, 7.78 mmol, 97.7%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H), 3.41 (t, J = 
6.9 Hz, 2H), 1.85 (p, J = 7.0 Hz, 2H), 1.51 (t, J = 6.8 Hz, 2H), 1.42 (t, J = 7.4 Hz, 2H), 1.28 (s, 
12H), 0.90 (s, 9H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 63.38, 34.09, 32.94, 32.91, 29.63, 
29.53, 29.47, 28.82, 28.24, 26.05, 25.85, 18.44, -5.19. ppm HRMS (AccuTOF): [MH]+ Calc’d for 
C17H37BrOSi m/z 365.1875. Found: m/z 365.1869. 
 
1-Bromobutane 
 
 A solution of 48% HBr (2.50 g) was added to a flame dried 25 mL round bottomed flask. 
Dropwise addition of H2SO4 (0.40 mL) was followed by stirring until the flask was cool to the 
touch.  Dropwise addition of butan-1-ol (1.00 g, 13.5 mmol) was followed by treatment with 
H2SO4 (0.35 mL).  A reflux condenser was attached and the solution was heated for 3 h. A vacuum 
distillation apparatus was set up through the top of the original reflux condenser. The product was 
gently vacuum-distilled into an ice-chilled flask while the vertical condenser was slowly warmed. 
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The distillate was dried over CaCO3 to yield 1-bromobutane
58 as a clear liquid (1.13 g, 8.25 mmol, 
61%). 1H NMR (400 MHz, CDCl3) δ 3.42 (t, J = 6.8 Hz, 2H), 1.84 (p, J = 6.9 Hz, 2H), 1.48 (hept, 
J = 7.5 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 34.83, 33.72, 21.37, 
13.23. 
 
d9-1-Bromobutane 
 
 A solution of 48% HBr (2.50 g) was added to a flame-dried 25 mL round bottomed flask. 
Dropwise addition of H2SO4 (0.40 mL) was followed by stirring until the flask was cool to the 
touch.  Dropwise addition of commercially available d9-butan-1-ol  (1.00 g, 12.0 mmol), was 
followed by addition of H2SO4 (0.35 mL).  A reflux condenser was attached and the solution was 
heated at reflux for 3 h.  A vacuum distillation apparatus was set up through the top of the original 
reflux condenser. The product was gently vacuum distilled into an ice-chilled flask while the 
vertical condenser was slowly warmed. The distillate was dried over CaCO3 to yield d9-1-
bromobutane59 as a clear liquid (0.99 g, 6.78 mmol, 56.4%). 
 
tert-Butyldimethyl(pentadecyloxy)silane, (29) 
 
 Magnesium turnings (33 mg, 1.37 mmol) were added to a 25 mL round bottomed flask that 
was fitted with a stirbar and the apparatus was flame-dried under a nitrogen atmosphere.  After 
cooling, the Mg turnings were suspended in dry THF (5 mL) and 1-bromobutane (0.13 mL, 1.20 
mmol) was rapidly added with vigorously stirring.  The reaction was stirred until the flask cooled 
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to ambient temperature and the flask was subsequently chilled to 0 °C. The Grignard reagent was 
added to a mixture of ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane (28, 0.250 g,0.684 
mmol), LiCl (0.88 mg, 0.021 mmol), copper (II) chloride (2.8 mg, 0.021 mmol), and N-methyl-2-
pyrrolidone (NMP, 0.30 mL, 3.11 mmol) dissolved in THF (5 mL) and held at 0 °C.  The mixture 
was slowly warmed to ambient temperature and stirred for 1 h. The reaction was quenched on ice 
with 1M HCl (10 mL) before being transferred to a separatory funnel with EtOAc (15 mL) and 
H2O (10 mL). The layers were separated and the aqueous layer was extracted once with EtOAc 
(15 mL).  The organic layers were combined and then washed with 1M HCl (10 mL), H2O (2 X 
10 mL), and brine (10 mL).  The organic phase was dried with MgSO4, gravity filtered, and 
solvents removed in vacuo. The crude product was purified by column chromatography on silica 
gel (hexane) to yield tert-butyldimethyl(pentadecyloxy)silane, 29, as a clear liquid (0.218 g,0.636 
mmol, 93.0%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H), 1.52 (d, J = 6.8 Hz, 2H), 
1.26 (s, 24H), 0.96–0.79 (m, 12H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 63.41, 32.97, 
31.99, 29.75, 29.72, 29.51, 29.42, 26.05, 25.87, 22.75, 14.18, -5.19. HRMS (AccuTOF): [MH]+ 
Calc’d for C21H46OSi m/z 343.3396. Found: m/z 343.3373. 
 
tert-Butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane, (37) 
 
 Magnesium turnings (133 mg, 5.48 mmol) were added to a 50 mL round bottom flask fitted 
with a stirbar and the apparatus was flame-dried under a nitrogen atmosphere.  After cooling, the 
Mg turnings were suspended in dry THF (10 mL) and d9-1-bromobutane (0.52 mL, 4.80 mmol) 
was rapidly added with vigorously stirring.  The reaction was stirred until the flask cooled to 
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ambient temperature and the temperature was lowered to 0 °C. The Grignard reagent was added 
to a mixture of ((11-bromoundecyl)oxy)(tert-butyl)dimethylsilane (28, 1.00 g, 2.74 mmol), LiCl 
(5.8 mg, 0.14 mmol), copper (II) chloride (9.2 mg, 0.069 mmol), and NMP (1.98 mL, 20.6 mmol) 
dissolved in THF (10 mL) and the reaction mixture was maintained at 0 °C.  The mixture was 
slowly warmed to ambient temperature and stirred for 1 h. The reaction was quenched on ice with 
1M HCl (25 mL) before being transferred to a separatory funnel with EtOAc (50 mL) and H2O 
(50 mL). The layers were separated and the aqueous layer was extracted once with EtOAc (50 
mL). The organic layers were combined and washed with 1M HCl (25 mL), H2O (2 X 25 mL), 
and brine (25 mL).  The organic phase was dried with MgSO4, gravity filtered, and solvents 
removed in vacuo. The crude product was purified by column chromatography on silica gel 
(hexane) to yield tert-butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane, 37,
 as 
a clear liquid (0.949 g, 2.69 mmol, 98.3%). 1H NMR (400 MHz, CDCl3) δ 3.60 (t, J = 6.6 Hz, 2H), 
1.51 (t, J = 6.8 Hz, 2H), 1.25 (s, 18H), 0.89 (s, 9H), 0.05 (s, 6H). 13C NMR (101 MHz, CDCl3) δ 
63.42, 32.96, 29.76, 29.72, 29.68, 29.52, 29.47, 26.05, 25.87, 18.44, -5.19. HRMS (AccuTOF): 
[MH]+ Calc’d for C21H37D9OSi m/z 352.3961. Found: m/z 352.3949. 
 
Pentadecan-1-ol, (30) 
 
 tert-Butyldimethyl(pentadecyloxy)silane (29, 678 mg, 1.98 mmol) was dissolved in 25 mL 
of dry THF under nitrogen.  The solution was cooled to 0 °C and was treated with 1 M TBAF (4.95 
mL, 4.95 mmol).  The reaction was slowly warmed to ambient temperature and stirred for 6 h.  
The solvent was removed under reduced pressure, and the resulting oil was purified by column 
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chromatography (15% EtOAc:Hexanes) to yield ethyl 3-hydroxyheptadecanoate,60 30, as a white 
solid (395 mg, 1.73 mmol, 87.4 %), MP 44-46 °C. 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.6 
Hz, 2H), 1.57 (t, J = 7.2, 6.7 Hz, 2H), 1.35–1.23 (m, 25H), 0.88 (t, J = 6.8 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 63.17, 32.88, 31.98, 29.74, 29.72, 29.66, 29.49, 29.41, 25.80, 22.75, 14.17. HRMS 
(AccuTOF): [M2H]+ Calc’d for C15H32O m/z 457.4985. Found: m/z 457.4998. 
 
Pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol, (38) 
 
 tert-Butyldimethyl((pentadecyl-12,12,13,13,14,14,15,15,15-d9)oxy)silane (37, 961 mg, 
2.73 mmol) was dissolved in 25 mL of dry THF under nitrogen.  The solution was cooled to 0 °C 
and was treated with 1 M TBAF (6.83 mL, 6.83 mmol).  The reaction was slowly warmed to 
ambient temperature and stirred for 6 h.  The solvent was removed under reduced pressure, and 
the resulting oil was purified by column chromatography (15% EtOAc:Hexanes) to yield 
pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol, 38, as a white solid (643 mg, 2.71 mmol, 99.1 %), 
MP 42-45 °C. 1H NMR (400 MHz, CDCl3) δ 3.64 (t, J = 6.6 Hz, 2H), 1.57 (p, J = 6.9 Hz, 2H), 
1.39–1.22 (m, 19H). 13C NMR (101 MHz, CDCl3) δ 63.18, 32.89, 29.72, 29.67, 29.49, 25.80. 
HRMS (AccuTOF): [M-OH]+ Calc’d for C15H23D9O m/z 220.2991. Found: m/z 220.2975. 
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Pentadecanal, (31) 
 
 4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium tetrafluoroboratesmith-bobbit 
(Bobbit’s salt, 3.552 g, 11.84 mmol) was added to pentadecan-1-ol (30, 2.351 g, 10.29 mmol) 
dissolved in 200 mL of dry DCM.  An equal mass of silica was slowly added to the stirring mixture.  
The bright yellow solution stirred at ambient temperature until the color faded, giving a solution 
with a pale yellow tint.  The solution was filtered to remove the silica, and the filtrate was 
concentrated in vacuo.  The crude product was purified by column chromatography (5% 
EtOAc:hexanes) to yield pentadecanal,61 31, as a clear solid, (2.116 g, 9.346 mmol, 90.8%), MP 
~25 °C. 1H NMR (400 MHz, CDCl3) δ 9.76 (t, J = 1.9 Hz, 1H), 2.41 (td, J = 7.3, 1.9 Hz, 2H), 1.63 
(p, J = 7.3 Hz, 2H), 1.35–1.22 (m, 22H), 0.88 (t, J = 6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
203.01, 43.98, 31.98, 29.70, 29.63, 29.48, 29.41, 29.23, 22.74, 22.16, 14.17. HRMS (AccuTOF): 
[M-H]+ Calc’d for C15H30O m/z 225.2218. Found: m/z 225.2216. 
 
Pentadecanal-12,12,13,13,14,14,15,15,15-d9, (39) 
 
 4-(Acetyamino)-2,2,6,6-tetramethyl-1-oxo-piperidinium tetrafluoroboratesmith-bobbit 
(Bobbit’s salt, 829 mg, 2.76 mmol) was added to pentadecan-12,12,13,13,14,14,15,15,15-d9-1-ol 
(38, 625 mg, 2.63 mmol) dissolved in 100 mL of dry DCM.  An equal mass of silica was slowly 
added to the stirring mixture.  The bright yellow solution stirred at ambient temperature until the 
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color faded, giving a solution with a pale yellow tint.  The solution was filtered to remove the 
silica, and the filtrate was concentrated in vacuo.  The crude product was purified by column 
chromatography (5% EtOAc:hexanes) to yield pentadecanal-12,12,13,13,14,14,15,15,15-d9, 39, 
as a clear solid, (468 mg, 1.99 mmol, 75.6%), MP, ~25 °C. 1H NMR (400 MHz, CDCl3) δ 9.76 (t, 
J = 2.0 Hz, 1H), 2.41 (td, J = 7.4, 1.9 Hz, 2H), 1.64 (p, J = 7.2 Hz, 2H), 1.32–1.20 (m, 16H). 13C 
NMR (101 MHz, CDCl3) δ 203.01, 43.98, 29.73, 29.69, 29.64, 29.48, 29.46, 29.41, 29.23, 22.16. 
HRMS (AccuTOF): [MH]+ Calc’d for C15H21D9O m/z 234.2783. Found: m/z 234.2808. 
 
Ethyl 3-oxoheptadecanoate, (32) 
 
 Tin (II) chloride dihydrate (52 mg, 0.231 mmol) was suspended in 20 mL of dry DCM.  
Ethyl diazoacetate (319 mg, 2.43 mmol) was added, dropwise via syringe, and the reaction was 
stirred for 15 min.  Pentadecanal (31, 524 mg, 2.31 mmol) was dissolved in 10 mL of DCM and 
added to the reaction, dropwise, via cannula.  The mixture was stirred at ambient temperature for 
about 6 h, until nitrogen evolution ceased.  The reaction mixture was diluted with 100 mL of DCM 
and washed with a saturated brine solution (2 X 50 mL).  The aqueous layers were combined and 
extracted with DCM (2 X 25 mL).  All organic layers were combined, dried with MgSO4, filtered, 
and solvents evaporated at reduced pressure.  The resulting crude product was purified via column 
chromatography (5% EtOAc:hexanes) to yield ethyl 3-oxoheptadecanoate,62 32, as a clear solid 
(642 mg, 2.07 mmol, 89.6%), MP 37-39 °C. 1H NMR (400 MHz, CDCl3) δ 4.20 (q, J = 7.1 Hz, 
2H), 3.42 (s, 2H), 2.53 (t, J = 7.4 Hz, 2H), 1.59 (p, J = 7.1 Hz, 2H), 1.34–1.22 (m, 25H), 0.88 (t, J 
= 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 203.03, 167.32, 61.38, 49.38, 43.12, 31.98, 29.71, 
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29.65, 29.50, 29.41, 29.09, 23.54, 22.75, 14.17. HRMS (AccuTOF): [MH]+ Calc’d for C19H36O3 
m/z 313.2743. Found: m/z 313.2724. 
 
Ethyl 3-oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9, (40) 
 
 Tin (II) chloride dihydrate (46 mg, 0.206 mmol) was suspended in 15 mL of dry DCM.  
Ethyl diazoacetate (0.275 mL, 2.27 mmol) was added, dropwise via syringe, and the reaction was 
stirred for 15 min.  The pentadecanal-12,12,13,13,14,14,15,15,15-d9 (39, 486 mg, 2.06 mmol) was 
dissolved in 10 mL of DCM and added to the reaction, dropwise, via cannula.  The mixture was 
stirred at ambient temperature for about 6 h, until nitrogen evolution ceased.  The reaction mixture 
was diluted with 100 mL of DCM and washed with a saturated brine solution (2 X 50 mL).  The 
aqueous layers were combined and extracted with DCM (2 X 25 mL).  All organic layers were 
combined, dried with MgSO4, filtered, and solvents evaporated at reduced pressure.  The resulting 
crude product was purified via column chromatography (5% EtOAc:hexanes) to yield ethyl 3-
oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9, 40, as a clear solid (534 mg, 1.66 mmol, 
80.6%), MP 36-38 °C. 1H NMR (400 MHz, CDCl3) δ 4.19 (q, J = 7.1 Hz, 2H), 3.42 (s, 2H), 2.52 
(t, J = 7.4 Hz, 2H), 1.59 (t, J = 7.2 Hz, 2H), 1.29–1.24 (m, 19H). 13C NMR (101 MHz, CDCl3) δ 
203.05, 167.32, 61.38, 49.38, 43.12, 29.73, 29.70, 29.65, 29.50, 29.46, 29.41, 29.09, 23.54, 14.16. 
HRMS (AccuTOF): [MH]+ Calc’d for C19H27D9O3 m/z 322.3308. Found: m/z 322.3324. 
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Ethyl 3-hydroxy-heptadecanoate, (33) 
 
 A solution of ethyl 3-oxoheptadecanoate (32, 620 mg, 1.98 mmol) in 2 mL of ethanol and 
18 mL of THF was cooled to 0 °C on an ice bath.  Sodium borohydride (60 mg, 1.59 mmol) was 
added and the resulting slurry was stirred vigorously for 1 h.  The reaction was quenched by the 
slow addition of 10 mL of a 10 % aq. citric acid solution.  Subsequent neutralization with satd. 
K2CO3 solution was followed by extraction with EtOAc (3 X 20 mL).  The organic layers were 
washed with 10 mL of satd. brine solution, dried with MgSO4, filtered, and the solvents were 
removed at reduced pressure.  The crude product was purified by column chromatography (10% 
EtOAc:Hexanes) to yield ethyl 3-hydroxy-heptadecanoate, 33, as a white solid (455 mg, 1.45 
mmol, 77.6 % brsm) MP 41-43 °C. 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.1 Hz, 2H), 3.99 
(tt, J = 7.9, 3.9 Hz, 1H), 2.90 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.1 Hz, 1H), 2.39 (dd, J = 
16.4, 9.0 Hz, 1H), 1.43 (dd, J = 8.5, 4.3 Hz, 2H), 1.38–1.19 (m, 27H), 0.88 (t, J = 6.6 Hz, 3H). 13C 
NMR (101 MHz, CDCl3) δ 173.19, 68.11, 60.71, 41.35, 36.59, 31.99, 29.74, 29.71, 29.64, 29.59, 
29.42, 25.54, 22.75, 14.25, 14.18. HRMS (AccuTOF): [MH]+ Calc’d for C19H38O3 m/z 315.2899. 
Found: m/z 315.2899. 
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Ethyl 3-hydroxyheptadecanoate-14,14,15,15,16,16,17,17,17-d9, (41) 
 
 A solution of ethyl 3-oxoheptadecanoate-14,14,15,15,16,16,17,17,17-d9 (40, 515 mg, 1.60 
mmol) in 2 mL of ethanol and 18 mL of THF was cooled to 0 °C on an ice bath.  Sodium 
borohydride (48 mg, 1.28 mmol) was added and the resulting slurry was stirred vigorously for 1 
h.  The reaction was quenched by the slow addition of 10 mL of a 10 % aq. citric acid solution.  
Subsequent neutralization with satd. K2CO3 solution was followed by extraction with EtOAc (3 X 
20 mL).  The organic layers were washed with 10 mL of satd. brine solution, dried with MgSO4, 
filtered, and the solvents were removed at reduced pressure.  The crude product was purified by 
column chromatography (10% EtOAc:Hexanes) to yield ethyl 3-hydroxyheptadecanoate-
14,14,15,15,16,16,17,17,17-d9, 41, as a white solid (392 mg, 1.21 mmol, 79.7 % brsm) MP 38-40 
°C. 1H NMR (400 MHz, CDCl3) δ 4.17 (q, J = 7.2 Hz, 2H), 4.00 (ddt, J = 12.0, 7.3, 4.0 Hz, 1H), 
2.90 (d, J = 4.0 Hz, 1H), 2.50 (dd, J = 16.4, 3.2 Hz, 1H), 2.39 (dd, J = 16.4, 9.0 Hz, 1H), 1.47–1.39 
(m, 2H), 1.39–1.12 (m, 21H). 13C NMR (101 MHz, CDCl3) δ 173.19, 68.11, 60.72, 41.35, 36.59, 
29.75, 29.71, 29.64, 29.59, 29.47, 25.54, 14.25. HRMS (AccuTOF): [MH]+ Calc’d for 
C19H29D9O3 m/z 324.3464. Found: m/z 324.2442. 
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3-Hydroxy heptadecanoic acid, (34) 
 
 Hydroxy ester 33 (440 mg, 1.40 mmol) was dissolved in 2 mL of MeOH and 4 mL of THF 
and 1 M aqueous LiOH (1.68 mL, 1.61 mmol) were added.  The mixture was stirred overnight at 
ambient temperature.  The reaction was then acidified with 1 M HCl and extracted with EtOAc (3 
X 15 mL).  The organic layers were washed with 10 mL of brine, dried with MgSO4, filtered, and 
the solvents were removed at reduced pressure.  The crude solid was recrystallized from hexanes 
to yield 3-hydroxy-heptadecanoic acid, 34, as a white solid (335 mg, 1.17 mmol, 83.6%), MP 86-
88 °C. 1H NMR (400 MHz, CDCl3) δ 4.04 (tt, J = 8.1, 3.8 Hz, 1H), 2.59 (dd, J = 16.6, 3.2 Hz, 1H), 
2.48 (dd, J = 16.6, 8.9 Hz, 1H), 1.55–1.43 (m, 3H), 1.40–1.15 (m, 24H), 0.88 (t, J = 6.7 Hz, 3H). 
13C NMR (101 MHz, CDCl3) δ 175.72, 68.07, 40.73, 36.62, 31.98, 29.75, 29.71, 29.63, 29.60, 
29.52, 29.42, 25.48, 22.75, 14.18. HRMS (AccuTOF): [MH]+ Calc’d for C17H34O3 m/z 287.2586. 
Found: m/z 287.2605. 
 
3-Hydroxyheptadecanoic-14,14,15,15,16,16,17,17,17-d9 acid, (42) 
 
 Ethyl 3-hydroxyheptadecanoate-14,14,15,15,16,16,17,17,17-d9, 41 (390 mg, 1.21 mmol) 
was dissolved in 2 mL of MeOH and 4 mL of THF and 1 M aqueous LiOH (1.45 mL, 1.39 mmol) 
were added.  The mixture was stirred overnight at ambient temperature.  The reaction was then 
acidified with 1 M HCl and extracted with EtOAc (3 X 15 mL).  The organic layers were washed 
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with 10 mL of brine, dried with MgSO4, filtered, and the solvents were removed at reduced 
pressure.  The crude solid was recrystallized from hexanes to yield 3-hydroxyheptadecanoic-
14,14,15,15,16,16,17,17,17-d9 acid,
 42, as a white solid (318 mg, 1.08 mmol, 89.3%), MP 79-81 
°C. 1H NMR (400 MHz, CDCl3) δ 4.03 (s, 1H), 2.58 (dd, J = 16.6, 3.2 Hz, 1H), 2.48 (dd, J = 16.6, 
8.9 Hz, 1H), 1.58–1.40 (m, 3H), 1.25 (s, 18H). 13C NMR (101 MHz, CDCl3) δ 175.79, 68.06, 
40.76, 36.63, 29.71, 29.63, 29.60, 29.53, 29.47, 25.49. HRMS (-TOF MS): [M-H]- Calc’d for 
C17H25D9O3 m/z 294.2995. Found: m/z 294.2982. 
 
Methyl-O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)-L-serinate, (35) 
 
 N-Hydroxy succinimide (185 mg, 1.61 mmol) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (308 mg, 1.61 mmol) were added to a stirring solution of 3-
hydroxyheptadecanoic acid (34, 401 mg, 1.40 mmol) in 25 mL of dry DCM.  The solution was 
stirred for 5 h at ambient temperature, filtered, and the filtrate was concentrated in vacuo.  The 
resulting white solid was dissolved in 25 mL of methanol and this solution was added via cannula 
to a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tert-butyldiphenylsilyl)-L-serinate 
(14, 960 mg, 1.75 mmol) and Pd/C (298 mg) in 50 mL of methanol.  The reaction vessel was 
flushed with H2 and the mixture was stirred overnight, filtered through Celite, and concentrated 
under reduced pressure. The crude product was purified via column chromatography (2% 
MeOH:DCM) to yield methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)-
L-serinate, 35, as a clear oil (641 mg, 0.938 mmol, 67.0%). 1H NMR (400 MHz, CDCl3) δ 7.58 (t, 
J = 7.0 Hz, 4H), 7.50–7.33 (m, 6H), 6.88 (dd, J = 28.7, 8.2 Hz, 1H), 6.39 (dt, J = 42.3, 5.5 Hz, 1H), 
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4.67 (dt, J = 7.7, 2.5 Hz, 1H), 4.19–3.76 (m, 5H), 3.75 (s, 3H), 3.43 (dd, J = 38.5, 3.6 Hz, 1H), 
2.41 (dt, J = 14.6, 2.2 Hz, 1H), 2.27 (dd, J = 13.9, 9.4 Hz, 1H), 1.52–1.35 (m, 3H), 1.33–1.22 (m, 
24H), 1.04 (s, 9H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 172.80, 172.75, 170.73, 
168.71, 168.71, 168.53, 135.56, 135.52, 132.98, 132.93, 132.69, 132.64, 130.08, 127.97, 127.94, 
127.90, 127.87, 68.93, 64.31, 64.27, 54.34, 52.63, 43.06, 43.02, 42.93, 42.81, 37.19, 37.15, 31.98, 
29.75, 29.72, 29.64, 29.57, 29.42, 26.80, 25.49, 22.75, 19.33, 14.17. HRMS (AccuTOF): [MH]+ 
Calc’d for C39H62N2O6Si m/z 683.4455. Found: m/z 683.4432.  
 
Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-
d9)glycyl)-L-serinate, (43) 
 
 N-Hydroxy succinimide (130 mg, 1.13 mmol) and N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (216 mg, 1.13 mmol) were added to a stirring solution of 3-
hydroxyheptadecanoic-14,14,15,15,16,16,17,17,17-d9 acid (42, 303 mg, 1.03 mmol) in 10 mL of 
dry THF.  The solution was stirred for 5 h at ambient temperature, filtered, and the filtrate was 
concentrated in vacuo.  The resulting white solid was dissolved in 25 mL of methanol and this 
solution was added via cannula to a solution of methyl N-(((benzyloxy)carbonyl)glycyl)-O-(tert-
butyldiphenylsilyl)-L-serinate (14, 563 mg, 1.03 mmol) and Pd/C (273 mg) in 50 mL of methanol.  
The reaction vessel was flushed with H2 and the mixture was stirred overnight, filtered through 
Celite, and concentrated under reduced pressure. The crude product was purified via column 
chromatography (2% MeOH:DCM) to yield methyl O-(tert-butyldiphenylsilyl)-N-((3-
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hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl)-L-serinate, 43, as a clear oil (555 
mg, 0.802 mmol, 78.2%). 1H NMR (400 MHz, CDCl3) δ 7.59 (tt, J = 8.1, 1.6 Hz, 4H), 7.49–7.33 
(m, 6H), 6.86 (dd, J = 26.2, 8.2 Hz, 1H), 6.34 (dt, J = 41.6, 5.4 Hz, 1H), 4.67 (dtd, J = 7.6, 2.9, 1.2 
Hz, 1H), 4.19–3.78 (m, 5H), 3.75 (s, 3H), 3.41 (dd, J = 35.9, 3.6 Hz, 1H), 2.40 (dt, J = 14.6, 2.5 
Hz, 1H), 2.26 (ddd, J = 14.6, 9.5, 2.1 Hz, 1H), 1.53–1.34 (m, 3H), 1.32–1.22 (m, 17H), 1.04 (s, 
9H). 13C NMR (101 MHz, CDCl3) δ 172.78, 172.73, 170.70, 168.66, 168.49, 135.57, 135.52, 
132.98, 132.93, 132.70, 132.64, 130.09, 127.96, 127.93, 127.90, 127.87, 68.92, 64.31, 64.26, 
54.34, 52.61, 43.05, 43.02, 42.94, 42.82, 37.19, 37.14, 29.72, 29.65, 29.57, 29.47, 26.80, 25.49, 
19.33. HRMS (AccuTOF): [MH]+ Calc’d for C39H53D9N2O6 m/z 692.5020. Found: m/z 692.5007.  
 
Methyl (3-hydroxyheptadecanoyl)glycyl-L-serinate 
 
 Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxy-heptadecanoyl)glycyl)-L-serinate (35, 
124 mg, 0.182 mmol) was dissolved in 10 mL of dry THF under nitrogen.  The solution was cooled 
to 0°C and was treated with 1 M tetrabutylammonium fluoride (TBAF, 0.20 mL, 0.200 mmol).  
The reaction was slowly warmed to ambient temperature and stirred for 6 h.  The solvent was 
removed under reduced pressure, and the resulting oil was purified by column chromatography 
(2.5 % MeOH:DCM) to yield methyl (3-hydroxyheptadecanoyl)glycyl-L-serinate as a white solid, 
(65 mg, 0.146 mmol, 80.5 %), MP, 104-111 °C.  1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 7.8 
Hz, 1H), 6.71 (d, J = 5.5 Hz, 1H), 4.66 (dt, J = 7.3, 3.4 Hz, 1H), 4.22–3.80 (m, 6H), 3.79 (s, 3H), 
3.55 (d, J = 23.0 Hz, 1H), 2.46 (dt, J = 13.9, 2.8 Hz, 1H), 2.36–2.24 (m, 1H), 1.52–1.36 (m, 3H), 
1.32–1.24 (m, 24H), 0.88 (t, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 173.30, 173.10, 
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171.07, 170.89, 169.39, 169.18, 69.59, 69.31, 62.92, 54.87, 54.83, 52.89, 43.69, 43.50, 43.46, 
43.32, 37.48, 37.27, 31.98, 29.75, 29.72, 29.65, 29.55, 29.42, 25.61, 25.54, 22.75, 14.17. HRMS 
(AccuTOF): [MH]+ Calc’d for C23H44N2O6 m/z 445.3278. Found: m/z 444.3278. 
 
Methyl (3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate 
 
 Methyl O-(tert-butyldiphenylsilyl)-N-((3-hydroxyheptadecanoyl-
14,14,15,15,16,16,17,17,17-d9)glycyl)-L-serinate, (43, 192 mg, 0.277 mmol) was dissolved in 10 
mL of dry THF under nitrogen.  The solution was cooled to 0°C and was treated with 1 M 
tetrabutylammonium fluoride (TBAF, 0.30 mL, 0.304 mmol).  The reaction was slowly warmed 
to ambient temperature and stirred for 6 h.  The solvent was removed under reduced pressure, and 
the resulting oil was purified by column chromatography (2.5 % MeOH:DCM) to yield methyl (3-
hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate as a white solid, (107 mg, 
0.236 mmol, 85.1 %), MP, 95-102 °C. 1H NMR (400 MHz, CDCl3) δ 7.47 (dd, J = 30.8, 7.7 Hz, 
1H), 6.93 (d, J = 6.2 Hz, 1H), 4.65 (dt, J = 7.4, 3.5 Hz, 1H), 4.23–3.78 (m, 6H), 3.78 (s, 3H), 2.45 
(dt, J = 14.0, 2.4 Hz, 1H), 2.36–2.25 (m, 1H), 1.54–1.37 (m, 3H), 1.33–1.23 (m, 17H). 13C NMR 
(101 MHz, CDCl3) δ 173.36, 173.21, 171.17, 170.97, 169.54, 169.39, 69.62, 69.30, 62.76, 54.92, 
54.87, 52.86, 43.72, 43.57, 43.35, 43.26, 37.49, 37.28, 29.76, 29.73, 29.67, 29.58, 29.47, 25.65, 
25.59. HRMS (AccuTOF): [MH]+ Calc’d for C23H35D9N2O6 m/z 454.3843. Found: m/z 454.3814. 
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(3-Hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, (26) 
 
 A solution of 1 M LiOH (0.12 mL, 0.12 mmol) was added to a solution of methyl (3-
hydroxyheptadecanoyl)glycyl-L-serinate (47 mg, 0.11 mmol) in 2 mL of methanol at 0 °C, and 4 
mL of THF was subsequently added.  The resulting solution was warmed to ambient temperature 
and stirred for 2 h. The solution was then neutralized with 10% HCl and diluted with 25 mL of 
H2O. The solution was then extracted with EtOAc (3 X 25 mL) and the organic layers were 
concentrated in vacuo. The resulting crude material was recrystallized from hot EtOAc to yield (3-
hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, 26, as a crystalline solid 
(38 mg, 0.088 mmol, 84 %), MP, 119-122 °C. 1H NMR (400 MHz, CDCl3) δ 4.64–4.40 (m, 1H), 
4.14–3.69 (m, 5H), 2.43–2.33 (m, 1H), 2.30–2.20 (m, 1H), 1.52–1.20 (m, 26H), 0.83 (t, J = 6.7 
Hz, 3H). 13C NMR (101 MHz, DMSO) δ 171.95, 171.25, 168.89, 67.48, 61.38, 54.54, 51.82, 43.63, 
41.83, 36.86, 31.27, 29.08, 29.03, 28.98, 28.68, 25.10, 22.07, 13.93.  HRMS (-TOF MS): [M-H]- 
Calc’d for C22H42N2O6 m/z 429.2965. Found: m/z 429.2989. 
 
(3-Hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, (24) 
 
 A solution of 1 M LiOH (0.28 mL, 0.28 mmol) was added to a solution of methyl (3-
hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-serinate (117 mg, 0.258 mmol) in 
2 mL of methanol at 0 °C, and 4 mL of THF was subsequently added.  The resulting solution was 
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warmed to ambient temperature and stirred for 2 h. The solution was then neutralized with 10% 
HCl and diluted with 25 mL of H2O. The solution was then extracted with EtOAc (3 X 25 mL) 
and the organic layers were concentrated in vacuo. The resulting crude material was recrystallized 
from hot EtOAc to yield ((3-hydroxyheptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-
serine, 24, as a crystalline solid (83 mg, 0.19 mmol, 73 %), MP, 118-122 °C. 1H NMR (400 MHz, 
CDCl3) δ 4.50 (dt, J = 11.0, 3.4 Hz, 1H), 4.17–3.65 (m, 5H), 2.37 (ddd, J = 13.6, 7.9, 2.8 Hz, 1H), 
2.29–2.19 (m, 1H), 1.49–1.16 (m, 20H). 13C NMR (101 MHz, DMSO) δ 171.78, 171.22, 168.96, 
67.47, 61.31, 54.51, 51.83, 43.60, 41.75, 36.84, 29.08, 29.04, 28.99, 28.74, 25.10. HRMS 
(AccuTOF): [MH]+ Calc’d for C22H33D9N2O6 m/z 440.3686. Found: m/z 440.3689. 
 
(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silaheptacosan-13-yl 13-methyltetradecanoate, (36) 
 
 13-Methyltetradecanoic acid (82 mg, 0.338 mmol) was dissolved in 15 mL of dry DCM 
and stirred at 0 °C. To the solution was then treated with DCC (87 mg, 0.423 mmol) and a catalytic 
amount of DMAP.  After stirring for 15 min, methyl (3-hydroxy-haptadecanoyl)glycyl-L-serine 
(35, 231 mg, 0.338 mmol) dissolved in 5 mL of dry DCM was added to the reaction via cannula.  
The resulting solution was warmed to ambient temperature and stirred overnight.  The solvent was 
removed under reduced pressure and the resulting oil was redissolved in 20 mL of diethyl ether.  
The resulting precipitate was filtered, and the filtrate washed with satd NaHCO3 (3 X 10 mL).  The 
organic layer was dried, filtered, and solvents evaporated under reduced pressure.  Purification via 
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column chromatography (1% MeOH:DCM) yielded (6S)-6-(methoxycarbonyl)-2,2-dimethyl-
8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-silaheptacosan-13-yl 13-methyltetradecanoate, 36, 
as a clear wax (123 mg, 0.136 mmol, 63.4% brsm). 1H NMR (400 MHz, CDCl3) δ 7.58 (t, J = 7.1 
Hz, 4H), 7.46–7.37 (m, 6H), 6.54 (t, J = 6.7 Hz, 1H), 6.37 (d, J = 4.9 Hz, 1H), 5.16 (p, J = 6.3 Hz, 
1H), 4.66 (d, J = 7.8 Hz, 1H), 4.14–3.82 (m, 5H), 3.74 (s, 3H), 2.55–2.42 (m, 2H), 2.29 (t, J = 7.5 
Hz, 2H), 1.50 (hept, J = 6.6 Hz, 1H), 1.31–1.24 (m, 42H), 1.15–1.10 (m, 4H), 1.03 (s, 9H), 0.89–
0.84 (m, 9H). 13C NMR (101 MHz, CDCl3) δ 173.45, 170.47, 169.98, 168.26, 135.56, 135.52, 
132.82, 132.64, 130.11, 130.06, 127.97, 127.88, 71.12, 64.15, 54.28, 52.58, 49.26, 42.88, 41.43, 
39.12, 34.56, 34.18, 34.00, 31.98, 30.01, 29.75, 29.62, 29.57, 29.42, 29.36, 29.21, 28.03, 27.48, 
26.78, 25.67, 25.32, 25.05, 24.99, 22.75, 22.72, 14.17. HRMS (AccuTOF): [MH]+ Calc’d for 
C54H90N2O7Si m/z 907.6596. Found: m/z 907.6570. 
 
(6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate, (44) 
 
 13-Methyltetradecanoic acid (130 mg, 0.535 mmol) was dissolved in 15 mL of dry DCM 
and stirred at 0 °C. To the solution was then treated with DCC (110 mg, 0.535 mmol) and a 
catalytic amount of DMAP.  After stirring for 15 min, methyl (3-hydroxyheptadecanoyl-
14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine (43, 322 mg, 0.465 mmol) dissolved in 5 mL of dry 
DCM was added to the reaction via cannula.  The resulting solution was warmed to ambient 
temperature and stirred overnight.  The solvent was removed under reduced pressure and the 
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resulting oil was redissolved in 20 mL of diethyl ether.  The resulting precipitate was filtered, and 
the filtrate washed with satd NaHCO3 (3 X 10 mL).  The organic layer was dried, filtered, and 
solvents evaporated under reduced pressure.  Purification via column chromatography (1% 
MeOH:DCM) yielded (6S)-6-(methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-
7,10-diaza-3-silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate, 44, as 
a clear wax (216 mg, 0.236 mmol, 79.6% brsm). 1H NMR (400 MHz, CDCl3) δ 7.63–7.55 (m, 
4H), 7.48–7.36 (m, 6H), 6.52 (d, J = 6.8 Hz, 1H), 6.33 (d, J = 5.0 Hz, 1H), 5.20–5.13 (m, 1H), 4.66 
(dd, J = 7.6, 3.4 Hz, 1H), 4.13 (dd, J = 10.3, 2.9 Hz, 1H), 4.01–3.81 (m, 3H), 3.75 (s, 3H), 2.54–
2.44 (m, 2H), 2.29 (t, J = 7.5 Hz, 2H), 1.51 (hept, J = 13.2, 6.6 Hz, 1H), 1.39–1.16 (m, 38H), 1.15 
(q, J = 6.7 Hz, 2H), 1.03 (s, 9H), 0.86 (d, J = 6.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 173.42, 
170.44, 170.40, 169.95, 168.21, 135.56, 135.52, 132.83, 132.65, 130.11, 130.06, 127.97, 127.88, 
71.10, 64.15, 54.28, 54.26, 52.57, 42.88, 41.43, 39.12, 34.56, 34.18, 30.01, 29.72, 29.62, 29.57, 
29.47, 29.42, 29.36, 29.21, 28.03, 27.48, 26.78, 25.32, 25.06, 22.72, 19.31. HRMS (AccuTOF): 
[MH]+ Calc’d for C54H81D9N2O7Si m/z 916.7160. Found: m/z 916.7154. 
 
1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1-
oxoheptadecan-3-yl 13-methyltetradecanoate 
 
 (6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silaheptacosan-13-yl 13-methyltetradecanoate (36, 123 mg, 0.136 mmol) was dissolved in 5 mL 
of dry THF under nitrogen.  The solution was cooled to 0 °C and was treated with 1 M TBAF (0.15 
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mL, 0.15 mmol).  The reaction was slowly warmed to ambient temperature and stirred for 1 h.  
The solvent was removed under reduced pressure, and the resulting oil was purified by column 
chromatography (5% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-
yl)amino)-2-oxoethyl)amino)-1-oxoheptadecan-3-yl 13-methyltetradecanoate as a white solid (69 
mg, 0.103 mmol, 76.1 % brsm) MP 84-92 °C. 1H NMR (400 MHz, CDCl3) δ 7.06 (dd, J = 46.7, 
7.5 Hz, 1H), 6.44 (s, 1H), 5.24–5.12 (m, 1H), 4.66 (t, J = 3.4 Hz, 1H), 4.11–3.89 (m, 4H), 3.79 (s, 
3H), 3.20 (d, J = 68.5 Hz, 1H), 2.49 (dd, J = 6.0, 3.2 Hz, 2H), 2.31 (td, J = 7.6, 2.1 Hz, 2H), 1.51 
(hept, J = 6.6 Hz, 1H), 1.38–1.20 (m, 40H), 1.15 (q, J = 6.8 Hz, 2H), 0.93–0.79 (m, 9H). 13C NMR 
(101 MHz, CDCl3) δ 174.55, 174.39, 170.78, 170.71, 170.66, 170.60, 168.97, 168.93, 71.53, 62.96, 
55.02, 52.76, 43.43, 42.04, 41.95, 39.12, 34.62, 34.55, 31.99, 30.01, 29.76, 29.71, 29.62, 29.57, 
29.42, 29.38, 29.33, 29.21, 28.03, 27.48, 25.32, 25.06, 25.00, 22.76, 22.72, 14.17. HRMS (-TOF 
MS): [M-H]- Calc’d for C38H72N2O7 m/z 667.5261. Found: m/z 667.5243. 
 
1-((2-(((S)-3-Hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1-
oxoheptadecan-3-yl-14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate 
 
 (6S)-6-(Methoxycarbonyl)-2,2-dimethyl-8,11-dioxo-3,3-diphenyl-4-oxa-7,10-diaza-3-
silaheptacosan-13-yl-24,24,25,25,26,26,27,27,27-d9 13-methyltetradecanoate (44, 192 mg, 0.277 
mmol) was dissolved in 5 mL of dry THF under nitrogen.  The solution was cooled to 0 °C and 
was treated with 1 M TBAF (0.30 mL, 0.15 mmol).  The reaction was slowly warmed to ambient 
temperature and stirred for 1 h.  The solvent was removed under reduced pressure, and the resulting 
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oil was purified by column chromatography (5% MeOH:DCM) to yield 1-((2-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-2-oxoethyl)amino)-1-oxoheptadecan-3-yl-
14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate as a white solid (107 mg, 0.236 mmol, 
85.1 % brsm) MP 82-88 °C. 1H NMR (400 MHz, CDCl3) δ 7.10 (dd, J = 43.2, 7.8 Hz, 1H), 6.48 
(d, J = 4.2 Hz, 1H), 5.18 (dt, J = 19.0, 6.4 Hz, 1H), 4.66 (t, J = 3.4 Hz, 1H), 4.14–3.89 (m, 4H), 
3.79 (s, 3H), 3.27 (d, J = 65.9 Hz, 1H), 2.49 (dd, J = 6.1, 3.1 Hz, 2H), 2.31 (td, J = 7.6, 2.3 Hz, 
2H), 1.50 (t, J = 7.0 Hz, 1H), 1.41–1.18 (m, 34H), 1.15 (q, J = 6.4 Hz, 2H), 0.86 (d, J = 6.6 Hz, 
6H). 13C NMR (101 MHz, CDCl3) δ 174.56, 174.39, 170.79, 170.73, 170.67, 170.61, 168.98, 
168.93, 71.53, 62.96, 62.92, 55.02, 52.76, 43.44, 43.40, 42.05, 41.94, 39.12, 34.62, 34.55, 30.01, 
29.78, 29.73, 29.62, 29.57, 29.48, 29.38, 29.33, 29.22, 29.19, 28.03, 27.48, 25.32, 25.06, 25.00, 
22.71. HRMS (AccuTOF): [MH]+ Calc’d for C38H63D9N2O7 m/z 678.5983. Found: m/z 678.5992. 
 
(3-((13-Methyltetradecanoyl)oxy)heptadecanoyl)glycyl-L-serine, (27) 
 
 A stirring solution of 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
oxoethyl)amino)-1-oxoheptadecan-3-yl 13-methyltetradecanoate (48 mg, 0.078 mmol), in 3 mL 
of dry DMF, was cooled to 0 °C.  Potassium trimethylsilonoate (11 mg, 0.083 mmol) was added, 
and the reaction was stirred on the ice bath for 1.5 h before being warmed to ambient temperature 
and stirred for an additional 1.5 h. The solution was diluted with 10 mL of 10 mL of H2O and 
acidified with 10% HCl.  The resulting cloudy precipitate was extracted with ethyl acetate (3 X 
15mL). The organic layer was dried, filtered, and solvents evaporated under reduced pressure. The 
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resulting solid was purified by column chromatography (10% MeOH:DCM) to yield (3-((13-
methyltetradecanoyl)oxy)heptadecanoyl)glycyl-L-serine, 27, as a white sticky solid (33 mg, 0.050 
mmol, 65 % brsm). 1H NMR (500 MHz, CDCl3) δ 7.07 (d, J = 8.4 Hz,0.5H), 6.77 (d, J = 8.2 
Hz,0.5H), 5.17–5.07 (m, 1H), 4.26 (s, 1H), 4.11–3.60 (m, 4H), 3.36–3.30 (m, 1H), 2.47 (s, 2H), 
2.23 (s, 2H), 1.67–1.41 (m, 6H), 1.21 (s, 41H), 0.82 (t, J = 7.0 Hz, 9H). 13C NMR spectrum could 
not be obtained due to liposome formation. HRMS (-TOF MS): [M-H]- Calc’d for C37H70N2O7 
m/z 653.5105. Found: m/z 653.5077. 
 
(3-((13-Methyltetradecanoyl)oxy)heptadecanoyl-14,14,15,15,16,16,17,17,17-d9)glycyl-L-
serine, (25) 
 
 A stirring solution of 1-((2-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-
oxoethyl)amino)-1-oxoheptadecan-3-yl-14,14,15,15,16,16,17,17,17-d9 13-methyltetradecanoate 
(98 mg, 0.144 mmol), in 3 mL of dry DMF, was cooled to 0 °C.  Potassium trimethylsilonoate (18 
mg, 0.144 mmol) was added, and the reaction was stirred on the ice bath for 1.5 h before being 
warmed to ambient temperature and stirred for an additional 1.5 h. The solution was diluted with 
10 mL of 10 mL of H2O and acidified with 10% HCl.  The resulting cloudy precipitate was 
extracted with ethyl acetate (3 X 15mL). The organic layer was dried, filtered, and solvents 
evaporated under reduced pressure. The resulting solid was purified by column chromatography 
(10% MeOH:DCM) to yield (3-((13-methyltetradecanoyl)oxy)heptadecanoyl-
14,14,15,15,16,16,17,17,17-d9)glycyl-L-serine, 25, as a white sticky solid (55 mg, 0.083 mmol, 
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58% brsm). 1H NMR (400 MHz, CDCl3) δ 7.09 (d, J = 8.1 Hz,0.5H), 6.78 (d, J = 8.4 Hz,0.5H), 
5.24–5.08 (m, 1H), 4.30 (s, 1H), 4.14–3.55 (m, 4H), 3.43–3.28 (m, 1H), 2.52 (s, 2H), 2.25 (t, J = 
7.4 Hz, 2H), 1.57 (d, J = 13.1 Hz, 4H), 1.51–1.44 (m, 1H), 1.42–1.15 (m, 30H), 1.12 (q, J = 6.8 
Hz, 2H), 0.83 (d, J = 6.6 Hz, 6H). 13C NMR spectrum could not be obtained due to liposome 
formation. HRMS (-TOF MS): [M-H]- Calc’d for C37H61D9N2O7 m/z 662.5670. Found: m/z 
662.5640. 
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1.4 NMR Spectra 
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Synthesis of Nitroimidazole Indocyanine Green Dye Conjugates for 
Targeting Hypoxia in Tumor Cells for Near Infrared Fluorescence 
Frequency Domain Optical Tomography 
 
2.1 Introduction 
2.1.1 Cancer 
 In 2016 there is an expected 1.6 million new cases of cancer and nearly 600 thousand 
cancer deaths, which contributes to the second most common cause of death in the United States.1 
Cancer refers to over a hundred different diseases that are characterized as abnormal and 
unregulated cell growth. Cells in the human body are constantly being recycled by programmed 
cell death, apoptosis, and then replaced by cellular division. Of the estimated 100 trillion cells in 
an average adult, 50-70 billion cells are turned over each day. Within this process there is a 
probability of reproductive error, which can develop damaged DNA or gene mutations that leads 
to cancer. Some of the main causes include UV/nuclear radiation, carcinogenic chemicals, 
infections, internal factors, and poor health.  
 Commonly, a cell has a mechanism in place to correct mutations by either fixing the 
damaged DNA, or triggering apoptosis so the cells cannot multiply. When this fails, defective 
genes are passed on and the cells begin to multiply at an uncontrollable rate. These cells form 
abnormal growths in tissues called neoplasms, or more often referred to as tumors. Tumors show 
“the six hallmarks of cancer”: evading apoptosis, sell-sufficiency in growth signals, insensitivity 
to anti-growth signals, tissue invasion and metastasis, limitless replicative potential, and sustained 
angiogenesis.2 Over time, the tumor cells develop malignancy and obtain the ability to metastasis 
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to other parts of the body through blood vessels or the lymph system. Once cancer has the ability 
to migrate throughout the body, it is considered stage 4 cancer and chances of remission drastically 
decrease.3 For this reason, tumor detection and eradication is of utmost concern in the fight against 
cancer.  
 
2.1.2 Tumor Hypoxia 
Once tumors grow to between 2-3 mm in size, they start to develop a tumor-specific 
microenvironment due to quick and uncontrolled growth. The growths are said to be hypoxic as 
low oxygen levels, pH, and glucose concentration are observed.4 Tumor hypoxia is a direct result 
from the accelerated growth rate of cancer cells not allowing for proper angiogenesis, blood vessel 
formation. Without proper blood flow, oxygen levels and nutrient supplies diminish compared to 
healthy tissues. Mutated cells have the ability to adapt by altering their metabolism to the 
environment but healthy cells do not and will eventually die. 
The cancer cells left in the hypoxic region start to exhibit a slow growth rate due to rapidly 
proliferating distal cancer cells not allowing the profusion into the tumor. This decrease in 
profusion often causes ineffectiveness of common chemotherapy drugs.5 Alternatively, radiation 
therapy is used to produce reactive oxygen species within the cells that will damage DNA and lead 
to cell death. However, hypoxia decreases the effectiveness due to low oxygen concentration. The 
longer a tumor remains, its resistance to anticancer drugs and the probability of the cells gaining 
the ability to metastasis will increase. For this reason, determining if a tumor is hypoxic and 
monitoring the effectiveness of chemotherapy or radiation treatments is vital to the fight against 
cancer. 
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2.1.3 Detecting & Imaging Hypoxia 
 The ineffectiveness of chemotherapy regimens and radiotherapy on hypoxic tumors creates 
the demand for safe procedures for detection and monitoring of such growths. Invasive procedures 
were among the first diagnostic tools for sampling tissues from infected areas and are still used on 
a limited basses today. Polarographic oxygen microelectrodes can be inserted into the tumors to 
directly quantify the levels of hypoxia from measuring partial pressure of oxygen.4,6 However, 
they are limited only to accessible tumors, mainly on surface areas of the body, such as cervix, 
head, and neck tumors.7  
 Non-invasive procedures offer alternatives to hypoxia imaging and are not limited to depth 
of the tumors while also being inherently safe measurements. Magnetic resonance imaging (MRI) 
and positron emission tomography (PET) are techniques that allow physicians to visualize tissue 
properties. To date, recent advances have allowed for the ability of both PET and MRI imaging to 
simultaneously scan for tumors within the body.8 This allows more accuracy in treatment planning, 
monitoring, and evaluation of response to radiation therapy. 
 PET imaging can be used for measuring several metabolic 
processes in the body associated with tumor growth.9 Most commonly, 
a 3-dimensional detector is used to measure gamma rays that are 
emitted by a exogenous tracer. The tracer is injected into the body and 
the detector measures its concentration as it localizes in the body. The 
structure of the tracer dictates what biological activity or function can 
be measured. The most common method for measurement of hypoxic 
tissue uses tracers encompassing nitroimidazoles. 2-nitroimidazole is 
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known to undergo intracellular metabolism in which a nitroreductase reduces the nitro moiety. The 
reduced compound can then bond with proteins within the cell, and as a result increases the 
retention time. The reverse reaction is directly dependent on the oxygen concentration and is 
minimal in hypoxic environments.10 Examples of the tracers are shown. The F-18 labeled 
derivative of EF5 is being studied for its effectiveness to study brain tumors due to its propensity 
to cross the blood brain barrier.11 The other two derivatives, 18F-FAZA and 18F-FMISO, take 
advantage of their high levels of biodiversity that makes it easy to get into tumor cells. As the 
metabolism progresses, the compound will concentrate in hypoxic tissue and release positrons that 
will build a picture of the tumor with PET imaging. 
 MRI is a type of imaging that takes advantage of the science of nuclear magnetic resonance 
(NMR). When some atomic nuclei are applied to a magnetic field they can absorb and emit distinct 
radio frequencies. Based on the frequency, a conclusion can be drawn about the environment of 
the atomic nuclei is in. MRI scans take advantage of the abundance of NMR active hydrogen nuclei 
in the body. Mostly, the hydrogen atoms in the body exist in water and fat molecules. As a result, 
MRIs can image the microanatomy of a tissue and distinguish the density or organization of 
intra/extracellular space that is indicative of tumor growth.12 Contrast agents can also be 
introduced to the body that can measure blood flow as it relates to permeability and perfusion. 
Hypoxic tumors can be indirectly illuminated by such contrast agents due to their poor vascular 
network and densely distributed cellular network. 
 Both non-invasive procedures discussed are widely used, however they do inherently 
possess some disadvantages and limitations. Some of these include as unfavorable imaging 
characteristics, such as high background counts and limited contrast ratio from hypoxic tumors to 
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normal tissues. Also, the high cost of these procedures make in unfeasible for routine imaging and 
drives the need for a cheap, safe, and non-invasive alternative. 
 Optical imaging is a non-invasive, low cost, and extremely safe alternative biological 
imaging. Near infrared (NIR) frequency domain optical tomography (FDOT) offers a highly 
sensitive technique for imaging targets within the body. A NIR fluorescent probe is administered, 
and the irradiation with NIR light 
allows for the collection of the emitted 
fluorescence signals from the 
fluorochrome. PET tracers are limited 
to a single decay event per molecule for 
imaging. A single fluorescent probe 
can produce absorb and emit nearly a 
hundred million photons per second for 
imaging. The released fluorescence 
signals are collected by detectors or a charge coupled device (CCD) camera for construction of the 
3D imaging. The near-Infrared window of 650 to 900 nm allows for maximum depth penetration 
of light because there is minimal absorbance and high scattering by biological tissue. Hemoglobin 
and water are the major contributors of light absorption within the body. Figure 5 demonstrates 
the fact that absorbing factors are at a minimum in the NIR range. This technique is capable of 
imaging targets at depths up to several centimeters from the skin surface. It is noteworthy that bone 
and muscular tissues do slightly diminish the penetration of light. However, several studies 
demonstrated the ability of NIR fluorochromes to be coupled with targeting agents to efficiently 
Figure 5. NIR window for optical imaging13 
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image receptors.13 The main difficulty is developing a fluorescence dye and altering it with 
targeting moieties, to effectively image hypoxic tissue. 
 
2.1.4 The Combination of Indocyanine Green Dye and Nitroimidazole for 
Optical Imaging 
Indocyanine green (ICG) is the only FDA approved fluorescence imaging agent for patient 
use. It is used for determining the function of cardiac and hepatic processes as it readily binds to 
plasma in the blood. The application of ICG is hindered slightly by the problems of a low quantum 
yield and quick loss of fluorescence after binding to proteins in circulating blood.14 However, its 
low toxicity and easy wash out rates gives ICG 
the ability to be a suitable scaffold for a 
fluorescence probe to be tailored towards 
targeting hypoxic tumors.  
Nitroimidazole derivatives have been used as common moieties when targeting hypoxic 
cells of an organism since its potential was discovered by Varghese et al.15 Specifically, 2-
nitroimidazole has been incorporated into several 
radiosensitizers and hypoxia targeting prodrugs.16 The 
sensitivity towards hypoxic cells is attributed to an 
enzyme mediated reduction of the nitro group by 
nitroreductase enzymes in the absence of oxygen. The 
reduction potentials for nitroimidazoles are shown in figure 6. 2-Nitroimidazole inherently has the 
highest reduction potential and therefore is the most widely used to target hypoxic cells. This 
 
Figure 6. Reduction Potentials of 
Nitroimidazoles 
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reduced imidazole ring is susceptible to nucleophilic addition from cellular macromolecules to 
form long lasting binding adducts. The proposed mechanism for hypoxia specificity is shown in 
part a of figure 7.  
 
Figure 7. Mechanism proposed for 2-nitroimidaze selectivity towards hypoxic cells.17 
 
Studies in vivo reveal the sensitivity towards hypoxia of 2-nitroimidazole is due to the 
bioactive reduction is dependent on oxygen concentration. In a normoxia environment the initial 
one electron activation reduction to a nitro radical is in competition with reverse reaction of O2 
oxidation. The reaction is highly reversible and high oxygen concentrations dictates the 
equilibrium between the two reactions making further reduction impossible because oxidation 
back to the parent nitro compound is inevitable. In Hypoxia, nitro radicals are further reduced by 
a nitroreductase to the nitroso derivative, and eventually to the hydroxyl-amine. Acid catalyzed 
dehydration creates a cyclic imine that is susceptible towards binding of certain nucleophilic 
proteins and locking the compound within the cell. A specific enzyme for the reductions is 
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unknown, however one-electron reductases such as NADPH–nitroreductases, NADPH–
cytochrome P450 reductase, cytochrome b5 reductase, aldehyde dehydrogenase, and xanthine 
oxidase, and two-electron reductases such as DT-diaphorase have been acciociated.18  
With a suitable fluorophore, nitroimidazole can be used to deliver and retain a fluorescent 
probe in hypoxic cells. ICG lacks a reactive functional group that can efficiently couple with 
targeting agents. Fortunately the development of ICG bis-carboxylic acid (1) has been achieved, 
while retaining all desirable characteristics of the parent ICG dye.19 Figure 8 shows how the 
carboxylic acid derivative can be built upon to increase its sensitivity towards hypoxic cells.  
 
 
 
 
Figure 8. Proposed Structure for Fluoresence Hypoxia Probe 
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2.1.5 Development of ICG Dye Conjugates   
The Smith group has developed a method for coupling nitoimidazoles to ICG bis-
carboxylic acid 1. Connecting the two fragments together with an appropriate linker was of the 
first priority. The first-generation protocol involved the incorporation of an ethanolamine linker in 
route to synthesizing dye conjugate (2).20  
 
The first generation targeted fluorophores showed great sensitivity in breast cancer cells 
treated under hypoxic conditions in vitro.21 The cells fluorescence intensities were integrated to 
revealed a ratio between hypoxia per normoxia conditions are 2.5 for 2-nitroimidazole (2) treated 
cells and 1.2 for ICG (1) treated cells.  These results were also verified in vivo using a murine 
model, which involved 4TI mammary cancer cells grown in balb/c mice.22 The targeted dye 2 
displayed a two-fold higher fluorescence at the hypoxic tumor site when compared to normal sites.  
Hypoxic sights showed no difference in flouresence when treated with the untargeted dye 1. It is 
also noteworthy for later discussion that the 4-nitroimidazole derivative of 2 revealed minimal 
differences in fluorescence at the tumor when compared to the nomoxia tissues. An attempt to 
increase the bioavailability of the dye lead to the development of a “2nd generation dye conjugate” 
(3).23 
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The linker of 3 was changed to a piperazine ring instead of the presumed to be labile 
ethanolamine linker used previously. The new linker is not believed to exhibit any direct influence 
on the targeting of hypoxia. However, the more robust piperazine moiety is presumed to be more 
metabolically stable because of the two secondary amide linkages. Increasing the number of 
carbon atoms and diminishing the polarity slightly, leads to greater solubility in tissue. We 
presume that for these reasons, the bioavailability is greatly increased. This increased 
bioavailability leads to a higher probability of the 2-nitroimidazole dye conjugate to perfuse into 
hypoxic cells, undergoing enzymatic reduction, and irreversibly binding to macromolecule 
nucleophiles. Since the reduction is selective towards hypoxia, this leads to an enhanced 
fluorescence intensity in cancerous tumors compared to other tissues. When compared in vivo, the 
fluorescence intensity of 3 was measured to be twice that of 2 in the tumor tissue (figure 9).23 
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 Figure 9. Fluoresence Intensity of 1st and 2nd Generation Dyes in Hypoxic Tumors  
  
 This work has demonstrated the effectiveness of coupling the fluorophore ICG with a 
known hypoxia-targeting agent to optically image cancerous tumors. Table 1 displays the optical 
properties of the synthesized dyes and comparison to the parent FDA approved ICG. The 
wavelengths of absorbance and emission all fall into the desired window for imaging human tissue. 
However the quantum yield, the ratio of emitted photons to absorbed photons, is considered very 
low in all cases. The introduction of the piperazine linker did slightly increase the quantum yield, 
but the dye conjugate is still low. This diminished florescent yield leads to the requirement of 
higher doses of dye for proper imaging. In addition, the toxicity of the dye conjugate is unknown.  
 The depth at which the dye conjugates can image will also be effected since the dye itself 
will inherently lose a large percentage of photons. For these reasons, there is a need for 
improvement upon the system. 
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Table 1. Optical Properties of ICG, ICG bis-carboxylic acid, and 1st & 2nd Generation Dye Conjugates 
 
   
  
Dye 
 
λabs (nm) 
 
λem (nm) 
Extinction Coefficient 
(M-1cm-1) 
Quantum 
Yield (Φ) 
FDA approved ICG 
 
 
780 
 
807 
 
115,000 
 
0.0120 
ICG bis-carboxylic acid (1) 
 
 
755 
 
790 
 
220,920 
 
0.0728 
2-Nitroimidazole-
ethanolamine-ICG (2a) 
 
760 
 
790 
 
159,141 
 
0.0420 
2-Nitroimidazole-
piperazine-ICG (3) 
 
760 
 
790 
 
229,543 
 
0.0825 
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2.2 Results & Discussion 
2.2.1 Synthesis of Nitroimidazole Piperazine ICG Dye Conjugates 
With the aim of optically imaging hypoxic tissues that are indicative of cancerous tumors, 
our lab set out a goal of linking nitroimidazole, a known hypoxia targeting agent, to an indocyanine 
green (ICG) dye, which is a FDA approved fluorophore used as a medical diagnostic tool. Using 
a targeting moiety on a dye allows for selective imaging of desired regions while avoiding healthy 
tissues. The main priorities of the project include: (1) coupling the two compounds together with 
a linker that is stable in a biological system, (2) insure that the fluorescence properties of the dye 
remain useful, and (3) the nitroimidazole moiety is still efficient in targeting hypoxic cells.  
To achieve the first priority, our lab identified ICG bis-carboxylic acid (1) as a suitable 
candidate to link with the targeting agent. It was first synthesized by Lindsey et al and the dye-
conjugate showed great retention of optical properties, with a 5-fold increase of quantum yield, 
when compared to its parent compound ICG.19a The two carboxylic acid groups give a worthy 
branching point to which the targeting agent can be coupled. Our synthesis is shown in scheme 10.  
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Compound 1 was prepared by a straightforward synthesis as it was previously reported by 
Lindsey et al.19a Starting with commercially available p-hydrazinobenzoic acid (4), treatment with 
3-methyl-2-butanone gave indole 5, via a Fischer indole synthesis. Subsequent heating at reflux 
with butanesultone in 1,2-dichlorobenzene gave a zwitterion 6. The assembly of dye 1 was 
completed by condensation of two equivalents of 6 with the commercially available glutacondianil 
hydrochloride (7). The synthesis of ICG bis-carboxylic acid (1) has a 55% overall yield through 3 
steps and is routinely completed in gram scale. 
To produce the target dye we envisioned a convergent synthesis in which the targeting 
agent is connected to the linker and then coupled together with dye 1. The preparation of the 
targeting agent portion is shown in scheme 11. 
 
 
 
Scheme 10. Synthesis of ICG bis-carboxylic Acid (1) 
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When designing this portion of the synthesis the main concern was to carry the expensive 
2-nitroimidazole through as few synthetic steps as possible. Building upon the linker was therefore 
a logical plan compared to linearly from the imidazole ring. Stoichiometric protection of 
piperazine with di-tert-butyl dicarbonate gave half protected Boc-piperazine via a literature 
protocol.24 Subsequent acyl substitution of the free amine with bromoacetyl bromide gave 8. 
Coupling the 2-nitroimidazole linker was achieved via SN2 of the primary halide to produce 
compound 9. Deprotection of the Boc protected amine was achieved by stirring with trifluoroacetic 
acid, followed by crystallization to produce TFA salt 10 in a 27% yield from piperazine.25 
 The TFA salt 10 was coupled to ICG dye 1 using PyBOP as the coupling reagent. BOP 
reagents have demonstrated great efficiency when coupling secondary amino groups to acids and 
ByBOP is specifically used to minimize the amount of hazardous biproducts.26 The synthesis is 
shown in scheme 12, producing 2-nitroimidazole-piperazine-ICG (3) in 28% yield.27  
 
 
 
 
Scheme 11. Synthesis of 2-nitroimidazole Piperazine Fragment (10) 
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The low yield of the coupling procedure is due to the production of half loaded dye (single 
equivalence of 10 coupling to 1) and the extreme difficulty of purification. Both the half loaded 
and fully loaded dyes exist in a mixture of rotational isomers that elute off of reverse phase 
columns in a wide overlapping range. For this reason multiple purification attempts are needed in 
small scales to achieve pure material. This is a problem that has yet to be solved. With an extreme 
amount of effort we managed to purify a large quantity of mostly pure material for toxicity testing. 
The results are expected in the near future, however stress tests did show minimal discomfort in 
mice injection experiments. 
Scheme 12. Synthesis of 2-Nitroimidazole Piperazine ICG (3) 
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 With the costly price of 2-nitroimidazole, $354.00 per gram (Sigma-Aldrich CAS=527-73-
1), and the low yields in mind, our lab set out to try and produce the cheaper fluorescence dye 13. 
Using 4-nitroimidazole, $1.86 pure gram (Sigma-Aldrich CAS=3034-38-6), should greatly 
decrease the cost. A literature search revealed that the 4-nitro does still retain hypoxia targeting 
properties with a minimal decrease in efficiency, but there is some concern of increased toxicity.28 
Scheme 13 displays the synthesis of 4-Nitroimidazole Piperazine ICG (12). 
Scheme 13. Synthesis of 4-Nitroimidazole Piperazine ICG (12) 
 Dye Conjugate 12 was synthesized in the identical straight forward manner as known targeting dye 
3 with similar yields.29 The only difference is the incorporation of 4-nitroimidazole instead of 2-
nitroimidasole. The two dyes used for in vivo studies to test the hypothesis that 4-nitroimidazole will still 
target hypoxic cells. For good measure, a control dye, a derivative with just imidazole linked to ICG, was 
synthesized to analyze the effect of having no targeting moiety on our synthetic dyes. The lack of a nitro 
group would create a unsuitable substrate for macromolecule binding within the cell. Scheme 14 shows the 
synthesis of imidazole-piperazine-ICG (14), a non-targeting second generation dye. 
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Scheme 14. Synthesis of imidazole-piperazine-ICG (14) 
Again the synthesis followed identical synthetic methodology with just the substitution of 
imidazole to couple with the linker.29 The only modification in the procedure was the duration of 
time and stoichiometry in which we allowed the substitution reaction of imidazole with 
intermediate 8. The absence of a nitro moiety on the imidazole ring displayed a higher reactivity 
of the second nitrogen and yielded undesired di-substituted imidazole. Stirring the reaction for a 
shorter amount of time and increased equivalence of imidazole gave the proper substitution. 
Coupling of 13 with synthetic 1 produced ICG dye conjugate 14 to be used as a control for optical 
imaging experiments. 
 
2.2.2 Hypoxia Targeting Evaluation of Nitroimidazole Piperazine ICG Dye 
Conjugates 
 Upon completion of the synthesis of the second generation dyes, in vivo testing was done 
in mice with hypoxic tumors.29 The protocol used a murine model, which involved 4TI mammary 
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cancer cells grown in balb/c mice. The tumors were grown on top of the right leg until diameter 
was approximately 7-8 mm. All injections were administered intravenously through retro-orbital 
venous sinus. The tumor was then imaged at designated time intervals and the measured 
fluorescence intensity for each imaging experiment were averaged and compared.  
 
 
 
 
 
 
Figure 10. In vivo Fluorescence of 2-Nitroimidazole-Piperazine-ICG (3) 
 
Figure 11. In vivo Fluorescence of 4-Nitroimidazole-Piperazine-ICG (12) 
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Figures 10, 11, and 12 shows images obtained over 48 h post injection of ICG dye 
conjugates 3, 12, and 14 respectively. Each image is averaged fluorescence distribution of a mouse 
injected with 100 μL of a 25 μM concentration of designated dye. The images show rapid uptake of 
the dye-conjugates in the tumor, as well as widespread distribution in the mouse. Washout rates in each 
case are rapid throughout the body, however 3 and 12 are retained in the tumor for a prolonged time relative 
to 14. This is indicative of the need for a nitroimidazole moiety to target and irreversibly bind to hypoxic 
cells. Interestingly with identical injection concentrations, 12 appears to accumulate and retain in the tumor 
at higher concentrations for longer amount of time compared to 3. Figure 13 is a graphical example of the 
maximum radiant efficiency for 3, 12, and 14 within the tumors vs. time. This is an aim to demonstrate the 
wash out rates of the three dye conjugates. 
 
Figure 12. In vivo Fluorescence of Imidazole-Piperazine-ICG (14) 
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Figure 13. Graphical Representation of Maximum Radiant Efficiencies for 2nd Generation Dye Conjugates Over 
Time 
 
 The in vivo imaging reveals that all three dye conjugates go into the tumors extremely fast, 
therefore displaying a high level of biodiversity. The maximum intensity for imaging is around 15 
minutes. Non-targeted dye 14 washes out of the tumor extremely fast as expected due to a lack of 
a binding potential. Targeted dyes 3 and 12 seem to wash out of the tumors at similar rates. This 
is most likely due to the cellular metabolism being identical for bound ICG dye conjugates. 4-
Nitroimidazole-piperazine-ICG (12) has a higher fluorescence intensity in the tumor with the same 
injection volume and concentration when compared to 2-nitroimidazole-piperazine-ICG (3). Since 
the quantum yield of 12 is slightly lower then 3, it implies that the 4-nitro derivative is actually 
slightly better at targeting hypoxia in our fluorescence probe system. The optical properties of all 
three second generation dyes are shown in Table 2.   
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Dye 
 
λabs (nm) 
 
λem (nm) 
Extinction Coefficient 
(M-1cm-1) 
Quantum 
Yield (Φ) 
FDA approved ICG 
 
 
780 
 
807 
 
115,000 
 
0.0120 
ICG bis-carboxylic acid (1) 
 
 
755 
 
790 
 
220,920 
 
0.0728 
Nitroimidazole- 
piperazine-ICG (14) 
 
755 
 
790 
 
204,100 
 
0.0610 
2-Nitroimidazole-
piperazine-ICG (3) 
 
755 
 
790 
 
229,543 
 
0.0825 
4-Nitroimidazole-
piperazine-ICG (12) 
 
755 
 
790 
 
207,519 
 
0.0711 
 
Table 2. Optical Properties of 2nd Generation Dye Conjugates 
  
2.2.3 Synthesis of Rigid ICG Dye Conjugate 
 
In an attempt to rigidify the dye conjugates and potentially increase the optical properties, 
Mohammad et al synthesized several ICG derivatives by altering the polyene chain.30 The theory 
was that an introduction of a ring into the chain or shortening it would decrease the rotation around 
the C-C bonds. The rotational isomers of ICG derivatives can quench absorbed energy and 
diminish the release of fluorescence. The result is a probe with a low quantum yield and a poor 
tool for fluorescence imaging. Only one of the newly synthesized dyes revealed a large increase 
in quantum yield and was worth exploring further. This gave birth to the idea of a “3rd generation 
dye conjugate” (15). The deletion of 2 carbons to a pentamethine polyene chain is only difference 
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between the 2nd and 3rd generation of dye conjugates. This minor difference leads to a restriction 
of rotation around the polyene chain due to an increased steric clash between the sulfate side 
chains. The synthesis of 15 and its precursor bis-carboxylic acid 18 is shown in figure 14.31 
The production of the shorten anilide 17 was achieved via condensation reaction of the 
bis(dimethyl acetal) of propanedial (16) with aniline in the presence of aqueous HCl. Reacting 2 
equivalence of indole 6 with 17 produced “rigid ICG di-acid” (18). Coupling the di-acid with 
targeting agent 10 synthesized 2-nitroimidazole-piperazine-rigid-ICG (15). Brief stability studies 
with UV light radiation showed nearly a 4-fold slower degradation half-life compared to the ICG 
counterparts. A small negative is that the max absorbance and fluorescence wavelengths displayed 
 Scheme 15. Synthesis of 3rd Generation Dye Conjugate 
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a slight blue shift, however still fall in the ideal window for tissue imaging. The quantum yield of 
15 and 18 greatly improved and are shown in table 3 with ICG comparisons.31  
  
Dye 
 
λabs (nm) 
 
λem (nm) 
Extinction Coefficient 
(M-1cm-1) 
Quantum 
Yield (Φ) 
FDA approved ICG 
 
780 
 
807 
 
115,000 
 
0.0120 
ICG bis-carboxylic acid (1) 
 
755 
 
790 
 
220,920 
 
0.0728 
2-Nitroimidazole-
piperazine-ICG (3) 
 
755 
 
790 
 
229,543 
 
0.0825 
Rigid bis-carboxylic acid 
(18) 
 
655 
 
672 
 
262,000 
 
0.403 
2-Nitroimidazole-
piperazine-rigid (15) 
 
653 
 
670 
 
268,000 
 
0.467 
 
Table 3. Optical Properties of 3rd  Generation Dye Conjugate 
  
2.2.4 Hypoxia Targeting Evaluation of Rigid ICG Dye Conjugates 
 Evaluation of third generation dye’s hypoxia imaging capabilities was done the same way 
as the previous in vivo studies.31 Figure 15 shows the graphical representation of fluorescence 
intensity in the tumor over the course of a 48 hour period. The rigid dyes 15 and 18 were compared 
to second generation 3 and ICG bis-carboxylic acid (1). As expected the rigid analogs showed a 
superior fluorescence detectability for hypoxic tumors in vivo. This was expected due to the nearly 
5-fold increase in quantum yield when compared to previous generation. Targeted dye conjugate 
15 showed a slower diminishment of fluorescence when compared to 3. This is likely the effect of 
increased stability of the rigid dyes. 
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Figure 14. In vivo Fluoresence Efficiency of 3rd Generation Dyes 
 
2.2.5 Synthesis of Biotin Derivative 
 It is important in our work to demonstrate proof that our dye conjugates are binding to targets in 
the cell and possibly understand the identity of that protein. Immunoprecipitation is a technique in which 
isolation of a protein is attained by selectively binding an antigen to the target protein. An antibody can 
bind the antigen and be used to separate the protein from others. An avidin-biotin pull down is a specific 
version of this.32 Bioactive molecules can be labeled with a biotin moiety (biotinylation) and bound to their 
respective proteins. Avidin then attaches to the biotin and easily co-purified with the targeted protein. 
Applying this chemistry to the nitroimidazole dye conjugates could elucidate the specific protein binding 
of the compounds. For this reason biotinylated unsymmetrical dye conjugate 16 was designed. 
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 An unsymmetrical dye conjugate’s synthesis is not as straight forward as the symmetrical 
targeted dye conjugates. Coupling bis-carboxylic acid ICG (1) with just one equivalence of 
targeting agent leads to a mixture of fully loaded (two targeting agents attached) and half loaded 
(one targeting agent attached). The mixtures are difficult to separate and deems the synthetic 
strategy useless. A way around this is by the production half methyl ester ICG 18. Treatment of 
indole acid 6 with oxalyl chloride in methanol produced indole methyl ester 17. One equivalence 
of each 6 and 17 can be coupled together to produced 18 with stepwise introduction of each indole. 
Then coupling the free acid with targeting agent 10 would produce half loaded dye 19. 
Unfortunately all attempts at saponification of the methyl ester failed due to the degradation of the 
dye. One idea that was not tried is the use of an esterase. Without easy accessibility to a library of 
enzymes, we changed routes to synthesis biotinylated 16. 
243 
 
 
 Attaching a biotin moiety to an earlier intermediate of the dye synthesis was a successful 
strategy. Biotin compound 21 was coupled to indole 5 to produce biotin-indole 22.33 Reaction with 
1,4-butane sultone produced 23, that could be linked to indole 6 with anilide 7 through a stepwise 
addition of each indole. This produced biotinylated dye 24 in an easily purified fashion. Final 
coupling with targeting agent 10 gave biotin dye conjugate 16. This product has been verified and 
awaits being applied to tumor cells for the “avidin pull down” experiment. 
 
Scheme 16. Attempted Synthesis of Biotinylated ICG Dye Conjugate via Half Methyl Ester ICG di-acid 
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2.2.6 Present Research & Future Work 
 Our current efforts are aimed towards the once again restrict the rotation around the polyene 
unit of our dye conjugates. The rigid dyes showed an excellent increase in quantum yield, however 
the blue shift fluorescence is a negative effect that may decrease tissue penetration. An SAR study 
has begun on the effects of the dye’s optical properties by increasing the steric bulk attached to the 
indole rings. This would be in the form of increasing the size of the methyl groups on compound 
1 (circled in red in figure 18). Preliminary studies are producing derivatives of the ethyl, pentyl 
and benzyl variety by incorporating them into the fisher indole synthesis. One possible structure 
that is highly interesting is macrocycle 26. The bridged bicyclic ring system is thought to be 
possible through ring closing metathesis of 25 or a derivative aimed towards a different ring 
 
Scheme 17. Successful Synthesis of Biotinylated Dye Conjugate 
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construction. Shown is just a generic olefin coupling, but this could be envisioned through other 
completely different derivatives for ring closer. The aim is to try and lock the polyene unit into as 
strict of a formation as possible and increase the dyes quantum yield. 
 
 
Figure 15. Current SAR Study towards a New Generation of Dye Conjugates 
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2.3 Experimental 
 All glassware was oven-dried, and all reactions were performed under a nitrogen 
atmosphere.  All chemicals were purchased from the Sigma-Aldrich Chemical Co., and used 
without further purification unless otherwise noted.  Tetrahydrofuran (THF) was distilled from 
sodium benzophenone ketyl, methylene chloride (dichloromethane, DCM) was distilled from 
calcium hydride, and dimethylformamide (DMF) was distilled in vacuo from calcium hydride.  
Ethyl acetate (EtOAc), methanol (MeOH), and diethyl ether were used as obtained from the 
vendor. 
 Thin-layer chromatography was done on Sorbent Technologies aluminum-backed TLC 
plates with fluorescent indicator and 0.2 mm silica gel layer thickness, and p-anisaldehyde or 
phosphomolybdic acid were used as developing agents.  Column chromatography was done using 
60 Å porosity, 32-63 µm silica gel. 1H and 13C NMR were collected on a Bruker Avance 300 
(300.13 MHz 1H, 75.48 MHz 13C), Bruker DRX-400 (400.144 MHz 1H, 100.65 MHz 13C) or a 
Bruker Avance 500 (500.13 MHz 1H, 125.65 MHz 13C).  Chemical shifts are reported in ppm 
downfield from tetramethylsilane (TMS) in the following format chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet). Coupling constants are reported in Hz.  
Mass spectrometry data was collected on a HP 5870B GC/MSD mass spectrometer with an HP-1 
column, and high resolution MS and MS/MS spectra were obtained by direct infusion into a QTOF 
mass spectrometer, QSTAR Elite from Sciex (Foster City, CA) or directly by using AccuTOF™ 
DART, JEOL (Peabody, MA).  Multiple reaction monitoring (MRM) transitions were selected 
based the MS/MS spectra.  IR spectra were taken on FT/IR-410/C031560585 JASCO and Nexus 
670 FT-IR E.S.P, neat, unless otherwise stated.  All melting points to an upper limit of 270 °C 
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were obtained using a Uni-melt capillary melting point apparatus or Digimelt MPA160. For 
products described as waxy solid or semi-solids, melting points could not be obtained. 
Repeated efforts to obtain the 13C NMR of dye conjugates failed to give a spectrum. We 
examined the possibility of aggregation, rotamers, relaxation time, and low concentration due to 
solubility issues. All of these issues can lead to poor 13C NMR spectra. Attempts to obtain 13C 
NMR spectra at 25 °C failed, and we heated the samples to 55 °C to promote deaggregation. We 
also explored different solvents, including CD3OD, (CD3)2CO, D2O. We examined extended delay 
(relaxation) times up to 10 to 15 s, as well as long acquisition times (up to 24 hours). None of these 
experiments led to a 13C NMR. We have attempted indirect 13C experiments, including HSQC, 
HMBC, and CIGAR. The problem is likely due to low solubility, coupled with the low isotope 
percentage of 13C relative to 12C versus the high percentage of 1H, but we do not have a definitive 
answer to this problem. No experiments have been successful, so only 1H NMR data is provided. 
It is noted that the commercial ICG obtained from SigmaAldrich, as well as derivatives 
prepared in our laboratory is a mixture of isomers as determined by high-performance liquid 
chromatography analysis. This mixture is undoubtedly a mixture of E/Z isomers of the polyene 
linker. No attempt was made to separate this mixture into the component stereoisomers, and in all 
cases, the mixture was used for in vivo studies. To the best of our knowledge, such mixtures are 
used in all biological studies that involve ICG.  
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2,3,3-Trimethyl-3H-indole-5-carboxylic acid, (5) 
 
A 100 mL round-bottumed flask was charged with 4-hydrazinobenzoic acid (4.892 g, 32.2 mmol), 
3-methylbutan-2-one (4.82 g, 45.1 mmol), sodium acetate (5.28 g, 64.4 mmol), and glacial acetic 
acid (50 mL). The mixture was stirred for 1 h and then heated at reflux overnight. The solvent was 
removed under reduced pressure to a sludge and then crystalized from 10% MeOH (80mL). The 
resulting precipitate was filtered and dried to yield 5 (3.66 g, 18.0 mmol, 55.9%) as a tan solid.20 
1H NMR (400 MHz, Chloroform-d) δ 8.13 (dd, J = 8.1, 1.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.63 
(d, J = 8.1 Hz, 1H), 2.36 (s, 3H), 1.36 (s, 6H). 13C NMR (101 MHz, Chloroform-d) δ 192.5, 171.0, 
158.1, 145.9, 131.0, 126.4, 123.4, 119.9, 54.1, 23.0, 15.8. 
 
5-Carboxy-1-(d-sulfobutyl)-2,3,3-trimethyl-3H-indolium betaine, (6) 
 
A mixture of 5 (3.66 g, 18.0 mmol) and 1,4-butanesultone (10.1 mL, 99.0 mmol) in 1,2-
dichlorobenzene (80 mL), was created under a nitrogen atmosphere. The mixture was heated at 
reflux overnight. The reaction solution was cooled to room temperature and the red precipitate was 
filtered, rinsed with acetone, and dried to give 6 (4.90 g, 14.4 mmol, 80.2 %).20 1H NMR (400 
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MHz, CD3OD) δ 8.40 (d, J = 1.3 Hz, 1H), 8.34 (dd, J = 8.4 Hz, 1H), 8.07 (d, J = 8.4 Hz, 1H), 4.63 
(t, J = 7.8 Hz, 2H), 4.43 (s, 3H), 2.93 (t, J = 7.1 Hz, 2H), 2.24-2.16 (m, 2H), 2.02-1.95 (m, 2H), 
1.68 (s, 6H). 13C NMR (101 MHz, CD3OD) δ 201.1, 167.9, 145.3, 143.6, 133.7, 132.3, 125.6, 
116.8, 56.2, 51.0, 27.3, 23.2, 22.6. 
 
N-(2-Hydroxyethyl)-2-(4-nitro-1H-imidazol1-yl)acetamido-ICG, (1) 
 
Indolium salt 6 (3.85 g, 11.3 mmol) and N-[5-(Phenylamino)-2,4-pentadienylidene]aniline 
monohydrochloride (1.79 g, 6.29 mmol) was added to a 100 mL round-bottomed flask. Then acetic 
anhydride (60 mL) and glacial acetic acid (36 mL) were added and stirred at room temperature. 
This solution was treated with sodium acetate (1.64 g) and then heated to reflux for 45 min. The 
blue solution was then cooled to room temperature before being poured into hot anhydrous ether 
(150 mL). The solution was cooled in the refrigerator overnight, and the green precipitate was 
vacuum filtrated and washed with ether. The product was recrystallized from a 1:4 mixture of 
water and propanol to yield 1 (2.94 g, 3.85 mmol, 68 %) as a green powder.20 1H NMR (400 MHz, 
DMSO-d6) δ 12.96 (bs, 1H), 8.08 (d, J = 7.3 Hz, 2H), 7.97 (d, J = 7.3, 2H), 7.84 (m, 2H), 7.52 (d, 
J = 9.1 Hz, 2H), 7.47 (s, 1H), 6.48 (m, 4H), 4.15-4.06 (m,4H), 3.86 (s, 3H), 1.73 (s, 8H), 1.63 (s, 
12H). 13C NMR (101 MHz, DMSO-d6) δ 167.7, 166.6, 147.1, 142.0, 131.3, 125.6, 124.0, 123.8, 
52.8, 51.4, 49.4, 41.8, 27.7, 26.8, 23.2. 
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Tert-butyl piperazine-1-carboxylate 
 
A solution of di-tert-butyl dicarbonate (3.80 g, 17.4 mmol) in CH2Cl2 (50 mL) was added dropwise 
to a stirring solution of piperazine (3.00 g, 34.8 mmol) in CH2Cl2 (60 mL) at room temperature 
and stirred for 16 h. The solvent were removed under reduced pressure and the residue dissolved 
in water (50 mL). The aqueous solution was extracted with methylene chloride (4 × 75 mL) and 
all the organic extractions were combined, dried over anhydrous magnesium sulfate, and 
concentrated to get tert-butyl piperazine-1-carboxylate as a white solid (1.5 g, 8.05 mmol, 34.7 
%).24 1H NMR (400 MHz, CDCl3) δ 3.37 (m, 2 H), 2.79 (m, 2 H), 1.72 (bs, 1 H), 1.44 (s, 9 H) 
ppm. 13C NMR (101 Hz, CDCl3) δ 154.3, 79.8, 45.6, 44.5, 28.8 ppm. 
 
Tert-butyl 4-(2-bromoacetyl) piperazine-1-carboxylate, (8) 
 
Triethylamine (2.8 mL, 20.3 mmol) was added to a stirring solution of tert-butyl piperazine-1-
carboxylate (3.44 g, 18.4 mmol) in dry dichloromethane (100 mL) at 0°C and stirred for 15 min. 
Bromoacetyl bromide (1.8 mL, 20.3 mmol) was added dropwise at 0°C, and the resulting mixture 
was stirred at room temperature overnight. Reaction progress was monitored by TLC, and after 
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disappearance of the starting material, the mixture was concentrated and purified via column 
chromatography (hexanes:ethyl acetate 20%) to give tert-butyl 4-(2-bromoacetyl) piperazine-1-
carboxylate (8, 3.36 g, 10.9 mmol, 59.3%) as a white solid. Mp: 95-97°C.24 1H NMR (400 MHz, 
Chloroform-d) δ 3.86 (s, 2H), 3.63–3.56 (m, 2H), 3.56–3.46 (m, 4H), 3.46–3.41 (m, 2H), 1.47 (s, 
9H). 13C NMR (101 MHz, Chloroform-d) δ 165.6, 154.6, 80.6, 46.7, 42.1, 28.5, 25.7. 
 
Tert-butyl 4-(2-(2-nitro-1 H-imidazol-1-yl)acetyl) piperazine-1-carboxylate, (9) 
 
Commercially available 2-nitroimidazole (0.100 g, .885 mmol) was dissolved in 2 mL of freshly 
distilled DMF, under N2, and cooled to 0°C. Sodium hydride (0.042 g, .106 mmol) was added to 
the reaction and stirred for 30 min before a dropwise addition of tert-butyl 4-(2- 
bromoacetyl)piperazine-1-carboxylate (8, 0.272 g, .885 mmol) dissolved in 2 mL of DMF. The 
mixture was slowly warmed to room temperature and stirred overnight. The reaction was 
concentrated under reduced pressure and then addition of 10 mL of water caused a white 
precipitate to form. The solid was filtered and dried under reduced pressure overnight to afford 
tert-butyl 4-(2-(4-nitro-1Himidazol-1-yl)acetyl)piperazine-1-carboxylate (9, 0.280 g, .825 mmol, 
93%). Mp: 197-199°C.27 1H NMR (400 MHz, Chloroform-d) δ 7.20 (s, 1H), 7.07 (s, 1H), 5.23 (s, 
2H), 3.65–3.55 (m, 4H), 3.54–3.44 (m, 4H), 1.48 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 
163.5, 154.5, 145.3, 128.3, 127.2, 80.7, 50.9, 45.1, 42.5, 28.5. 
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tert-Butyl 4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)piperazine-1- carboxylate 
 
Commercially available 4-nitroimidazole (0.55 g, 4.9 mmol) was dissolved in 2 mL of freshly 
distilled DMF, under N2, and cooled to 0°C. Sodium hydride (0.14 g, 5.9 mmol) was added to the 
reaction and stirred for 30 min before a dropwise addition of tert-butyl 4-(2- 
bromoacetyl)piperazine-1-carboxylate (1.50 g, 4.9 mmol) dissolved in 2 mL of DMF. The mixture 
was slowly warmed to room temperature and stirred overnight. Addition of 10 mL of water caused 
a white precipitate to form. The solid was filtered and dried under reduced pressure overnight to 
afford tert-butyl 4-(2-(4-nitro-1Himidazol-1-yl)acetyl)piperazine-1-carboxylate (1.26 g, 3.7 
mmol, 76%).29 Mp: 197-199 °C. 1H NMR (400 MHz, CDCl3) δ 7.82-7.81 (d, J = 1.5 Hz, 1H), 
7.45-7.44 (d, J = 1.4 Hz, 1H), 4.86 (s, 2H), 3.65-3.63 (m, 2H), 3.56-3.54 (m, 2H), 3.50-3.47 (m, 
4H), 1.48 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 163.1, 154.6, 148.2, 137.1, 120.9, 81.1, 48.8, 
45.0, 42.5, 28.5. HRMS (ESI-TOF): [M+H] Calc'd for C14H22N5O5 m/z 340.1621. Found m/z 
340.1607.29 
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tert-Butyl 4-(2-(1H-imidazol-1-yl)acetyl)piperazine-1- carboxylate 
 
Commercially available imidazole (0.33 g, 4.9 mmol) was dissolved in 2 mL of freshly distilled 
DMF, under N2, and cooled to 0°C. Sodium hydride (0.14 g, 5.9 mmol) was added to the reaction 
and stirred for 30 min before a dropwise addition of tert-butyl 4- (2-bromoacetyl)piperazine-1-
carboxylate (1.50 g, 4.9 mmol) dissolved in 2 mL of DMF. The mixture was slowly warmed to 
room temperature and stirred overnight. Addition of 10 mL of water caused a white precipitate to 
form. The solid was filtered and dried under reduced pressure overnight to afford tert-butyl 4-(2-
(1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.97 g, 3.3 mmol, 67%).29 Mp: 147-149°C. 1H 
NMR (400 MHz, Chloroform-d) δ 7.50 (s, 1H), 7.10 (s, 1H), 6.95 (s, 1H), 4.78 (s, 2H), 3.61 (d, J 
= 5.3 Hz, 2H), 3.49–3.39 (m, 6H), 1.47 (s, 9H). 13C NMR (101 MHz, Chloroform-d) δ 164.9, 
154.5, 138.1, 129.9, 120.1, 80.8, 48.2, 45.1, 42.2, 28.5. HRMS (ESI þ TOF): [M þ H] þ Calc'd for 
CH23N4O3 m/z 295.1770. Found, m/z 295.1751. 
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4-(2-(2-Nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (10) 
 
A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0°C under a nitrogen 
atmosphere. tert-Butyl 4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.280 g, 
0.823 mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The solution was 
slowly warmed to room temperature and stirred overnight. The reaction was concentrated in vacuo 
to a crude oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration 
and dried under reduced pressure to yield 4-(2-(2-nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium 
tri-fluoroacetate (10, 0.214 g, 0.636 mmol, 77%).27 1H NMR (400 MHz, D2O) δ7.58 (s, 1 H), 7.40 
(s, 1 H), 5.68 (s, 2 H), 4.08 (t, J ¼ 4 Hz, 2 H), 4.03 − 4.00 (m, 2 H), 3.59 (t, J ¼ 4 Hz, 2 H), 3.50-
3.47 (m, 2 H); 13C NMR (100 MHz, D2O) δ166.9, 163.3, 162.9, 162.6, 149.0, 129.2, 128.4, 121.0, 
118.1, 115.2, 112.2, 51.3, 43.3, 42.2, 39.6; HRMS Calcd C10H14F3N5O5 240.1096, found 
240.1149. 
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4-(2-(4-Nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (11) 
 
A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0 C under a nitrogen 
atmosphere. tert-Butyl 4-(2-(4- nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.250 g, 
0.73 mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The solution was 
slowly warmed to room temperature and stirred overnight. The reaction was concentrated in vacuo 
to a crude oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration 
and dried under reduced pressure to yield 4-(2-(4-nitro-1H-imidazole-1-yl)acetyl)piperazin-1-ium 
tri- fluoroacetate 9b (0.193 g, 0.55 mmol, 74%).29 mp: 228e229 C; 1 H NMR (400 MHz, D2O) d 
8.20 (bs, 1H), 7.79 (bs, 1H), 5.32 (s, 2H), 3.92e3.89 (m, 4H), 3.47e3.37 (m, 4H); 13C NMR (100 
MHz, CDCl3) d 166.6, 163.4, 163.0, 162.5, 162.0, 146.7, 138.7, 123.5, 118.7, 49.0, 42.9, 41.7, 
39.2; HRMS (ESI-TOF): [M þ H] þ Calc'd for C9H14N5O3 m/ z 240.1096. Found, m/z 240.1100. 
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4-(2-(1H-Imidazole-1-yl)acetyl)piperazin-1-ium trifluoroacetate, (13) 
 
A solution of trifluoroacetic acid (1 mL) and chloroform (6 mL) was cooled to 0 C under a nitrogen 
atmosphere. tert-Butyl 4-(2- (1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (0.250 g, 0.85 
mmol) dissolved in 3 mL of chloroform was added dropwise via cannula. The reaction mixture 
was slowly warmed to room temperature, stirred overnight, and concentrated in vacuo to a crude 
oil that was crystalized from ethyl acetate. The product was isolated by vacuum filtration and dried 
under reduced pressure to yield 4-(2-(1H-imidazole-1-yl)acetyl)piperazin-1-ium trifluoroa cetate 
9a (0.161 g, 0.52 mmol, 61%).29 mp: 129e130 C; 1 H NMR (400 MHz, D2O) d 8.76 (s, 1H), 7.53 
(s, 1H), 7.46 (s, 1H), 5.43 (s, 2H), 3.90e3.87 (m, 4H), 3.44e3.41 (m, 2H), 3.36e3.34 (m, 2H); 13C 
NMR (100 MHz, CDCl3) d 166.0, 163.4, 163.0, 136.5, 123.6, 119.8, 118.0, 115.1, 50.1, 42.9, 
41.8, 41.7, 39.3; HRMS (ESI þ TOF): [MCF3COO þ H] Calc'd for C9H15N4O m/z 195.1246. 
Found, m/z 195.1231. 
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Sodium 4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(2-nitro- 1H-imidazol-1-
yl)acetyl)cyclo-hexane-1-carbonyl)-1-(4- sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-
trien-1-ylidene)- 3,3-dimethyl-5-(4-(2-(2-nitro-1H-imidazol-1-yl)acetyl) cyclohexane-1-
carbonyl)indolin-1-yl)butane-1-sulfonate, (3) 
 
A stirred solution of ICG bis (carboxylic acid) (1, 0.139 g, 0.182 mmol) in dry DMF (2 mL) at 
0°C was treated with benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
(0.208 g, 0.400 mmol), 1-hydroxybenzotriazole (0.054 g, 0.400 mmol), and diisopropylethylamine 
(69.9 μL, 0.400 mmol) in that order, and stirred at 0°C for 15 min. At this time, 2-(2-nitro-1H-
imidazol-1-yl)-1-(piperazin-1-yl)ethanone, TFA salt (10, 0.135 g, 0.400 mmol) was added and the 
resulting mixture stirred at room temperature for 48 h. The DMF was evaporated and the resulting 
solid was purified using C18 reverse phase column chromatography to yield compound 3 as an 
amorphous green solid (0.044 g, 0.037 mmol, 20.0%).27 1H NMR (400 MHz, D2O): δ7.84 (t, J ¼ 
12 Hz, 2 H), 7.57 (s, 2 H), 7.45 (bs, 5 H), 7.35–7.33 (m, 2 H), 7.27 (s, 2 H), 6.57 (t, J ¼ 12 Hz, 2 
H), 6.29 (d, J ¼ 12 Hz, 2 H), 5.57 − 5.51 (m, 4 H), 4.15 (bs, 4 H), 3.86 − 3.52 (m, 16 H), 2.97 (t, 
J ¼ 8 Hz, 4 H), 1.99 − 1.97 (m, 4 H), 1.91 − 1.87 (m, 4 H), 1.61 (bs, 12 H). HRMS Calcd protonated 
formula C55H67N12O14S2 1183.4341, found 1183.4399. 
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Sodium 4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(4-nitro- 1H-imidazol-1-
yl)acetyl)cyclo-hexane-1-carbonyl)-1-(4- sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-
trien-1-ylidene)- 3,3-dimethyl-5-(4-(2-(4-nitro-1H-imidazol-1-yl)acetyl) cyclohexane-1-
carbonyl)indolin-1-yl)butane-1-sulfonate, (12) 
 
A total of (0.150 g, 0.197 mmol) of 2 was dissolved in 1 mL freshly distilled DMF under N2 and 
cooled to 0 C. The reaction was then charged with pyBop (0.220 g, 0.0423 mmol), HOBt (0.065 
g, 0.423 mmol), DIPEA (0.074 mL, 0.423 mmol) and stirred for 15 min before the addition 4-
nitroimidazole piperazine TFA (0.149 g, 0.423 mmol). The solution was warmed to room 
temperature and let stir overnight. The solvent extensively removed and the resulting sold was 
washed with EtOAc (15 mL), chloroform (15 mL), and acetonitrile (15 mL) before being 
recrystallized from methanol/ diethyl ether. The crude material was purified by C18 reverse phase 
chromatography to yield 6 as a green solid (0.049 g, 0.041 mmol, 21%).29 mp: decomposed >250 
C; 1 H NMR (400 MHz, D2O) d 8.26 (s, 2H), 7.92 (t, J ¼ 12 Hz, 2H), 7.81 (s,2H), 7.75 (s, 2H), 
7.69 (s, 2H), 7.72e7.48 (m, 4H), 6.65e6.59 (m, 2H), 6.51 (d, J ¼ 8 Hz, 2H), 5.21 (bs, 4H), 4.11 
(m, 4H), 3.58 (m, 16H), 1.80e1.71 (m, 8H), 1.68 (s, 12H); HRMS (ESI-TOF): [M-Na]- Calc'd for 
C55H65N12O14S2 m/z 1181.4185. Found, m/z 1181.4174. 
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Sodium 4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(1Himidazol-1-yl)acetyl)cyclohexane-
1-carbonyl)-1-(4- sulfonatobutyl)-3H-indol-1-ium-2-yl)hepta-2,4,6-trien-1-ylidene)- 3,3-
dimethyl-5-(4-(2-(1H-imidazol-1-yl)acetyl)cyclohexane-1- carbonyl)indolin-1-yl)butane-1-
sulfonate, (14) 
 
A total of (0.301 g, 0.39 mmol) of 2 was dissolved in 1 mL freshly distilled DMF under N2 and 
cooled to 0 C. The reaction was then charged with pyBop (0.45 g, 0.86 mmol), HOBt (0.117 g, 
0.86 mmol), DIPEA (0.200 mL, 0.1.18 mmol) and stirred for 15 min before the addition imidazole 
piperazine TFA (0.266 g, 0.86 mmol). The solution was warmed to room temperature and let stir 
overnight. The solvent extensively removed and the resulting sold was washed with EtOAc (15 
mL), chloroform (15 mL), and acetonitrile (15 mL) before being recrystallized from 
methanol/diethyl ether. The crude material was purified by C18 reverse phase chromatography to 
yield 5 as a green solid (0.065 g, 0.0058 mmol, 15%).29 mp: decomposed >250 C; 1 H NMR (400 
MHz, D2O) d 7.92 (t, J ¼ 12 Hz, 2H), 7.69 (s,2H), 7.51 (d, J ¼ 16 Hz, 6H), 7.06 (s, 2H), 7.05e6.95 
(m, 1H), 6.87 (s, 2H), 6.62 (t, J ¼ 12 Hz, 2H), 6.50 (d, J ¼ 12, 2H), 5.06 (s, 4H), 4.10 (bs, 4H), 
3.57 (bs, 16H), 1.77 (m, 8H), 1.67 (s, 12H); HRMS (ESITOF): [M-Na]- Calc'd for 
C55H67N10O10S2 m/z 1091.4483. Found, m/z 1091.4456. 
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Sodium 4-[2-[(1E,3E,5Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)- indol-2-ylidene]penta-1,3-
dienyl]-1,1-dimethylindol-3-ium-3-yl]- butane-1-sulfonate, (18) 
 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (6, 0.14 g, 0.41 mmol) and 7 (0.05 g, 0.19 mmol) in acetic anhydride (1 mL) and acetic 
acid (0.5 mL) was treated with sodium acetate (0.054 g, 0.66 mmol) and heated at reflux (120 °C) 
for 45 min. The reaction mixture was cooled to ambient temperature and anhydrous diethyl ether 
(5 mL) was added. The resulting precipitate was isolated by vacuum filtration to give a crude solid 
that was recrystallized (methanol : water) to give 8 as a blue solid (0.09 g, 0.12 mmol, 63%);22 
mp: decomposition at 287 °C; 1 H NMR (400 MHz, CD3OD) δ 12.92 (bs, 2H), 8.43 (t, J = 13 Hz, 
2H), 8.17 (s, 2H), 8.00 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 6.71 (t, J = 12.4 Hz, 1H), 6.50 
(d, J = 13.7 Hz, 2H), 4.15 (bs, 4H), 1.18–1.76 (m, 8H), 1.73 (s, 12H).31 13C NMR (100 MHz, 
CD3OD) δ 175.7, 169.2, 156.8, 147.4, 142.8, 132.3, 128.7, 128.6, 124.6, 112.0, 106.0, 51.7, 50.4, 
45.1, 27.9, 27.2, 23.5; 13C NMR (100 MHz, MeOD) d 175.7, 169.2, 156.8, 147.4, 142.8, 132.3, 
128.7128.6, 124.6, 112.0, 106.0, 51.7, 50.4, 45.1, 27.9, 27.2, and 23.5 ppm. HRMS (TOF): [M + 
H]+ Calc’d for C35H43N2O10S2 m/z 715.2359. Found, m/z 715.2321. 
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Sodium 4-((Z)-2-((2E,4E)-5-(3,3-dimethyl-5-(4-(2-(2-nitro-1Himidazol-1-yl)acetyl)-
piperazine-1-carbonyl)-1-(4-sulfonatobutyl)- 3H-indol-1-ium-2-yl)penta-2,4-dien-1-
ylidene)-3,3-dimethyl-5- (4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-
carbonyl)indolin- 1-yl)butane-1-sulfonate, (15) 
 
A total of 78 mg (0.149 mmol) of PyBOP was added to a stirring solution of bis-(carboxylic acid) 
8 (50 mg, 0.0068 mmol) in dry DMF (2 mL) at 0 °C. This solution was subsequently treated with 
HOBt (hydroxybenzotriazole, 20 mg, 0.149 mmol), followed by diisopropylethylamine (DIPEA, 
0.026 mL, 0.149 mmol). This mixture was stirred for 15 min before the addition of 2-
nitroimidazole piperazine 11 (54 mg, 0.149 mmol) followed by stirring at room temperature for 
48 h in the dark. The DMF was removed by air-drying to yield a thick blue oil and further 
concentrated in vacuo overnight. The crude mixture was recrystallized from methanol (15 mL) via 
the dropwise addition of diethyl ether (50 mL), and the resulting blue solid was washed with 
acetonitrile (2 × 25 mL), ethyl acetate (2 × 25 mL), and chloroform (2 × 25 mL). The crude was 
purified by C18 reverse phase column chromatography (H2O : MeOH) to yield 12 (25 mg, 0.021 
mmol, 31%) as a blue solid.31 mp: decomposed to black residue >250 °C; 1 H NMR (400 MHz, 
D2O) d 8.17 (m, 3H), 7.71 (s, 2H), 7.63 (d, J = 8 Hz, 2H), 7.55 (s, 2H), 7.50 (d, J = 8, 1H), 7.38 
(s, 1H), 6.76 (t, 2H), 6.47 (d, 2H), 5.64 (bs, 4H), 4.27 (bs, 4H), 3.66–4.05 (bs, 16H), 3.06 (t, 4H), 
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2.10 (m, 4H), 1.97 (m, 2H), 1.80 (bs, 9H), 1.44 (m, 3H); HRMS (ESI-TOF): [M − Na]− Calc’d for 
m/z C53H63N12O14S2 1155.4034. Found, m/z 1155.4028. 
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2.4 NMR Spectrum 
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